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ABSTRACT 
 
Mitragyna speciosa Korth (Kratom), a herb of the Rubiaceae family is indigenous 
in southeast Asia mainly in Malaysia and Thailand. It is used as an opium 
substitute and has been increasingly abused by drug addicts in Malaysia. 
Recently, the potent analgesic effect of plant extract and its dominant alkaloid 
mitragynine (MIT) were confirmed in vivo and in vitro. MIT acted primarily on µ- 
and δ-opioid receptors, suggesting that MIT or similar compounds could be 
promising alternatives for future pain management treatments.  However the 
potential cytotoxicity of this plant is unknown. Therefore, the cytotoxicity of 
methanol-chloroform extract (MSE) and MIT on human cell lines (HepG2, HEK 
293, MCL-5, cHol and SH-SY5Y cells) has been examined. MSE appeared to 
exhibit dose-dependant inhibition of cell proliferation in all cell lines examined, at 
concentration > 100 µg/ml with substantial cell death at 1000 µg/ml. SH-SY5Y 
was the most sensitive cell line examined.  MIT showed a similar response.  
Clonogenicity assay was performed to assess the longer- term effects of MSE and 
MIT. The colony forming ability of HEK 293 and SH-SY5Y cells was inhibited in 
a dose-dependant manner. Involvement of metabolism in cytotoxicity was further 
assessed by clonogenicity assay using rat liver S9 (induced by Arochlor 1254); 
toxicity increased 10-fold in both cell lines.  To determine if cytotoxicity was 
accompanied by DNA damage, the Mouse lymphoma tk gene mutation assay was 
used.  The results were negative for both MSE and MIT.  Studies on the 
involvement of metabolism in cytotoxicity of MSE and MIT were performed 
using MCL-5 and it appeared that CYP 2E1 is involved in activation of 
cytotoxicity. Studies with opioid antagonists were performed using SH-SY5Y 
cells treated with MSE and MIT. Naloxone (µ and δ receptor antagonists), 
naltrindole (δ receptor antagonist) and cyprodime hydrobromide (µ receptor 
antagonist) confirmed that MSE cytotoxicity was associated with µ and δ receptor 
while MIT mainly acted on µ receptor. Studies on mechanism of MSE and MIT 
cytotoxicity showed that cell death observed at high dose was preceded by cell 
cycle arrest, however MSE cell arrest was independent of p53 and p21 while MIT 
showed opposite result. Studies have been undertaken to examine the nature of 
this cell death. Morphological examinations showed that cell death induced by 
MSE was cell type dependant, in which SH-SY5Y cells appeared to die via 
apoptosis-like cell death while HEK 293 and MCL-5 cells predominantly via 
necrosis. Biochemical assessments confirmed that MSE induced cell death 
independent of p53 or caspases pathway while MIT cell death appeared to be 
associated with p53 and caspases pathway. The involvement of reactive oxygen 
species (ROS) generation in MSE and MIT mediating cell death was performed 
using SH-SY5Y cells. The results appeared negative for both MSE and MIT 
treated cells. Collectively, the findings of these studies suggest that MSE and its 
dominant alkaloid MIT produced cytotoxicity effects at high dose. Thus, the 
consumption of Mitragyna speciosa Korth leaves may pose harmful effects to 
users if taken at high dose and the evidence for involvement of CYP 2E1 in 
increasing the MSE cytotoxicity suggests that caution may be required if the 
leaves are to be taken with CYP 2E1 inducers. 
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1.0 Overview 
Treating ailments with phytopharmaceuticals is immemorial. In fact almost every 
culture in diverse global populations uses various forms of its local plants to treat 
illnesses (Houghton, 2001).  The use of traditional medicines from natural 
products, mainly of terrestrial (higher) plants, is increasingly high especially in 
developing countries, as modern medicine is considered expensive.  Although the 
safety and efficacy of most of the traditional medicines for human use are yet to 
be thoroughly investigated, people still turn to its use due to its availability.  In 
Malaysia, one of the pytopharmaceutical sources with unique therapeutic 
properties is Mitragyna speciosa Korth. The leaves of this plant have been used 
traditionally as a stimulant and have been reported to be effective as an opium 
substitute, antidiarrhea, antitussive and antidepression (Shellard, 1974; Suwarnlet, 
1976; Kumarnsit et al, 2007).  Recent findings on the congener of mitragynine 
(the major alkaloid of this plant),  7-hydroxymitragynine which has been 
suggested to be an active principle producing potent antinociceptive (analgesic) 
effect (Matsumoto et al, 2004), has made this plant a promising alternative source 
for pain management therapy. Since little is known of the potential toxicity of this 
plant, this study assessing the in vitro potential of cytotoxicity will serve as a 
safety database for the plant.  
 
1.1 Pharmaceuticals from plants 
1.1.1 Drug discovery from plants and the central nervous system 
Plants have a long history as a source of drugs for treating human diseases (Chin 
et al, 2006). Some of the well-known plants first reported to have such use include 
licorice (Glycyrrhiza glabra), myrrh (Commiphora species) and poppy capsule 
latex (Papaver somniferum). The chemical entities derived from opium plant, P. 
somniferum such as morphine, codeine, noscapine (narcotine) and papaverine are 
still used clinically (Newman et al, 2000). This P. somniferum plant has narcotic 
properties which mainly affecting the central nervous system (CNS) function. 
Addiction is a major side effect of using such drugs (Vetulani, 2001), however 
their use as potent pain killers for severe pain has made this plant a source of 
choice for clinically used drug. Until now, very few alternative drugs are proven 
to be as good as morphine as a potent pain killer for chronic pain management.  
Cannabinoid, a psychoactive compound from the plant Cannabis sativa also has a 
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good analgesic effect (Watts, 2004) and the potential to treat other neurological 
illnesess (Fernández-Ruiz et al, 2007; ); however its narcotic effects and 
undesirable  side effects such as addiction and high potential for toxicity are 
drawbacks of its use and thus made it illegal in most countries. The cannabis plant 
is widely abused as a recreational drug and is well known as marijuana, ganja and 
has many other street names (Watts, 2006). Other alternatives drugs of the kappa-
opioid group such as nalbuphine, pentazocine and butharphanol were clinically 
available as morphine alternatives but the controversy around the actual analgesic 
effects of these drugs remain debated (ScienceDaily, 2000). 
 
Other specific plants which are frequently used by the public and have direct and 
indirect effects on the central nervous system include Ephedra or Ma huang 
(Ephedra spp), which are good nasal decongestants due to vasodilation effects 
however can also stimulate CNS side effects from nervousness to imsomnia; 
gingko (Gingko biloba L.) a breakthrough herb in the late 1990’s, was found to be 
effective in improving cognitive performance and social functioning of demented 
patients, with a lower incidence of side effects; St. John’s wort (Hypericum 
perforatum L.), one of the five most popular herbs in the U.S.  is proven to be 
effective in treating mild to moderate depression states; kava (Piper methysticum 
G. Forst) which has narcotic-like effects such as sedation and is effective in 
treating conditions such as nervous anxiety, stress and restlessness, was reported 
to have no addictive properties. Valerian (Valeriana officinalis L.) which has long 
use and a reputation as a sleep aid and a mild tranquiliser has also been shown to 
produce CNS depression (Tyler, 1999).  
 
There are many more drugs derived from plants, which are successfully 
established as pharmaceuticals which I have not covered in this section. Scientific 
research in phytopharmaceutical is on going and is growing rapidly especially in 
countries like Malaysia which have an abundance of natural resources. In spite of 
much activity on the chemistry and pharmacology of phytopharmaceuticals, 
thorough investigations on their potential toxicology are lacking.  
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1.1.2 Safety concern on the use of pharmaceutical from plant 
The World Health Organisation (WHO) has estimated that 65-80% of the world’s 
population use traditional medicine as their primary health care and herbal 
medicine or pharmaceuticals from plants represent the majority of this health care 
and are growing in use especially in developing countries (Drew and Myers, 
1997).  The use of phytopharmaceuticals has also increased in Western countries, 
as alternative medicines to treat various conditions and diseases. Parallel with 
their usage, safety concerns with such medicine has also increased and 
committees and bodies were established to tackle this safety issue. In the UK, the 
Medicines and Healthcare products Regulatory Agency (MHRA) play significant 
roles in ensuring that herbal medicines marketed in UK are acceptably  safe 
(MHRA, 2008). In the U.S., safety concern on use of herbal medicines is 
regulated under U.S. Food and Drug Administration (FDA) and also a body called 
the National Center for Complimentary and Alternative Medicines (NCCAM) 
(Tilburg and Kaptchuk, 2008). European countries also have legislation in 
controlling the entrance of herbal medicines to the market as framed in their 
European Directive 2001/83/EC (Steinhoff, 2002). In Malaysia the safety of 
herbal medicines or pharmaceuticals from plants is regulated under a government 
agency, National Pharmaceutical Control Bureau (NPCB) which is also a WHO 
collaborating Centre for Regulatory Control of Pharmaceuticals. 
 
Popular belief has regarded that anything ‘natural is safe’. The ‘father’ of 
toxicology, Paracelsus has made an important statement concerning safety and his 
most popular quote is ‘all substances are poisons; there is none that is not a 
poison; the right dose differentiates a poison and a remedy’ (Timbrell, 2002). Of 
course this statement is applied to everything and includes the natural resources 
such as herbal medicine as well. In fact, Houghton in an editorial note stressed the 
issue that even in ‘problem plant’ (which refer to plants affecting the central 
nervous system, e.g opium), correct dose and use provide useful pharmaceuticals 
(Houghton, 2003). As most of the time herbal medicines are supplied as dietary 
supplements or without prescription, they should be used with caution, as many 
common herbal medicines used in irregular, high doses or in combination with 
other medications, may pose toxic effects. The toxic effects can range from 
allergic reactions to cardiovascular, hepatic, renal, neurological and 
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dermatological effects (Pharmar, 2005). Sometimes the herb itself is not toxic, 
however if adulteration occurs during preparation or processing (e.g. by heavy 
metals), toxic effects may be exhibited such as poisoning by the Chinese herbal 
medicine podophyllum (But et al, 1996). 
 
1.2 The plant Mitragyna speciosa Korth and Mitragynine 
1.2.1 Description of the plant 
Mitragyna speciosa Korth is a native tropical herb plant belonging to the family 
of Rubiaeceae (Coffee family). This species of Mitragyna genus is found mainly 
in Southeast Asia countries such as Malaysia, Thailand, Myanmar etc.  In 
Malaysia, this plant is locally known as ‘ketum’ or ‘biak-biak’ and is indigenous 
in the swampy area especially in the northern and west coast part of Peninsular 
Malaysia, in the states of Perlis, Kedah, Kelantan and Terengganu and also in the 
west coast states like Selangor and Perak. In Thailand, this plant is well known as 
‘ithang’, ‘thom’, ’kakuam’ or ‘kratom’. However, people globally recognise this 
plant as ‘Kratom’. The genus was named ‘Korth’ after the name of botanist, 
William Korthal who found the stigma of its flower resembles a bishop’s mitre 
(Shellard, 1974). This plant is a large leafy tree, which can grow up to 15 metres 
tall.  The leaves are dark green in colour and can grow over 7 inches long and 4 
inches wide, whilst the flower is yellowish and has a globular pattern with up to 
120 florets (Shellard, 1974) (Fig. 1.1 and 1.2).   There are two main varieties of 
this plant which can be differentiated by its leaves. The leaves have special 
characteristics which are easily distinguishable in which the petiole (vein) could 
either be red or white-greenish and it was believed that they produced different 
strength of effects (Murple, 2006). The leaves with white-greenish type of vein 
were suggested to have stronger effects (Suwarnlet, 1975). The M. speciosa leaves 
collected for my PhD project were of white-greenish vein type. 
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Fig. 1.1 Young plant of Mitragyna speciosa Korth. The photo was taken at the site 
of sampling, Behrang stesen, Selangor state of Malaysia in 2005. 
 
 
 
                            
Fig. 1.2  The branch of Mitragyna specisoa Korth leaves with flowers. The image 
was taken from http://www.erowid.org  and the photo was taken by Paul E. 
Wogg). 
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1.2.2 Chemical constituents of the plant 
Mitragynine (MIT) is the major alkaloid present in the leaves of this plant (Fig. 
1.3). It was Hooper who actually first isolated this alkaloid however the name 
mitragynine was given by Field who repeated its isolation in 1921 (Shellard, 
1974).  MIT is structurally similar to yohimbine alkaloid as first determined by 
Zacharias et al in 1964 (Shellard, 1974). Since then further chemistry and 
pharmacology investigations of this plant were continued and to date, over 25 
alkaloids have been isolated and chemically elucidated especially from the leaves 
of the young plant. Among the well-studied alkaloids, apart from MIT, which are 
present in Thailand plants are speciogynine, speciociliatine, paynanthiene and 
recently 7-hydroxymitragynine (Fig.1.3) (Ponglux et al, 1994; Takayama, 2004); 
whereas for Malaysian plant, 3,4-dehyromitragynine (Houghton and Said, 1986), 
mitragynaline, corynantheidaline, mitragynalinic acid and coryntheidalinic acid 
(Houghton et al, 1991; Takayama, 2004) have been reported.  As a dominant 
constituent of this plant, MIT was reported to be present approximately at 0.2% 
by weight in each kratom leaf and approximately 17 mg in 20 leaves (Grewal, 
1932; Suwanrlert, 1975). However the MIT content in kratom leaves varies 
between countries and even between states of each country as it depends on the 
geographical location and also the season (Shellard, 1974).   
 
                                       
              
 
Fig. 1.3 Chemical structures of mitragynine (MIT), dominant alkaloid and its 
congener, 7-Hydroxymitragynine present in the leaves of Mitragyna speciosa 
Korth.  
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1.2.3 Biological activity of this plant 
Mitragyna speciosa Korth plant especially its leaves has been consumed since 
time immemorial, where village people such as farmers and labourers chew the 
fresh leaves, smoke the dry leaves or drink as a tea suspension (Jansen and Prast, 
1988) or even eat it in the form of resin, for stimulant effects to overcome the 
burden of hard work under scorching sun.  It was way back in 1897, when the 
leaves and the bark of this plant were reported by Ridley as a cure for opium habit 
which was further quoted by Hooper in 1907. In the same year, Holmes also 
referred to its leaves as an opium substitute (Shellard, 1974).   Jansen and Prast 
(1988) mentioned in their report that Burkill (1930) recorded other uses of kratom 
as a wound poultice, cure for fever and as a suppressor of the opiate withdrawal 
syndrome.  This plant has unique dual opioid properties which exert a stimulant 
effect at low doses and sedative and analgesic effects at the higher doses in 
humans (Grewal, 1932; Suwarnlet, 1975). These effects have also been observed 
in animal models as reported by Macko et al (1972). 
 
Pharmacology activities of kratom and its dominant alkaloid, MIT have long been 
reported and reviewed since 1970’s. MIT was reported to exert antinociceptive 
and anti-tussive effects upon oral, subcutaneous and intraperitoneal administration 
to rodents (Macko et al, 1972). The crude methanol (MeOH) extract of Thai 
kratom was used in in vitro assay (twitching contraction induced by electric-
stimulation of guinea-pig ileum preparation) in which the opioid antagonist, 
naloxone successfully inhibited the contraction, implying that the crude extract is 
an opioid agonist (Takayama, 2004; Watanabe et al, 1992). Several in vitro and in 
vivo studies followed and support the analgesic properties of both crude extract 
and MIT such as reported by Matsumoto et al (1996), Watanabe et al (1997) and 
Idid et al (1998). Crude extract and MIT was also reported to successfully act 
mainly via supraspinal µ, δ and κ opioid receptors (Tsuchiya et al, 2002; Tohda et 
al, 1997; Thongpradichote et al, 1998) in various in vitro and in vivo studies.  
Recently, a minor constituent of this plant and congener for MIT, 7-
hydroxymitragynine was found to potently exhibit antinociceptive activities via 
opioid receptors, mainly µ-receptors in in vitro studies, which interestingly 
showed 13-fold and 46-fold higher activity than morphine and MIT respectively. 
This promising finding is further supported by an in vivo study in mice, which 
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again showed higher antinociceptive activity than morphine (Matsumoto et al, 
2004). Based on these findings, it was claimed that 7-hydroxymitragynine could 
be the active principle for the antinociceptive effects exerted by this plant 
(Takayama, 2004). 
 
It was reported that chewing the leaves has greater effects for lower doses of MIT 
properties (Grewal, 1932) and neuropsychiatric effects could be achieved within 5 
to 10 minutes post consumption and would last up to 1 hour (Grewal, 1932; 
Suwarnlet, 1975). In in vivo studies, it was reported that MIT doses as high as 920 
mg/kg have been administered without overt clinical effect (Macko et al, 1972).  
With regards to the clinical use in humans, the doses for the stimulant effects, the 
antinociceptive events and the toxicity effects are yet to be fully established (Babu 
et al, 2008).  Some tolerance effects have been reported among users and clinical 
effects such as antitussive, antinociceptive and anti-diarrhoeal effects of MIT use 
was also described to be similar to codeine (Suwarnlet, 1975; Jansen and Prast, 
1988). Other side effects have been described among kratom users and include 
nausea, vomiting, diarrhoea, nystagmus and tremor (Grewal, 1932) and for 
chronic users anorexia, weight loss, hyperpigmentation and prolonged sleep 
(Suwarnlert, 1975). Addiction has also been reported by Thuan (1957) (Babu et al 
2008). Suwarnlet (1975) in his report also mentioned the opioid abstinence 
syndrome such as irritability, yawning, rhinorrhoea, myalgias, diarrhoea and 
arthralgia. 
 
Recently, major concern has arisen in Malaysia as the narcotism properties of this 
plant have attracted the misuse of it by drug addicts as an opium substitute. Due to 
this, an act was passed in 2004 (under the poison control act 1952) which makes 
the possession of any form of the plant by the public illegal. In fact, Thailand has 
legislated this plant since 1946. Australia also followed to criminalise the 
possession of this plant in 2005. However, in other parts of the world, kratom is 
currently not scheduled. The availability of kratom over the internet has attracted 
many Western populations to use the plant as self-treatment in opioid withdrawal 
and chronic pain (Boyer et al, 2007). 
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1.3 Xenobiotic-induced cytotoxicity 
Xenobiotics or in other words a foreign chemical compound not arising from host 
organisms; have been a major concern in causing cytotoxicity to living organisms.  
In normal circumstances, any xenobiotic which gains entry to the body will be 
directly or indirectly eliminated or metabolised to harmless (detoxification) or 
harmful metabolites by major defence organs such as liver, kidney etc. However, 
under circumstances such as any failure of these defense systems or under the 
increased burden of overt toxicity, this will trigger a series of cytotoxicity events 
involving the cellular components and or DNA. In the case of xenobiotic induced 
DNA damage, if repair is not complete and DNA damage is severe, this may lead 
to cell death or mutation and genetic alterations which could lead to other major 
problems, such as carcinogenesis. 
 
1.4 The cell cycle 
1.4.1 Review of the cell cycle 
The cell cycle can be defined as a highly regulated series of events that leads to 
eukaryotic cell reproduction (Morgan, 2007).  Studies of the cell cycle began as 
early as the mid-nineteenth century, when there was the discovery of cell division. 
Pioneering work by Wilson (1925) placed the cell cycle with a firm role in the 
growth, development and heredity of living organisms (Nurse, 2000).   
 
The first part of the cycle, involves DNA replication and chromosome duplication 
in a phase called ‘synthesis phase’ (S phase).  During this phase, DNA is 
synthesised from the original DNA template (replication origins) to yield two 
DNA strands and duplication of chromosomes (sister chromatids) which involves 
protein synthesis and packaging of the DNA into chromosomes.   Another major 
phase of the cell cycle, the ‘Mitosis phase’ (M phase), involves two important 
events, the nuclear division (mitosis) and cell division (cytokinesis). The term 
‘interphase’ refers to the period between one M phase to another. There are four 
major phases involved in mitosis which are known as prophase (visible chromatin 
condensation), metaphase (aligning condensed chromatin in the middle of the 
cell), anaphase (separation of chromatin each to opposite pole of the cell) and 
telophase (a completion of cytokinesis in which two daughter cells each have a 
complete copy of the genome and the end stage of mitosis).There are two 
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additional phases in between the S and M phase, known as ‘gap phases’. G1, the 
first gap phase before S phase and G2, the second gap phase before M phase. 
These two gaps provide important function in giving more time for cell growth 
and as a regulatory transition controlled by intracellular and extracellular signals 
(Mitchison, 1971; Nurse, 2000). However, if there are unfavourable 
circumstances which require the cell cycle to pause in G1 phase or when entering 
a prolonged non-dividing state (many cells in human body are in this state), the 
cells were referred to be in  quiescent state or in G0 phase (G zero) (Morgan, 
2007). 
              
Fig. 1.4 Illustration of the cell cycle process.  Four main stages of the cell cycle, 
G1, S, G2 and M as briefly described in the diagram.  The original diagram was 
taken 
from:http://ghs.gresham.k12.or.us/science/ps/sci/soph/cells/cycle/cyclerev.htm. 
Additional G0 phase is added to the diagram. 
1.4.2 The cell cycle control system and check points 
The passage of a cell through cell cycle is governed by an independent control 
system that programmes the cell cycle event, especially the S and M phase, to be 
in the correct order at the specific intervals. These control systems are mainly 
proteins that exist in the cytoplasm of the cells; a family of enzymes called cyclin-
dependant kinases (Cdks) and regulatory proteins called cyclins (Morgan, 1997; 
Morgan, 2008).  Cdks were proposed as a ‘cell cycle engine’ which drive cells 
through the cell cycle (Murray and Hunt, 1993) and they bind tightly with their 
regulatory subunit cylins to form a complex. There are three regulatory 
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transitions, known as checkpoints, in which the cell cycle control system is 
driven; namely Start or G1/S checkpoint, G2/M checkpoint and metaphase-
anaphase transition. 
 
Different cyclin types are produced at different phases of cell cycle, thus resulting 
in different Cdk-cylin complexes (G1-, G1/S-, S- and M-Cdks).  The level of 
cylins in the cell rise and fall depending on the stages of cell cycle, however the 
Cdk level is normally constant and higher than cylins. As shown if fig. 1.5, the 
enzymatic activities of cyclin-Cdks complexes also rise and fall depending on the 
levels of cyclins. The formation of G1/S-Cdks complexes trigger cells to enter cell 
division at Start checkpoint in the late G1 phase, followed by activation of S-Cdk 
complexes which initiate the cell to undergo DNA replication (S phase).  M-Cdk 
activation occurs at the end of S phase, causing the progression via G2/M 
checkpoint and assembly of mitotic spindle. The anaphase-promoting complex 
(APC) is then activated to complete the mitosis events (anaphase to metaphase 
transition) in which it causes the destruction of S and M cylins, thus deactivation 
of Cdks leading to completion of mitosis and cytokinesis.  This APC will exist in 
the G1 phase until the levels of G1/S-Cdks increase again for the next cell cyle 
(Morgan, 2007). 
 
 
Fig. 1.5 Overview of the cell cycle control system which shows the enzymatic 
activities of cyclin-Cdks complexes in which their levels rise and fall depending 
on the cyclins levels. This diagram was taken from Morgan (2007). 
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1.4.3 Cell cycle arrest: Roles of p53 and its target gene, p21 protein 
Mammalian cells have several systems to interrupt the normal cell cycle under 
unfavourable condition such as insult by DNA damage agents. In response to the 
DNA damage, activation of the cell cycle checkpoints serves as a control 
mechanism for a temporary arrest at the specific stage to provide time for cells to 
repair the defects (Weinert and Hartwell, 1988; Hartwell and Kastan, 1994; 
Pellegata et al, 1996). The p53 protein has multiple roles in the cell and one of 
them is directly involved in cell cycle arrest. In humans, p53 gene is mapped at 
chromosome 17 (Miller et al, 1986). P53 is a well known tumour suppressor gene, 
which plays an important role in preventing cancer thus popularly known as 
‘guardian of the genome’. A highly expressed wild type p53 level in cells has two 
outcomes: cell cycle arrest or cell death (apoptosis) (Ko and Prives, 1996). P53 
was thought to be a crucial component in the cell cycle control systems (Pellegata 
et al, 1996). Refer fig. 1.6 and 1.7 for p53 structure and involvement of p53 in the 
cell cycle control system. 
 
In the normal cell, p53 is actually inactive and normally binds to the protein 
MDM2 (murine double minute 2) or in humans HDM2 (human double minute 2), 
which prevents p53 activation and promotes its degradation by acting as an 
ubiquitin ligase (Wallace et al, 2006; Michael and Oren, 2003). DNA damage 
agents will trigger the checkpoint controls of cell cycle thus activating proteins 
such as ATM (ataxia telangiectasia-mutated gene), which will phosphorylate the 
p53 at a site close to or within the MDM2 binding site. This damage signal will 
further activate the protein kinases Chk1 and Chk2 (effector kinases of damage 
response). Thus this p53 action is therefore leading to cell cycle arrest or cell 
death (Morgan, 2007).  At least two checkpoints are involved in cell cycle arrest; 
G1/S and G2/M checkpoints (Pellegata et al, 1996).  The G1/S checkpoint 
prevents the damaged DNA being replicated, thus causing arrest at G1 phase and 
G2/M checkpoints cause inhibition of cell replication (Weinert and Hartwell, 
1988; Hartwell and Kastan, 1994) thus causing arrest at G2 phase. However the 
G2 phase arrest was also reported to be p53 independent as seen in p53 null cells 
or mutated p53 cells (Kastan et al, 1991; Kuerbitz et al, 1992).  
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Increases in p53 levels can also lead to increased expression of numerous p53 
target genes and one of the most important is cyclin-dependant kinase inhibitor A 
(CDKN1A) or p21.  Cdk inhibitor p21 (p21CIP1) is also regarded as a downstream 
effector gene (Pellegata et al, 1996). Human p21 gene located at chromosome 6, 
can act as a regulator for cell cycle progression controlled by p53 (Gartel and 
Radakrishnan, 2005). Thus, the positive links between p53 and its effector gene 
p21, lead to binding of p21 to Cyclin-Cdks complexes which in turn inhibit the 
cells in G1 phase (Morgan, 2007). 
 
     
 
 
 
Fig. 1.6 Structural organisation of p53 protein. The p53 393 amino acids, 
comprise five main domains, including acidic N-terminal region containing the 
transactivation domain and mdm2 binding site (1-50), a proline rich domain (63-
92), a central domain containing the sequence-specific DNA-binding domain 
(100-300) and c-terminal or tetramerisation domain consists of the 
oligomerisation domain (323-358) containing nuclear export signal  and the 
regulatory domain (363-393) containing the nuclear localisation signals, a non-
specific DNA binding domain that bind to damaged DNA and act as negative 
regulator of DNA binding of the central domain. This diagram was taken from 
http://www.expertreviews.org/  p53 protein structure, vol.5: 19 November 2003, 
Cambridge University Press. 
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Fig. 1.7 Diagram showing mammalian cell cycle respond to DNA damage 
stimulus.  ATM and/or ATR trigger the activation of a checkpoint that leads to 
cell cycle arrest or delay. Checkpoint pathways are characterized by cascades of 
protein phosphorylation events (indicated with a "P") especially p53, Cyclin-
dependant kinases (Cdks) and Cyclins that alter the activity, stability, or 
localization of the modified proteins. 
This diagram was taken from:  
http://www.rndsystems.com/mini_review_detail_objectname_MR03_DNADamag
eResponse.aspx 
 
 
1.5 Genotoxicology 
In general, genotoxicity describes the deleterious action on the cell genome 
affecting its integrity. Genotoxic chemicals are known to produce mutagenicity 
(the capacity to induce permanent alteration in the genetic material (mutation) 
within living cells) and may proceed to carcinogenicity (formation of cancer).  
There is always some confusion related to use of these terms. Mutagenesis is 
important in the carcinogenesis process however not all carcinogenesis is due to 
mutagens. This is due to the fact that carcinogenesis could also occur via 
epigenetic (not involving the DNA) mechanisms.  
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1.5.1 Overview of DNA damage and repair 
DNA damage can either be regarded as ‘endogenous DNA damage’ or 
‘environmental DNA damage’. Endogenous DNA damage mainly involves 
hydrolytic and oxidative reactions with DNA following the interaction between 
DNA,  reactive oxygen species (ROS) and water within the cells; whereas the 
environmental DNA damage refers to external physical or chemical agents that 
cause DNA damage (Friedberg et al, 2006). 
 
The alkylating agents are examples of chemicals with the ability to damage DNA. 
They are electrophilic compounds with affinity for nucleophilic centres in organic 
macromolecules. Examples of chemicals in this class are methylnitrosourea 
(MNU), methylmethanesulfonate (MMS), ethyl methanesulfonate (EMS) etc. 
Other chemicals require metabolic activation in order to become potent 
genotoxins for example benzo[a] pyrene which metabolised by microsomal 
mixed-function oxygenase to 7,8-diol-9,10-epoxide and the natural products, 
aflatoxins which are mycotoxins produced by fungi Aspergillus flavus and A. 
parasiticus (Friedberg et al, 2006). Cytochrome P-450 enzymes are those most 
frequently involved in activating genotoxic chemicals; others include microsomal 
and cytoplasmic glutathione-s transferases, sulfotransferases, methylating 
enzymes etc ( Anders and Dekant, 1994).  
 
DNA damage can also occur in the form of strand breaks, either single strand 
breaks which involved only one DNA strand or double strand breaks in which 
both double helix strands are severed. The latter is the more hazardous as it can 
lead to genome rearrangement.  Topoisomerase inhibitor compounds such as 
camptothecin and etoposide are the well known chemicals which cause strand 
break formation. Bacterial toxin, for instance cytolethal distending toxin (CDT) 
produced by human E.coli in the gut, also can caused DNA strand breaks 
(Friedberg et al, 2006). 
 
In response to DNA damage as described above, cells have certain mechanisms to 
correct the DNA damage. DNA repair is an active process as everyday, millions 
of cells are exposed to various metabolic activities and environmental factors and 
the majority of this exposure leads to structural damage of the DNA. However 
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based on the severity of the damage and also other factors that include cell types, 
age of the cells and also the extracellular environment, the rate and success of the 
repair varies. The higher the severity of DNA damage, the higher the possibility 
of ineffective DNA repair, which could lead to either the cells undergoing 
senescence (irreversible state of dormancy), cell death (apoptosis) or permanent 
alterations of DNA structure and function leading to irregular cell division that 
could ultimately lead to carcinogenesis (Friedberg et al, 2006). 
 
More than 130 human genes have been found to be involved in DNA repair 
mechanisms (Wood et al, 2001).  As soon as the damage has been indentified, 
specific molecules are brought to the site of damage and induce other molecules 
to bind and form a complex for repair. Most of the time, if small areas of DNA are 
affected, such as in nearly all oxidative damage (e.g. ROS) as well as single strand 
breaks, the damage will be repaired by DNA base excision pathway (BER).  BER 
is the most active repair process which allows specific recognition of and excision 
of damaged DNA bases (Friedberg et al, 2006).  
 
The second most important mechanism of DNA repair is via nuclear excision 
repair (NER) pathway. NER enzymes recognise damaged lesions by their 
abnormal structure; this is followed by excision and replacement (Friedberg et al, 
2006).  There are two sub pathways for NER, the global genome repair-NER 
(GGR) and transcription coupled repair-NER (TCR); both share the same repair 
mechanisms but with different recognition steps and use different sets of proteins 
(Bohr et al, 1985; Hanawalt, 2002). In principle, GGR works by eliminating the 
lesions from the entire genome whereas TCR repairs the damage at DNA strands 
that actively transcribe the gene (Altieri et al, 2008). When the DNA damage 
occurs during cell cycle phases such as during DNA replication, correction needs 
to be performed to avoid permanent mutation in subsequent DNA replications. A 
repair system called mismatch repair (MMR) recognises and repairs the erroneous 
insertion, deletion and mis-incorporation during DNA replications and also 
recombination (Iyer et al, 2006). For instance, the mismatches of G/T or A/C 
pairing bases will be repaired by excising the wrong bases and replace it with the 
right nucleotides. 
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Exogenous DNA damaging agents or endogenous ROS formation can cause 
double DNA strand breaks (DSBs) which promote genome rearrangements and 
thus initiate carcinogenesis or apoptosis ( Hoiejmakers, 2001; Alteiri et al, 2008). 
Therefore the evolved mammalian system has two mechanisms to repair such 
damage. The first is by homologous recombination (HR) and use instructions 
from sister or homologous chromosomes for a proper repair of the breaks. The 
second mechanism is called non- homologous end joining (NHEJ) where the two 
severed DNA ends are rejoined in a sequence independent fashion (Helleday et al, 
2007; Weterings and van Gent, 2004). 
 
1.5.2 Carcinogenesis 
Genotoxins or mutagens can both lead to carcinogenesis. Irregular cell division 
during cell cycle due to mutations and ineffective repair processes may lead to 
this hazardous process.   Although mutations play a significant role in the 
carcinogenic processes, however not all types of mutation may lead to tumour or 
cancer formation. Mutations of proto-oncogenes will normally modify their 
normal expression and activity, and they can be transformed to oncogenes via 
mutation. This can lead the cell to proliferate abnormally. Tumour suppressor 
gene (TSG), another important gene that regulates the normal cell growth and 
mitosis also plays a significant role in cancer formation. In cases of cellular stress 
or DNA damage, the TSG will suppress normal function and promote cell cycle 
arrest, to allow enough time for repair and to prevent mutations from passing to 
new cells. However, if the TSG itself has been mutated, the original functions of it 
can be switched off and DNA damage without repair may lead to mutation.  One 
of the most important TSG is p53.  It has been reported that the mutation of p53 
has high prevalence in human cancers (50%) and cells that lack this p53 exhibit 
genetic instability and defects in cell-cycle control (Hollstein et al, 1991; 
Greenblatt et al, 1994; Soussi and Wiman, 2007). 
 
The term ‘neoplasia’ (new growth from Greek word) has been referred to the 
group of diseases called cancer. In general, the formation of tumour or cancer 
involves a series of complex processes which usually proceeds over years. The 
multistage process of carcinogenesis involves three main stages namely, initiation, 
promotion and progression (Cohen 1991, Mehta, 1995, Hasegawa et al, 1998, 
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Trosko, 2001).   In general, the genome continually changes throughout the three 
stages of carcinogenesis (Pitot, 2001, Oliveira et al, 2007) (refer fig. 1.8). DNA 
damage is the earliest event and has a key role in carcinogenesis. Thus following 
DNA damage during initiation stage, the cell undergoes mutations which induce 
more proliferation but not differentiation. (Trosko, 2001). Rapidly dividing cells 
have less time for DNA to get repaired and to remove the DNA-adducts (covalent 
binding of chemicals with DNA) (Richardson et al, 1986; Frowein, 2000) and 
these cells may remain latent over time (Player et al, 2004) until the next stage, 
promotion. This second stage starts when promoter influences increase the cell 
proliferation in susceptible tissues, increases the genetic changes and also the cell 
growth control (Mehta, 1995, Oliveira et al, 2007). Such examples of promoter 
compounds include phenobarbital, benzene, asbestos, arsenic, etc (Trosko, 2001; 
Oliveira et al, 2007). The ‘promoted’ cells which survived apoptosis may proceed 
to the final stage of neoplasia, ‘progression’ which cells are characterised by 
irreversibility, genetic instability, rapid growth, invasive, metastasize and have 
various changes biochemically, metabolically and morphologically (Pitot and 
Dragan, 1991; Butterworth et al, 1998; Dixon and Kopras, 2004; Oliveira et al, 
2007). 
 
 
Fig. 1.8 A diagram illustrating a chemical-induced carcinogenesis involving the 
three stages, initiation, promotion and progression. This diagram was taken from 
Oliveira et al (2007). 
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1.5.3 Genotoxicity testing 
Genotoxicity tests are described as in vitro and in vivo tests designed to detect 
compounds that induce genetic damage directly or indirectly via various 
mechanisms (ICH, 1997).  In the UK, Committee on Mutagenicity of Chemicals 
in Food, Consumer products and the Environment (COM) is an independent 
advisory committee responsible for tackling the issue of potential mutagenicity of 
chemicals that arises from natural product or synthetic compounds used in food, 
pesticides or pharmaceutical or consumer product industries (DoH, 2008).  
Internationally, two main bodies are responsible for providing the guidance and 
tests methods in assessing genotoxicity; they are Organisation of Economic 
Cooperation and Development (OECD) and International Conference on 
harmonisation of Technical Requirements for Registration of Pharmaceutical for 
Human Use (ICH). The guidance and methods are reviewed and refined 
continuously to improve the approaches for genotoxicity testing and assessment 
and also to provide a common strategy to increase the harmonisation of the 
genotoxicity testing and risk assessment due to difference legislation between 
countries ( Müller et al, 2003).  
 
As part of the registration requirement, chemicals (natural or synthetic) used for 
pharmaceutical products or any other consumer product needs to be assessed for 
genotoxic potential. To detect and predict the genotoxic potential of such 
compounds is not a straightforward task and a single test is not sufficient to fulfil 
this regulatory requirement. Thus, ICH for instance has come out with a standard 
approach to carry out the testing using both in vitro and in vivo methods in order 
to complement each other in predicting the genotoxicity.  There are three standard 
battery tests originally recommended by ICH (1997): 
1) A test for gene mutation in bacteria – bacterial reverse mutation test 
(Ames test). This test has shown that many compounds that mutagenic are 
rodent carcinogens. 
2) An in vitro test with cytogenetic evaluation of chromosomal damage with 
mammalian cells (e.g. Mammalian aberration test) or an in vitro mouse 
lymphoma tk gene mutation assay.  
3) 3) An in vivo test for chromosomal damage using rodent hematopoietic 
cells (e.g. Micronucleus assay). This test provides additional information 
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(absorption, distribution, metabolism and excretion) which could influence 
the genotoxicity of the compounds. 
 
Recently the use of this battery of tests has been modified and new guidelines are 
about to be introduced in which two options of standard battery testing can be use 
instead of one. These options were optimised for improvement in predicting 
genotoxic compounds and in conjunction with the latest OECD guidelines and 
reports from International Workshop on Genotoxicity testing (IWGT) (ICH 
Expert Working Group, 2008).  The following two options were considered 
equally suitable: 
Option 1: 
i)   A test for gene mutation in bacteria (Ames test). 
ii) A cytogenetic test for chromosomal damage (in vitro metaphase chromosome 
aberration or in vitro micronucleus assay) or in vitro mouse tk gene mutation 
assay. 
iii) An in vivo test for chromosomal damage using rodent hematopoietic cells 
(either micronucleus test or chromosomal aberration using metaphase cells). 
Option 2:   
i)   A test for gene mutation in bacteria (e.g. Ames test). 
ii) An in vivo test using two tissues (in vivo using rodent hematopeitic cells and 
another in vivo assay using other tissues e.g. liver) 
 
The well known bacterial mutation test, Ames test, was first described by Bruce 
Ames and his colleague way back in early 1970’s when they found that several 
metabolites of the carcinogen 2-acetyl-aminofluorene are potent frame shift 
mutagens in bacteria Salmonella typhimurium (Ames et al, 1972). Principally this 
test employed bacterial strains of S. typhimurium which carry mutation in 
histidine synthesis (required for normal growth) and measure the effect of 
mutagen on the reversion of the growth on histidine-free medium of the tester 
strain. Therefore, only bacteria mutated to histidine independence may continue to 
grow and form colonies. Based on this finding, Ames and his colleague carried 
out a series of work improving the use of bacterial strains for classification of 
mutagen and carcinogens such as using forward mutagenesis test (Ames et al, 
1973a), introduced more bacterial strains for better sensitivity (McCann et al, 
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1975) and also using metabolic activation systems such as liver homogenate to 
activate the compounds under study (Ames et al, 1973b). Other types of bacteria 
such as E. coli strains have also been successfully used for mutagenicity testing, 
which principally detect the mutation of tryptophan by reverse mutation assay 
(Mortelmans and Riccio, 2000).  The Ames test is widely accepted worldwide and 
remains one of the tests for predicting genotoxicity potential. 
 
Mouse lymphoma tk gene mutation assay (MLA) is one of the tests specifically to 
evaluate mutagenesis in mammalian cells. The first test was developed by Clive 
and his colleague in 1970’s (Clive and Spector, 1975; Clive et al, 1979). Since 
then the test was gradually optimised until it is widely acceptable for genotoxicity 
testing. MLA is not only capable of detecting gene mutations (point mutations) 
but also for clastogenic effects (deletion, translocation, mitotic 
recombinations/gene conversions and aneuploidy)(US FDA/CFSAN, 2006; 
Applegate et al, 1990; Sawyer et al, 1989, 1985; Moore et al, 1985). Another in 
vitro assay, chromosome aberration assay, also provides the same performance 
and limitations as MLA (Kirkland et al, 2005), however,  MLA offers advantages 
such as simplicity, less time consuming and able to detect some aneugens (Lorge 
et al, 2007). In principle, MLA uses the L5178Y TK+/- -3.7.2c mouse lymphoma 
cell line and examines mutation at thymidine kinase (tk) gene. The tk mutated cell 
lines are resistant to the lethal pyrimidine analogue, trifluorothymidine (TFT) 
which is toxic to normal cells (causing inhibition of cellular metabolism and halts 
the cell division). In MLA, the test agent is used with or without exogenous 
metabolic activation system (post supernatant rat liver S9 induced with Arochlor 
1254 or phenobarbital/β-naphthoflavone) for appropriate time points (3 -4 hr with 
S9 and 24 hr without S9). Exogenous metabolic activation system is important as 
it mimics the in vivo metabolism thus converting the compound to its mutagenic 
metabolites (Prieto-Alamo et al, 1996). The level of toxicity of the compound can 
also increase as the metabolism could convert it to toxic metabolites. Thus, high 
cytotoxicity of the compounds in the MLA (with metabolic activation) may lead 
to some irrelevant in vitro positive findings as it may damage the DNA of the 
surviving cells (e.g. higher toxicity leads to increased number of  dying cells thus 
releasing ROS to the medium ) (Lorge et al, 2007). Another issue that needs to be 
taken into account is if there is some dysfunction of p53 protein, which may lead 
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to DNA damage and give false-positive results (Lorge et al, 2007; Storer et al, 
1997).  
 
Additional tests are sometimes needed in order to help understand the mode of 
action of the compounds. Alternative in vitro tests which can be used include the 
chromosome aberration test or micronucleus test or use other mammalian cell 
lines such as Chinese hamster cell lines (CHO, V79) or human lymphoblastoid 
cells (TK 6) which detect different end-point of genetic events such as at 
hypoxanthine-guanine phosphoribosyl transferase (HPRT) or a transgene of 
xanthine-guanine phosphoribosyl transferase (XPRT) (USFDA/CFSAN, 2006). 
Collectively, the batteries of genotoxicity tests that are used provide a weight of 
evidence approach to evaluate a chemical’s genotoxic potential. 
 
1.6 Cell death 
1.6.1 Various ways of cell death : Apoptosis vs necrosis 
Cell death represents an ultimate cycle for any living organism and the 
equilibrium between cell division and cell death is important in determining the 
development and maintenance of multicellular organisms.  Cell death can either 
be part of normal physiological processes or abnormal pathological processes 
following endogenous or exogenous physical or chemical insults. Numerous 
studies have demonstrated various ways a cell can commit to their death. The 
most well studied types of cell death are programmed cell death or apoptosis and 
necrosis. However, there are other ways for cells to die which are currently being 
investigated such as oncosis (derived from ónkos, meaning swelling), autophagy 
and mitotic catastrophe (Kroemer et al, 2007; Cruchten and Broeck, 2002).  
 
Cell death was first reported by Virchow in 1858 where he describes macroscopic 
observations using the terms degeneration, mortification and necrosis (Cructen 
and Broeck, 2002). Since then cell death research has expanded intensively and in 
1972, programmed cell death was first coined as apoptosis by Kerr et al (1972).  
Morphologically, both apoptosis and necrosis are distinguishable microscopically 
either by light or electron microscopy (Cruchten and Broeck, 2002; Häcker, 2000) 
(refer to fig. 1.9). Under light microscopy, apoptosis is seen as individual cells 
having cellular shrinkage, condensation and margination of the chromatin with 
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formation of ‘blebbing’ (budding of plasma membrane and followed by formation 
of apoptotic bodies consisting of cell organelles or nuclear material surrounded by 
intact plasma membrane. Ultimately, this apoptotic body will be removed from 
the tissue by engulfment by neighbouring cells or macrophages (Kerr et al, 1972). 
The recognition of apoptotic bodies by macrophages was suggested due to the 
externalisation of phosphatidylserine to the outer plasma membrane (Fadok et al, 
1992); this is now exploited as a basis for early apoptotic detection by flow 
cytometry (Darynkiewicz et al, 2001; Fadok et al, 1992).  However, sometimes 
the recognition of apoptotic bodies by phagocytes was not possible, thus leading 
them to commit cell death as secondary degeneration as seen in necrosis (Sanders 
and Wride, 1995) or apoptotic necrosis (Majno and Joris, 1995). 
 
In the early stage of cell death research, apoptosis and necrosis was described as 
different forms of cell death (Wyllie et al, 1980). Necrosis has previously been 
described as cells undergoing swelling and often accompanied by chromatin 
condensation which is then followed by cellular and nuclear lysis and 
inflammation (Wyllie et al, 1980). Necrosis is always regarded as a pathological 
response generated by chemical or physical insults whereas apoptosis could either 
be physiological or pathological generated and most of the physiological death is 
apoptotic (Sanders and Wride, 1995).  
 
Majno and Joris (1995) proposed another term ‘oncosis’ as a designated way of 
cell death. Oncosis (Greek= swelling) described the marked swelling of the cells 
and also relates to nuclear changes such as pyknosis (condensation of chromatin), 
karyorhexis (nucleus fragmentation) and karyolysis (lysis of nucleus). Sanders and 
Wride (1995) also mentioned that pyknosis and karyorhexis are common features 
for both apoptosis and oncosis while karyolysis is more to oncosis.  These recent 
insights give new perspectives on how cell death may be differentiated and the 
oncosis term is now more accepted such as in the work by Park et al (2000) which 
showed that the majority of bone marrow-derived mast cells undergo oncosis after 
IL-3 deprivation (IL-3 have been shown in other studies to be an apoptotic 
inducer) and only at the later stage showed some apoptotic features (refer to fig. 
1.10). 
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Fig. 1.9 The illustration of morphology of apoptosis and necrosis as originally 
described by Kerr et al (1972). This diagram was taken from Cruchten and Broeck 
(2002).  
 
                                 
 
 
Fig. 1.10 Recent illustration of morphology of apoptosis, oncosis and necrosis as 
described by Majno and Joris (1995). This diagram was taken from Cruchten and 
Broeck (2002). 
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1.6.2 Mechanisms of apoptotic and necrotic cell death 
1.6.2.1 Apoptosis pathways 
Apoptosis is a mechanism by which cells undergo death in response to damage 
including DNA damage or to control cell proliferation (Ghobrial et al, 2005). 
Various stimuli can trigger apoptosis and activate two principle signalling 
pathways namely, extrinsic or cytoplasmic pathway and intrinsic or mitochondrial 
pathways (Ashkenazi, 2002; Ghobrial et al, 2005). The final execution of 
apoptosis through these pathways is linked and converges to a common pathway 
by activating a series of proteases called caspases.  These cleave regulatory and 
structural molecules to execute the cell death programme (Ghobrial et al, 2005). 
 
Extrinsic pathway 
The extrinsic pathway or death receptor pathway triggers apoptosis via various 
pro-apoptotic protein receptors located on the plasma membrane of the cells 
(Fulda and Debatin, 2006) which mainly belong to the tumour necrosis factor 
(TNF) receptor superfamily (Zapata et al, 2001). These proteins include death 
receptors, the membrane bound Fas ligand (FasL), the Fas complexes and the Fas 
associated death domain (FADD) and also the initiator caspase 8 and 10 (Ghobrial 
et al, 2005). Fas is also known as APO-1 or CD95 (Krammer, 1999). Other 
receptors which may be involved in this pathway include TNF R1, DR3 (Apo 2), 
DR4 (tumor necrosis factor related apoptosis-inducing ligand receptor or TRAIL 
R1) and DR5 or TRAIL R2 (Ashkenazi and Dixit, 1998). Upon receiving the 
death stimulus, the FasL interacts with inactive Fas complex and forms the death-
inducing signalling complex which contains the adaptor protein Fas-associated 
death domain and also procaspases 8 and 10. This leads to activation of caspase 8 
and further activation of downstream or executioner caspases, 3, 6 and 7 
(Ghobrial et al, 2005). In some cells, caspase 8 may interact with the intrinsic 
pathway in cleaving the Bid (pro-apoptotic from Bcl-2 family) causing released of 
cytochrome c from mitochondria (Wajant, 2002). 
 
Intrinsic pathway 
In response to death stimulus such as DNA damage, the intrinsic pathway or 
mitochondrial pathway will trigger the activation of tumour suppressor protein, 
p53 in which further up regulates the pro-apoptotic members of Bcl-2 family such 
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as Bax, Bak, Bad, Bcl-Xs, Bid, Bik, Bim, and Hrk to promote the release of 
cytochrome c from mitochondria. Bcl-2 family also comprise anti-apoptotic 
members such as Bcl-2, Bcl-XL, Bcl-W, Bfl-1, and Mcl-1, which act as 
suppressors for cytochrome c release and the action of these proapototic and 
antiapoptotic members depends on their balance (Reed, 1997; Ghobrial et al, 
2005). The activation of Bcl-2 members such as Bax may cause an increase of 
mitochondrial membrane permeability thus releasing cytochrome c and also 
second mitochondria-derived activator of caspase (SMAC) or inhibitor of 
apoptosis proteins (IAPs) into cytosol.  Cytochrome c will react with APAF-1 
(apoptosome) and together with IAP will activate the initiator caspase 9. Active 
caspase 9 will activate the downstream caspases, 3, 6 and 7 for cells to execute 
apoptosis (Ghobrial et al, 2005) (refer to fig. 1.11). 
 
Final execution: Caspases pathway 
As described above in the two main pathways, caspases which belong to cycteine 
proteases family play important roles in the initiating and executing the final 
apoptosis events.  The well known caspases which are involved in apoptosis are 
initiator or upstream caspases 8, 9 and 10 and executor or downstream caspases, 
3, 6 and 7. The upstream or initiator caspases 8, 9, and 10 converge from both 
pathways to activate the downstream caspase 3, which in turn activates the other 
caspases. The downstream or executioner caspases, 3, 6 and 7 play the final role 
in morphological manisfestation of apoptosis such as DNA condensation and 
fragmentation and blebbing formation as the cleavage activities of these caspases 
change the cytoskeletal structures, DNA repair proteins and destroy the cellular 
function (Thonberry and Lazebnik, 1998; Mancini et al, 1998; Ghobrial et al, 
2005). 
 
Caspases- independent pathway 
Caspases are well known as the final executioner for apoptosis events. However, 
recently there is accumulating evidence that indicates that cells may commit to 
death via programmed fashion but may not require caspase activation. This latest 
view is also in line with the current proposed alternative models of programmed 
cell death (PCD) such as autophagy, paraptosis (formation of vacuoles in the cell 
cytoplasm, along with mitochondrial swelling), mitotic catastrophe, apoptosis-like 
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and necrosis-like PCD. As in usual apoptosis events, mitochondria are again 
involved, however other organelles such as lysosomes and endoplasmic reticulum 
are also becoming key players in releasing other death factors  such as cathepsins, 
calpains and other proteases (Bröker et al, 2005). Apoptotic inducing factor (AIF) 
released from mitochondria as a result of changes in membrane permeability due 
to activation of Bcl-2 family is known to be involved in the intrinsic pathway of 
apoptosis. However, apart from AIF, evidence suggests that changes in membrane 
permeability also may cause release of endonuclease G (Endo-G)-triggering cell 
death. Both AIF and EndoG represent the caspase independent pathway as cells 
commit suicide with apoptosis –like features when both were transferred into 
nuclei (Jiang et al, 2006; Li et al, 2001; Cande et al, 2001) (refer to fig. 1.12). 
 
As discussed by Jiang et al (2006), evidence also shows that lysosomal pathways 
may lead to different cell death depending on the type of cells and stimuli. 
(Roberg et al, 2002; Guicciardi et al, 2000). The release of lysosomal poteases 
such as cysteine cathepsin B and L and aspartyl cathepsin D may lead to necrosis, 
apoptosis or necrosis-like cell death (Katunuma et al, 2004; Brunk et al, 1997).  
Active calpains (cytosolic calcium-activated neural cysteine proteases) which are 
also associated with lysosome are also shown to be involved in regulation of 
apoptosis and necrosis events (Yamashita et al, 2003); Leist  and Jaattela, 2001; 
Brunk et al, 1997). Jiang et al (2006) in their own work also showed that 
kanamycin, an aminoglycoside antibiotic triggers  apoptotic and necrotic-like 
appearance in hair cell nuclei in which the classic markers for apoptosis were 
absent and the activation of cathepsin D, µ-calpains and translocation of Endo-G 
were evident. Other cytotoxic agents which are known to be mediated by caspase 
independent cell death includes camptothecin (via cathepsin D) (Roberts et al, 
1999), doxorubicin (via calpains) (Lim et al, 2004), paclitaxel (via AIF) (Ahn et 
al, 2004), etc.  
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Fig. 1.11 Illustration of two main pathways of apoptosis, extrinsic (death receptor) 
and intrinsic (mitochondria) pathways with the final execution via caspases 3, 6, 
and 7. This diagram was taken from Igney and Krammer (2002).  
 
 
Fig. 1.12 Diagram showing the cross-talk of organelles during cell death. Cells 
can execute cell death via apoptosis or caspase- independent pathway (necrosis-
like PCD or apoptosis-like PCD). This diagram is taken from Bröker et al (2005). 
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1.6.2.2 Necrotic cell death 
 
Necrosis (in Greek = corpse or dead) describes the pathological ways of cell death 
to various stimuli and this term was originally used to describe all types of cell 
death until Kerr et al (1971, 1972) introduced the concept of apoptosis (Zong and 
Thompson, 2006). Classic morphological necrosis has been described in section 
1.6.1.  Necrotic cells in the first place were thought to be a different way of cell 
death that lack the features of apoptosis and is usually considered to be 
uncontrolled (Golstein and Kroemer, 2006). In recent years, research has geared 
towards better understanding of molecular mechanisms of necrosis and two 
mammalian models system are often used, the nematode Caenorhabditis elegans 
and slime mold, Dictyosterlium discoideum.  Golstein and Kroemer (2006) in 
their review described that the early biochemical signs of necrotic events include 
the dysfunction of mitochondria by increased production of reactive oxygen 
species (ROS), swelling of mitochondria, ATP depletion, failure of Ca2+ 
homeostasis, perinuclear clustering of organelles, activations of proteases such as 
calpains and cathepsins and lysosomal rupture in which all these sequences of 
events lead to early morphological manifestion of plasma membrane rupture.  The 
latest finding by Golstein and his colleague again showed similar manifestations 
(Laporte et al, 2007). 
 
Zong and Thompson (2006) in their review have suggested that the bioenergetics 
failure and rapid loss of plasma membrane integrity was the core for necrotic cell 
death. The rapid loss of cellular membrane potential may lead to mitochondrial 
dysfunction hence depletion of ATP production. Thus the decline of ATP 
dependant ion pump in cytoplasmic membrane activates the opening of the death 
channel to force the entry of colloids and cations which in turn causes the 
membrane to swell and finally rupture. Calcium is also reported to be the mediator 
for necrotic cell death. Under normal circumstances, plasma membrane and 
intracellular membrane are impermeable to Ca2+ and the cytosol usually has low 
concentration of Ca2+ which is stored in endoplasmic reticulum (ER). However 
under certain pathological conditions, extracellular ligand either at plasma 
membrane or ER membrane will be activated. The Ca2+ from ER may leak out to 
the cytosol, thus activating the death receptor due to activation of Ca2+ dependant 
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proteases and /or mitochondrial Ca2+ overload.  ROS is also proposed to be the 
initiator of necrosis in which the mitochondria is the main source. Under 
pathological stimulus which causes mitochondrial dysfunction, excess production 
of ROS may cause DNA damage to activate p53 and poly-ADP ribose polymerase 
(PARP) which has an important role in the recognition of DNA damage and in 
DNA repair (Herceg and Wang, 2001). P53 activation may cause apoptosis or cell 
arrest, whereas the hyperactivation of PARP may cause necrosis. In addition, ROS 
may cause lipid peroxidation in plasma membrane which in turn causes loss of 
membrane integrity including the intracellular membranes such as ER and 
lysosomes, leading to consequences of leaking proteases, Ca2+  influx and 
ultimately necrosis (Zong and Thompson, 2006; Waring, 2005). Other proteases 
also could trigger apoptosis, such as calpains and cathepsins, which were already 
discussed in section 1.6.2.1. As mentioned previously, necrotic cell death may 
cause a subsequent inflammation process. A lack of signalling during necrosis 
may prevent phagocyte recruitment to clean up the cell debris. Numerous studies 
have indicated that the subsequent inflammation event in necrotic cell death is due 
to the release of chromatin protein called high mobility group 1 (HMGB1) which 
leaks rapidly when membrane integrity is lost  and which becomes a potent 
mediator for the inflammatory process ( Scaffidi et al, 2002; Andersson et al, 
2000). 
 
As described in section 1.6.2, necrosis also has currently been viewed differently 
as Majno and Joris (1995) regarded necrosis as not the way of cell death but 
representative of the end stage manifestation of cell death. According to them, 
upon receiving certain stimulus, the cells may undergo apoptosis at low doses and 
necrosis at higher dose and sometimes both apoptotic and necrotic features 
present in the same cells. At the end of apoptotic death if the cells fail to be 
engulfed by neighbour cells or macrophages, then cells may die by necrosis as the 
plasma membrane and cellular energy were compromised. Thus a new term 
‘apoptosis necrosis’ or ‘secondary necrosis’ was introduced (Majno and Joris, 
1995).  
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1.6.3 In vitro cell death assessment 
Various in vitro test systems are available to determine the cell death upon 
xenobiotic insult. This assessment can either be tailored to determine cell 
morphology characteristics, biochemical or even the molecular changes. Various 
methods have been developed for identification of living and dead cells which 
could easily be differentiated during microscopic examinations or by other means 
such as fluorescence using a plate reader or by flow cytometry analysis. The 
methods developed were based on difference capability of intracellular intake or 
dye processing between live and dead cells. Such methods includes the use of 
coloured dyes such as trypan blue, eosin, nigrosin or fast green or fluorescence 
dyes such as fluoresceine diacetate, propidium iodide, acridine orange or ethidium 
bromide (Cianco et al, 1988). As discussed in section 1.6.1 morphology of 
apoptosis and necrosis can be detected via microscopic examinations. The use of 
common histochemistry staining such as Wright-Giemsa stain which contains 
methylene blue and eosin will aid in identifying the nucleus and cytoplasm based 
on different  colouration, methylene blue stained nucleus  blue-purplish and eosin 
stained cytoplasm pink (Colomick et al, 1979). Microscopic technique may also 
be used to study the detailed morphology of cell death (apoptosis) by using 
electron microscopy (Odaka and Ucker, 1996). Other common techniques to 
identify apoptosis use specific immunochemical labelling and proceed with 
microscopic examination include TUNEL assay (terminal deoxynucleotidyl 
transferase dUTP nick end labeling) (Negoescu et al, 1998). 
 
The trypan blue exclusion assay using trypan blue dye is a reliable, inexpensive 
and common test for viability (Puranam and Boustany, 1998; Perry et al, 1997). 
The principle of using this dye is that viable cells will exclude the dye and remain 
clear or white whereas the non-viable cell will take up the dye and thus stain blue 
when visualised under microscopic examination. The cells which have lysed 
plasma membrane, such as in late apoptosis, are permeable to dye (Puranam and 
Boustany, 1998). The trend in using combinations of two different dyes is 
becoming common in differentiating the mode of cell death, such as combination 
of Hoechst dye and propidium iodide (PI) in determining cell cycle specific cell 
death (Cianco et al, 1988); Annexin V conjugate dyes with fluorescein dye either 
33 
 
FITC (fluorescein isothiocyanate) or PI (Vermes et al, 1995) or 7-AAD (7-
Amino-actinomycin D) (Schmid et al, 1992).  
 
Other in vitro cytotoxicity assays which assess the biochemical activity of 
damaged cells include lactate dehydrogenase assay (LDH) which in principle 
measures the release of lactate dehydrogenase enzyme during pathological states 
such as cell injury due to chemical insults (Legrand et al, 1992). Other well 
known assays includes MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) which is a metabolic assay in which tetrazolium salt 
is metabolised by mitochondrial dehydrogenase enzyme to form dark blue 
formazan in living cells. Therefore the level of colorimetric detection of formazan 
is proportional to the number of surviving cells (Mosman, 1983). A longer term 
assessment for determining the capability of cells to retain the capacity for 
proliferating after treatment with cytotoxic agents is the clonogenicity assay. 
Principally, this colony formation assay is a survival based assay to see the ability 
of single cells to form a colony that contains at least 50 cells (Ansah et al, 2004). 
 
As a protease family, caspases play an important role in initiation and execution 
of apoptosis, therefore in vitro assessment using these enzymes as a marker of 
apoptosis is essential in apoptosis research (Lavrik et al, 2005). Many commercial 
kits tailored to detect several important caspases such as Caspase 3, 7, 8, and 9 are 
readily available and most of them can either be analysed via flow cytometry, 
fluorescence or even absorbance measurement. The assessment of p53 levels and 
its target gene p21 which are highly associated with apoptotic cell death can also 
be investigated using many in vitro approach such as immunoblotting (Western 
blot), fluorescence image cytometry etc (Mckenzie et al, 1999).  The generation of 
ROS in mediating the cell death should also be a major concern in investigating 
the in vitro assessment of cell death as ROS is a major indicator for mitochondrial 
dysfunction which in turn could activate many forms of programmed cell death 
(Tan et al, 1998) and a common method to measure the ROS generation in live 
cells is using the 2,7-dichlorofluorescein dye (DCFH) (Esposti, 2002). 
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1.7 Justification, Objectives and Hypothesis 
1.7.1 Justification 
The use of Mitragyna speciosa Korth or kratom leaves is now popular among 
traditional users and drug addicts in Southeast Asia mainly in Malaysia and 
Thailand. With no legislation against possession in other countries, apart from the 
source countries including Australia, kratom leaves are becoming popular for self-
treatment and as an aid for opiate withdrawal treatment and furthermore the 
numerous vendors selling this plant over internet has made it widely available to 
people around the globe. The recent findings on its potent analgesic properties and 
other benefits such as for antidepression and antitussive have also added potential 
therapeutic values for human use.  To date, despite the chemical and 
pharmacological effects which are well established, there is no published report 
on the potential cytotoxicity of this plant or its derivatives.  
 
1.7.2 Hypothesis 
To my knowledge, this study is the first to assess cytotoxicity potential of MSE 
and MIT. MIT is believed to be a major contributor to the analgesic effects of this 
plant. Therefore, it is hypothesised that ‘The use of MSE and MIT may have 
potential cytotoxicity effects’ 
 
1.7.3 Aims and Objectives 
Since the potential toxicity of this plant is yet to be elucidated, I am aiming to 
initiate toxicology research of this plant using in vitro studies to investigate the 
possible mechanisms involved. The overall objective for this study is: 
‘ Characterisation of in vitro cytotoxicity and genotoxicity effects of MSE and 
MIT’  
 
The sub-objectives are to be: 
1. Examine the cytotoxic effects of MSE and MIT on cell growth and cell 
cycle of panels of human cell lines. 
2. Investigate the potential genotoxicity of MSE and MIT in mammalian cell 
lines. 
3. Determine the possible mechanisms of MSE and MIT induced-cell death. 
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CHAPTER 2 
 
EFFECTS OF MSE AND MIT ON THE GROWTH AND 
SURVIVAL OF HUMAN CELL LINES 
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2.1 Introduction 
MSE is a methanol-chloroform extract of Mitragyna speciosa Korth (MSE) or 
also known as alkaloid extract from which the dominant alkaloid mitragynine 
(MIT) is obtained.  The chemistry and pharmacology of the leaves of this plant, 
especially the extract and MIT, has already been established and known to exert 
opioid agonistic effects (Jansen and Prast 1988, Thongpradichote et al 1998, 
Takayama 2004). MIT congener, 7-hydroxymitragynine was confirmed in in vivo 
and in vitro to have potent opioid effects (Matsumoto et al, 2006). Despite the 
well-established pharmacological properties of this plant, the toxicological 
outcomes are yet to be fully established.  In spite of abuse by drug addicts as an 
opium substitute, there is little information on its potential toxicity.  The adverse 
effects reported upon consumption of this plant especially on drug addicts and 
traditional users are dry mouth, thin body with unhealthy complexion (dry skin 
and dark lips resembles hepatic face), frequent urination, constipation coupled 
with small and blackish stools, loss of appetite, weight loss, central nervous 
depression, reduced smooth muscle tone and for heavy users prolonged sleep 
(Grewal 1932, Suwanlert 1975). 
 
In this part of the study therefore, the in vitro toxicology of MSE and MIT has 
been examined with several mammalian cell lines.  In addition, currently nothing 
is known on any involvement of mammalian metabolism in MSE and MIT 
associated toxicity.  Therefore, to examine this objective, both metabolically 
competent and non-competent cell lines and also rat liver post mitochondrial 
supernatant (S9) have been used to examine the potential role of metabolism in 
toxicity.  MSE was the main agent used in this study. It has been proposed that 
MSE extracted using modification of Houghton and Ikram method (1986) 
contains more MIT than any other reported crude extraction processes 
(Baharuldin, 2000). MIT was obtained from two sources; IMR, Malaysia and 
from Japan.  
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2.2 Materials and methods 
2.2.1 Chemicals and reagents 
The young leaves of Mitragyna speciosa Korth were collected from the forest in 
Behrang Stesen, Selangor, Malaysia and were processed to obtain the methanol-
chloroform extract (MSE) at International Islamic University of Malaysia (IIUM).  
Trace amounts of MIT were obtained from Institute of Medical Research (IMR) 
Kuala Lumpur, Malaysia and used as a reference sample.  Larger quantities of 
MIT were a kind donation from Prof. Hiromitsu Takayama from University of 
Chiba Japan, and were used throughout the study.  The MSE was analysed with   
UV-VIS spectroscopy to determine the percentage of MIT present.  MIT of the 
different sources was compared via 1D-H-NMR spectra to confirm its purity.  
 
Minimum Essential Medium (MEM), Dulbecco’s Minimum Essential Medium 
(DMEM) with high glucose (Glutamax®) but without sodium pyruvate), DMEM 
with high glucose with sodium pyruvate, fetal bovine serum (FBS), L-glutamine, 
antibiotics (100 iu/ml penicillin and 100 µg/ml streptomycin) and hygromycin B,   
trypsin/ethylenediamine tetra-acetic acid  (Trypsin/EDTA), Dulbecco’s phosphate 
buffer saline (D-PBS without magnesium and calcium)  were purchased from 
Invitrogen Corporation (Paisley, Scotland, UK). Essential amino acids (1% v/v), 
phosphate buffer saline tablets, trypan blue solution (0.4%) and all other 
chemicals unless stated in the text were obtained from Sigma-Aldrich Company 
(Poole, England).  Reagents used for the 1D-NMR studies were purchased from 
Sigma-Aldrich Company. 
 
2.2.2 Cell Lines and culture conditions 
Human hepatoblastoma epithelial (HepG2) cells, MCL-5 cells, a human 
lymphoblastoid cell lines transfected with two plasmids encoding multiple 
cytochrome P450s – CYP1A2, 2A6, 2E1, 3A4 and epoxide hydroxylase genes, 
and  inducible constitutive CYP1A1 (Crespi et al., 1991),  and cHol cells (human 
lymphoblastoid) cells without metabolic activities (metabolically non-competent),  
were from tissue culture stock of the Unit of Molecular Toxicology, Department 
of Biomolecular Medicine, Faculty of Medicine, Imperial College London.  HEK 
293 (Human embryo kidney cells) was a kind donation from Professor Tony 
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Magee, Department of Molecular and Cellular Medicine, Division of National 
Heart and Lung Institute, Faculty Medicine, Imperial College London. 
 
SH-SY5Y (Human neuroblastoma cells) was a kind donation of Dr. Huseyin 
Mehmet from the Institute of Reproductive and Developmental Biology, Division 
of Clinical Sciences, Faculty of Medicine, Imperial College London.  This cell is a 
subclone of SK-N-SH (another human neuroblastoma cell) and exhibits a 
heterogenous population of µ- and δ-types of opioid binding sites (Kazmi and 
Mishra, 1986).   
 
HepG2 cells, an adherent cell line, was routinely cultured in pre-warmed sterile 
MEM  (37ºC in water bath) supplemented with 10% of fetal bovine serum (FBS), 
antibiotics (100 iu/ml penicillin and 100 µg/ml streptomycin), 1% v/v essential 
amino acids and 2 mM L-glutamine. This cell was grown in culture flasks with 
media (15ml media/175 cm3) and incubated at 37ºC, in a humidified atmosphere 
of 95%/5% air/CO2.  Cells were harvested after reaching ~ 80% confluence where 
the cells were present as monolayer.  Media was aspirated and the cells were 
washed with pre-warmed PBS (7.5 ml/175 cm3) to remove all traces of serum.   
Trypsin-EDTA (0.25% Trypsin; 1mM EDTA, 2 ml/75cm2 flask) was pipetted 
onto the flask surface, covering all cells and the culture flask was returned to the 
incubator for 5 minutes to facilitate cell detachment.  An equal volume of media 
was added to inactivate the trypsinisation process and dislodgement of the 
monolayer cells was confirmed microscopically with gentle tapping of the flask.  
The mixture was transferred into a 20 ml universal tube and centrifuged at 1000 
rpm (200 g) for 5 min at 25ºC.  The supernatant was aspirated and the cell pellets 
were resuspended in appropriate volume of media.  Subculture was routinely 
carried out, with cells seeded at 1:5 dilutions.  For cryo-storage, harvested cells 
(1x 106) were suspended in 10% dimethyl sulfoxide (DMSO) in culture medium 
in 1 ml sterile vials.  They were then frozen at -80ºC overnight before final 
transfer and storage in vapour phase liquid nitrogen (-196ºC). 
 
MCL-5 cells, a suspension cell, were grown in pre-warmed RPMI 1640 (without 
histidine and with 2mM histidinol for plasmid selection), supplemented with 9% 
horse serum, 2mM L-glutamine, 100 iu/mg penicillin and 100 µg/ml streptomycin 
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and 100 µg/ml hygromycin B (at each sub-culturing for plasmid maintenance). 
cHol, also a suspension cell, was cultured in  MCL-5 medium but without 
hygromycin B.  Sub-confluent cells were centrifuged (1000 rpm for 5 minutes) 
and seeded at 2.5 x 105 cells/ml and allowed to grow to a density of 106 cell/ml.  
Sub-culturing was carried out approximately every 48 hrs by dilution with pre-
warmed medium to the initial density of 2.5 x 105 cells/ml.   
 
HEK 293 cells, adherent cells, were grown in DMEM (with high glucose, sodium 
pyruvate and L-glutamine) and supplemented with 10 % FBS, 100 iu/ml penicillin 
and 100 µg/ml streptomycin.  Cells were harvested upon reaching 80-90% 
confluence.  The media was removed and the cells were washed with D-PBS.  
One ml Trypsin-EDTA was added, spread over the cells surface.  Excess Trypsin-
EDTA was removed prior to incubating for 1-2 minutes for detachment of the 
cells.  Fresh medium was added to inactivate the trypsinisation process and for 
detachment of cells.  The suspended cells were split 1:3, every 3-4 days.   
 
SH-SY5Y cells, also an adherent type of cell, were grown in DMEM (with high 
glucose, Glutamax® without sodium pyruvate) and supplemented with 10% of 
FBS, 100 iu/ml penicillin and 100 µg/ml streptomycin.  Cells were grown to 
subconfluency and harvested as described for HepG2 cells.  
 
2.2.3  Resuscitation of frozen cells 
Vials recovered from liquid nitrogen storage were rapidly brought up to room 
temperature (1 min) then transferred to 37ºC in a water bath (1 min) in order to 
minimises the toxic effects exerted by the cryoprotectant DMSO on thawed cells.  
The content of the vial (1.0 ml) was transferred to a culture flask containing pre-
warmed media and incubated as described above.   
 
2.2.4  Cell quantification and viability 
For the purpose of quantification, 50 µl of cells suspended in media were diluted 
by trypan blue solution (0.4%) (1:3) and an aliquot (5 µl) transferred to the 
chambers of an improved Neubauer haemocytometer by capillary action.  
Viability was determined by counting the viable and non-viable cells in at least 
four of the nine major squares of the haemocytometer; viable cells appear white 
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and non-viable cells appear dark blue (take up the trypan blue dye).  Derived 
values were used to estimate cell concentration and percentage viability. The cell 
concentration was calculated based on the volume underneath the cover slip 
occupied one large square (see W in fig. 2.1 has a volume of 0.0001 ml, length x 
width x height; i.e., 0.1 cm x 0.1 cm x 0.01 cm) (Hansen, 2000). 
Cell concentration per/milimeter = Total cell count in 4 squares x 2500 x dilution 
factor. 
 
 
 
 
 
 
 
 
 
                            
 Fig. 2.1 Counting procedure for haemocytometer 
 
2.2.5 Preparation and analysis of methanol-chloroform extract of 
Mitragyna speciosa Korth (MSE) 
2.2.5.1 Chemicals and reagents 
Methanol and Chloroform were obtained from BDH (UK).  Bismuth (III) nitrate 
pentahydrate, acetic acid and potassium iodide for preparation of Dragendorf test 
solution, was obtained from Sigma-Aldrich (UK). 
 
2.2.5.2 Sample 
The young leaves of Mitragyna speciosa Korth were obtained from Behrang 
Stesen, Selangor state in February 2005.  The leaves were identified with the help 
of a police officer from the Narcotic Department of Selangor state and further 
verified by a researcher from the Herbal and Medicine Research Centre (HMRC) 
of the Institute of Medical Research (IMR) Kuala Lumpur.  The leaves were air 
dried for a few hours and further dried overnight in an oven at 60ºC.  They were 
ground with the special plant grinder at IMR.  The rough parts of the leaves were 
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separated from the powder.  The powdered form of the leaves was kept in an air 
tight container in a dry room to avoid humidity.   
 
2.2.5.3 Extraction using organic solvent (modification of Houghton and 
Ikram Method, 1986) 
About 500 g of dried powdered leaves were soaked in 2 L of methanol for about 3 
days.  The mixture of methanol and the leaves were filtered and the filtrate was 
dried using a rotary evaporator.  The crude methanol extract obtained appeared 
greasy with a dark green colour.  
 
The crude methanol extract was re-dissolved in 300 ml chloroform and the 
mixture was transferred into a separating funnel.  Four hundred (400 ml) of 
distilled water was added  to the separating funnel and the mixture was shaken 
thoroughly then left to stand  until two layers were formed. The bottom layer 
(organic layer) was collected and the upper layer (aqueous layer) was re-extracted 
with the chloroform again and this step was repeated three times.  The collected 
organic layer was filtered through sodium sulphate anhydrous and the organic 
filtrate was further dried by rotary evaporator.  The crude chloroform extract 
obtained appeared greasy and very dark green in colour.  
 
2.2.5.4 Analysis of MSE and MIT 
Dragendorf test was used to confirm the presence of alkaloids in the extract of 
Mitragyna speciosa Korth.  Under these conditions, alkaloids present appeared 
orange in colour.  MSE fractionation was performed using solid phase extraction 
(SPE) method using polymeric strong cationic exchange sorbent which was a kind 
gift from Phenomenex Company (U.K). The extraction method was a modified 
procedure of the SPE method, also obtained from Phenomenex Company. Briefly, 
0.4076g MSE was weighed and dissolved with 3 ml absolute methanol and 21 ml 
20% formic acid. The mixture was filtered with 0.45 µM filter to obtain a 
yellowish-orange colour filtrate (18.7 ml filtrate). Replicate filtrates (4.5 ml each) 
were used for SPE separation. Each SPE was conditioned with 4.5 ml absolute 
methanol followed by equilibration with 4.5 ml phosphoric acid buffer at pH 3. 
Filtrate sample (4.5 ml) was loaded into the SPE and the eluant was collected in a 
glass vial. The SPE column was then washed with 2% formic acid (4.5 ml) and 
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the second fraction was collected in different vial. Methanol (4.5 ml) was used for 
the next washing and the fraction was again collected. Finally, the SPE was eluted 
with 5% ammonia in acetonitrile: methanol (1:1) (4.5 ml) and the final fraction 
was collected.  The MSE fractions obtained were analysed for MIT-like 
compound by UV-VIS spectroscopy (WPA lightwave II).  The maximum 
absorbance of varying concentrations of MIT was determined. A standard curve 
was generated using synthetically pure MIT from which the MIT content in MSE 
fractions was estimated.   
 
1D-NMR analyses of MSE and MIT of the different sources (Malaysia and Japan) 
were performed using 1H-NMR 400 Mhz spectrometer (Bruker). MSE sample 
was dissolved in absolute ethanol and centrifuged at 1000 r.p.m for 5 minutes and 
the supernatant was collected. The MSE supernatant (100 µl) was then transferred 
into a NMR tube (Norell, USA) and diluted with deuterated methanol (CD3OD) 
(500 µl) and 0.01% of internal standard, 3-(Trimethylsilyl)propionic-2,2,3,3-d4 
acid sodium salt (TSP) which act as a standard reference signal was added to the 
sample. MIT sample was also prepared as MSE however did not undergo 
centrifugation process.  
 
2.2.6 Wound assay 
The ‘wound assay’ is a simple and effective method to determine the effects of 
treatment on cell growth and migration.  The principle of this method is to create a 
‘wound’ in a confluent monolayer of cells and monitor the growth and migration 
of the cells across the wound after chemical treatment.  
 
SH-SY5Y cells were seeded in 6 well plates and allowed to grow to confluence in 
DMEM Glutamax® media. The cells were then maintained in serum free media 
for 24 hr. After 24 hr, the medium was aspirated, the cells were washed twice with 
PBS and a 200 µl pipette tip was used to mark a cross in the monolayer of cells in 
each well (refer to figure 2.2).  Enough pressure was applied to completely cut 
through the layers of cells. The cells were then washed with PBS again and 
visualised microscopically to ensure adequate cut had been made in a cross 
pattern in each well. 
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Fig. 2.2. View of a well from above. This diagram shows the cross pattern made 
in the monolayer of the cells. Indicated numbers 1-4 are the sites where digital 
photographs were taken. 
 
Serum free media was added to respective wells and treated with various 
concentrations of MSE. Triplicate wells of 10% FBS media for control group 
were also added for comparison. After 24 hr incubation, the medium was 
aspirated and the cells were washed with PBS. Digital photographs were taken of 
each well at magnification x400. Two pictures were taken for each well as 
indicated in the figure 2 above. The medium was replaced and the cells were 
treated again as before and returned to incubator. This process was repeated at 48 
hrs.   
 
2.2.7 Cytotoxicity assay and proliferation assay using CytoTox-One™  
homogenous membrane integrity assay kit 
This is a homogeneous fluorometric method for estimating non-viable cells and 
also to estimate the total number of cells present in culture.  The basic principle of 
the assay is measurement of fluorescence due to the release of lactate 
dehydrogenase (LDH) from cells with a damaged membrane.  LDH released into 
the culture medium is measured with a 10-minute coupled enzymatic assay that 
results in the conversion of resazurin into resorufin.  For cytotoxicity assay; MSE 
treated HepG2 cells were cultured as described in section 2.2.2 in 96 well plates 
for 24, 48, 72 and 96 hour-period.  Lysis solution (containing Triton®X-100) was 
added to the positive control wells and  CytoTox-One™ reagent (Promega) was 
added to all samples and incubated at 37ºC for 10 min.  The reaction was 
terminated with stop solutions provided with the kit.  The plate was read using a 
fluorescent plate reader with an excitation wavelength of 560 nm and emission 
wavelength of 590 nm.  The percentage of cytotoxicity was calculated by : 
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Percent toxicity = 100 x   (Experimental – Culture medium background) 
   (maximum LDH release – Culture medium background) 
 
The total number of cells in each assay well was assessed using the proliferation 
assay protocol.  This involved lysing all cells to release LDH followed by adding 
the Cyto-Tox™ reagent.  The total number of cells present was directly 
proportional to the background-subtracted fluorescence values, which were 
proportional to LDH activity. 
 
2.2.8 Cell viability by Trypan blue exclusion assay 
In order to estimate the percentage of dead cells after treatment with MSE or MIT, 
cells were harvested by centrifugation and with trypsinisation for adherent cells.  
The cells were then stained with trypan blue solution (0.4%) and the number of 
trypan blue-positive and trypan blue negative cells were counted with a 
haemocytometer under a light microscope.   
 
2.2.9 Colony survival (clonogenicity assay) 
For survival studies, 24 hour-treated cells (SH-SY5Y and HEK 293 cells) were 
trypsinised, centrifuged and reseeded at 100 cells per well in 6 well plate for each 
dose of MSE, in 2 ml drug-free medium and incubated for a period of 6-7 days.  
The wells were stained with methylene blue (1% in 50% methanol) and colonies 
that contained 50 or more cells were scored as survivors. Relative cell survival 
was expressed as percentage of appropriate vehicle-treated controls. 
 
2.2.10 Investigation of the possible role of metabolic involvement in the 
toxicity of MSE  
The effect of possible involvement of metabolism was investigated using post 
mitochondrial supernatant S9 from rat liver induced by Arochlor 1254, a kind gift 
from Prof. Costas Ionnides of University of Surrey, U.K.  Cells (0.5 x 105) were 
treated with various concentrations of MSE with or without S9 (8.71 µg/µl 
protein).  Cells treated with S9 and MSE were incubated with shaking at 37ºC (50 
rpm speed) for 3 hr. After 3 hr incubation, the cells were washed with PBS (for 
SH-SY5Y cells) or D-PBS (for HEK 293 cells) by centrifugation, resuspended in 
drug-free medium and reseeded for clonogenicity as described above. 
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To further examine the involvement of metabolism in MSE and MIT associated 
toxicity, specific inhibitors of metabolic enzymes were used.  The inhibitors used 
were 25 µM ketoconazole (KT), a CYP 3A4 inhibitor (Gibbs et al., 2000); 100 
µM diethyldithiocarbamate (DED), a CYP 2A6 inhibitor (Chang et al, 1994); 25 
µM alpha-naphthoflavone (α-N), a CYP 1A inhibitor (Chang et al, 1994) and 25 
µM 3-amino-1,2,4-triazole (ATZ), a CYP2E1 inhibitor (Koop, 1990).  MCL-5 
cells (1 x 105) were seeded overnight in 24 well plates, then treated with various 
concentrations of MSE or MIT in the presence of metabolic inhibitors and 
incubated for 24hr (at 37ºC in 5% CO2).  AlamarBlue® (10% v/v) (AbD Serotec, 
U.K) was added to each well and further incubated for 1 hr prior to fluorescence 
measurement (530 nm excitation/590 nm emission). The cells were returned to the 
incubator for another 24 hr and another reading was made at the 48 hr time point. 
 
Another set of experiment were also performed to support the AlamarBlue® 
finding. Trypan blue exclusion assay was employed using MCL-5 cells (1 x 105) 
treated with the same enzyme inhibitors and MSE /MIT concentrations as 
described earlier and the cells were incubated for 48 hr time point. Cell viability 
was assessed as routine Trypan blue exclusion procedure described in section 
2.2.8. 
 
2.3 Statistical analysis 
One way Analysis of variance (ANOVA) with Tukey-Kramer or Dunnet post tests 
was conducted to calculate the significant of differences where p-values of <0.05 
were considered significant. 
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2.4 Results 
2.4.1 Analysis of MSE using UV-VIS spectrometer 
A UV-VIS spectrometer (WPA Lightwave II) was utilised for estimating the MIT 
content in the MSE fraction samples by measuring UV spectral characteristics of 
MIT.  Using pure MIT referral compound, the UV spectrum exhibited a maximum 
absorbance at 227 nm. A standard curve for MIT was generated (Fig. 2.3). The 
absorbance reading for each MSE fraction at 227 nm wavelength was recorded. 
Using the equation derived from the MIT standard curve, an estimation of MIT 
present in each MSE fraction was calculated (refer to Appendix 1 for details of 
calculations).    Based on this calculation, it was estimated that MSE contained 
approximately 42% MIT-like compound. 
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Fig. 2.3  Calibration curve for MIT. The UV spectra were determined using UV-
VIS spectrometer at concentrations of 1 to 500 µM under standard conditions of 
room temperature.   
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2.4.2 Analysis of MSE and MIT using 1H-NMR 
The 1H-NMR spectra in fig. 2.4 confirms the similarity of the spectral peaks 
present in both sources of pure MIT compound. However after expansion of 
spectral region between 4.5 – 8.2 ppm the presence of an extra minor peak 
identified as chloroform (CHCl3) is evident in the MIT sample from Japan. The 
same peak at the same region was also observed in the MSE spectral. Any 
chloroform contamination of the mitragynine sample from Malaysia was below 
the limit of detection.   
 
 
 
Fig. 2.4 400 MHz 1H-NMR spectra of MSE and MIT standards from Malaysia 
and Japan. The arrows indicate the presence of chloroform (CHCl3) peak at 7.9 
ppm . Spectral region between 4.5-8.2 ppm (       )   was expanded 7 times for 
clarity. 
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2.4.3 Digital photographs from the wound study  
Wound study or also known as wound healing assay is a simple, inexpensive 
method to estimate the migration and proliferation rates of different cells under 
different culture conditions. The method has been described as a wound healing 
assay as it mimics cell migration during wound healing in vivo (Rodriguez et al, 
2005).  As described in the procedure in section 2.2.6, the wound created in a 
monolayer of SH-SY5Y cells was assessed and photographs were taken at 24 and 
48 hrs after treatment with various concentrations of MSE.  
 
In the absence of FBS (Panel A), the SH-SY5Y cells failed to proliferate or 
migrate into the wound area (refer to fig. 2.5).  In the presence of FBS (Panel B), 
it can clearly be seen that the cells proliferated and migrated into the wound area.  
In the presence of MSE (without FBS), no proliferation or migration was 
observed (Panels C,D, E and F).  In fact cell toxicity was observed with increasing 
dose of MSE, to the extent that at the highest dose (250 µg/ml) all cells were dead 
by the 24 hr time point. 
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                           24 hrs                                                           48 hrs 
       A                                               
                                           Control (Ethanol) -0% FBS media 
       B                              
                                            Control (Ethanol) – 10% FBS media 
        C                             
                                            10 µg/ml MSE -0% FBS media 
        D                             
                                          50 µg/ml MSE -0% FBS media    
        E                             
                                        100 µg/ml MSE -0% FBS media 
        F         
                                         250 µg/ml MSE -0% FBS media 
 
 
Fig. 2.5  Digital photographs of the effects of MSE on proliferation and migration 
of  SH-SY5Y cells after 24 and 48 hr treatment  in serum-free media. The arrow  
(        ) indicated wound area. 
Photograph not taken 
as cells were already 
dead at 24 hrs   
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2.4.4 Effect of MSE on HepG2 cells: Cytotoxicity and proliferation using 
CytoTox-One™ homogenous membrane integrity assay kit 
In order to examine the in vitro toxicity of MSE, the effect of the mixture on 
HepG2 cells was examined.  In the first instance, MSE was incubated with cells 
and toxicity examined using the CytoTox-One™ Homogenous Membrane 
Integrity Assay.  The basis of the assay is measurement of fluorescence due to the 
release of lactate dehydrogenase (LDH) from cells with a damaged membrane.  
After 24 hr of treatment, there was a dose-dependant toxicity trend seen with the 
MSE (Fig. 2.6A).  However the trend towards toxicity was only seen at doses of 
MSE in excess of 0.113 μg/ml but failed to reach statistical significance over the 
concentration range examined (Fig. 2.6A).  Similarly no statistically significant 
toxicity was observed on HepG2 proliferation over this dose range (Fig. 2.6B). A 
complication found using this assay was that high concentrations of MSE 
interfered with the assay measurement.  Therefore an alternative assay (Trypan 
blue exclusion) was used to examine the effect of higher concentrations of MSE 
on cell toxicity. 
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Fig. 2.6 Effect of MSE on cytotoxicity (A) and proliferation (B) of HepG2 cells 
after 24 hr of treatment.  The enzymatic reaction (LDH activity) was determined 
by fluorescence with an excitation wavelength of 560 nm and emission 
wavelength of 590 nm.  Values are means of triplicates. Bars are standard error of 
the mean (SEM). 
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2.4.5 Cell viability by Trypan blue exclusion assay 
To assess the effect of MSE on cell proliferation and viability, the Trypan Blue 
exclusion assay was performed. This assay could be used with much higher 
concentrations of MSE and showed dose and time-dependency in cell 
proliferation and viability.  The individual results for each type of cell line are as 
follow: 
a.  HepG2 cells 
Within 24 hr, there was a clear dose-dependent loss of cell proliferation compared 
to the vehicle-treated control (Fig. 2.7A).  The effect became pronounced at doses 
higher than 1.13 µg/ml and there was considerable inhibition of growth at the two 
highest doses. With vehicle-treated control, there were very few cell dead cells, 
irrespective of the time in culture.  There was a distinct threshold for cytotoxicity 
at doses higher than 11.3 µg/ml.  After 24 hr incubation with MSE, it appeared 
that 100 % of HepG2 cells were dead at the highest concentration of MSE tested, 
1130 µg/ml (Fig. 2.7B).  The IC50 value for MSE cytotoxicity in this cell is 
estimated as 230.8 µg/ml MSE for 24 hr treatment (Table 2.1). 
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Fig.2.7 Cell proliferation (A) and percentage of dead cells (B) in MSE treated 
HepG2 cell cultures as determined by the Trypan blue exclusion assay.  Cells 
were treated for 24, 48 and 72 hrs and harvested as described in the methods.  
Values are the mean of duplicate cultures. 
 
b. MCL-5 cells 
With the metabolically competent MCL-5 cells, there was a pronounced dose-
dependent inhibition of cell proliferation at all concentrations of MSE within 24 
hr (Fig. 2.8A).  By 48 hr, proliferation of cells treated with the lowest 
concentration of MSE (1.13 µg/ml) had recovered and was similar to vehicle-
treated control; however, inhibition of proliferation remained pronounced at all 
other MSE concentrations. 
 
As with the HepG2 cells, MSE associated cell death was only apparent at doses 
higher than 11.3 µg/ml (Fig. 2.8B).  Hundred percent of mortality rate was 
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observed in MCL-5 cells after 24hr incubation with the highest concentration of 
MSE, 1130 µg/ml.  The viability of the cells at 113 µg/ml also remains low 
throughout the experiment (Fig. 2.8A).  The IC50 for this cell at 24 hr period is 
410.3 µg/ml MSE (Table 2.1). 
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Fig. 2.8  Proliferation (A) and percentage of dead cells (B) in MSE treated MCL-5 
cell cultures as determined by the Trypan blue exclusion assay.  Cells were treated 
for 24, 48 and 72 hrs and harvested as described in the methods.   Values are the 
mean of duplicate cultures. 
 
c.  cHol cells 
As before, with cHol cells (identical to MCL-5 cells, but metabolically non-
competent) there was a dose-dependent inhibition of cell proliferation at doses 
higher than 11.3 µg/ml MSE (Fig.2.9A).  In fact at both 113 and 1130 µg/ml 
MSE, there was a pronounced loss of cell number below the initial seeding 
density. 
As with HepG2 and MCL-5 cells, the cHol cells also show the same effects 
(100% death) after 24 hr treatment with MSE at the highest concentration, 1130 
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µg/ml (Fig. 2.9B).  The IC50 for this cell at 24 hours treatment is 282.1 µg/ml 
MSE (Table 2.1). 
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Fig. 2.9  Proliferation (A) and percentage of dead cells (B) in MSE treated cHol 
cell cultures as determined by the Trypan blue exclusion assay.  Cells were treated 
for 24, 48 and 72 hrs and harvested as described in the methods.  Values are the 
mean of duplicate cultures. 
 
 
d. HEK 293 cells 
With HEK 293 cells, MSE again caused a dose-dependent inhibition of cell 
proliferation that became particularly evident at doses equivalent or higher than 
113 µg/ml (Fig. 2.10A).  This inhibition of proliferation persisted up to 72 hr (the 
duration of the study).  In parallel, cell death became prominent at all time points 
with 113 and 1130 µg MSE/ml (Fig. 2.10B).  
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Using pure compound, MIT induced a differential response with the HEK 293 
cells.  At very low doses (3.33 x 10-9 - 3.33 x 10-5 M), MIT apparently stimulated 
cell proliferation that persisted up to 96 hr (Fig.2.10C).  This stimulation was 
small but consistent at 48 hr to 96 hr.  At higher doses of MIT (3.33 x 10-4 – 3.33 
x 10-3 M), cell proliferation was inhibited (Fig. 2.10C).  These concentrations also 
induced substantial cell death (Fig. 2.10D).  The IC50 of these cells at 24 hours 
treatment are estimated as 282.1 µg/ml MSE and 2.4 x 10-4 M MIT respectively 
(Table 2.1). 
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Fig. 2.10  Proliferation (A & C) and percentage of dead cells (B & D ) in MSE 
and MIT treated HEK 293  cells as determined by the Trypan blue exclusion 
assay.  Cells were treated for 24, 48, 72 and/or 96 hrs and harvested as described 
in the methods.   Values are the mean of duplicate cultures. 
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e. SH-SY5Y cells 
With SH-SY5Y cells, low doses MSE (0.0113 – 1.13 µg/ml) increased cell 
proliferation compared to vehicle-treated control at 24 hr (Fig. 2.11A), whereas 
higher doses (113 – 1130 µg/ml) inhibited proliferation at all time points. These 
higher doses of MSE also substantially increased cell death within 24 hr (Fig. 
2.11B).   
 
With pure MIT, there was again a stimulation of cell number at low doses (< 11.3 
µg/ml) and inhibition of cell proliferation at higher concentrations (> 11.3 µg/ml) 
(Fig. 2.11C).  As with the other of cell lines, this inhibition of proliferation was 
accompanied by a dose-dependent increased cell death (Fig. 2.11D).  The 
estimated IC50 values of these cells at 24 hr treatment were 91.2 µg/ml MSE and 
7.5 x 10-5 M MIT (Table 2.1).                           
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Fig. 2.11  Proliferation (A & C) and percentage of dead cells (B & D ) in MSE 
and MIT treated SH-SY5Y  cells as determined by the Trypan blue exclusion 
assay.  Cells were treated for 24, 48 and 72 hrs and harvested as described in the 
methods. Values are the mean of quadruplet cultures of MSE experiment and 
duplicate cultures of MIT experiment.  Bars are SEM. *P<0.05 vs control, 
ANOVA with Dunnet post test.   
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Table 2.1:  IC50 values (Inhibition concentration that caused 50% cell death) of 24 
hr treatment with MSE and MIT treated cell lines.  The values were interpolated 
from percentage dead cells curves obtained from the Trypan blue exclusion 
experiments. 
___________________________________________________ 
                                                                      IC50                           
   ____________________________________ 
 
Cell line  MSE (µg/ml)             MIT  (Molar) 
 
SH-SY5Y         91.2   7.5 x 10-5 
 
HEK 293         282.1   2.4 x 10-4 
 
MCL-5          410.3       NA 
 
cHol          282.1       NA 
 
HEPG2          230.8       NA 
________________________________________________________ 
 
Table 2.1 show variability in the sensitivity of the different cell lines to MSE and 
MIT.  From these estimates, it appears that the SH-SY5Y cells are the most 
sensitive, of those examined, to the cytotoxic and possibly cytostatic effect of 
MSE.  Based upon my estimation of 42% MIT-like compound in MSE extract, the 
SHSY5Y cell IC50 for MSE is equal to 9.6 x 10-5 M MIT-like compound.  This is 
not dissimilar to the experimentally determined IC50 for pure MIT of 7.5 x 10-5 M. 
 
2.4.6 Colony forming ability of treated cells (clonogenicity assay) 
To assess the long-term effect of MSE on surviving cells after acute treatment, a 
clonogenicity assay was performed after 24 hr treatment on HEK 293 and SH-
SY5Y cells.  Additional clonogenicity assays using chloroform and combinations 
of chloroform and MSE were also carried out to determine whether potential 
chloroform contamination of MSE could influence cytotoxicity. 
  
MSE (Fig. 2.12A and B) appeared to inhibit colony forming ability of both cell 
lines in a dose –dependent manner. Cells treated with ≥ 500 µg/ml MSE were 
unable to generate colonies. 
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Fig.2.12 Clonogenicity of A) HEK 293 cells and B) SH-SY5Y cells after 24 hr 
treatment with MSE.  N= 6 ± SEM, ** P< 0.01 vs control, ANOVA with Dunnet 
post test.  
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MIT treatment of SH-SY5Y cells as shown in figure 2.13 appeared to be less 
toxic compared to cells treated with MSE (figure 2.12B). Interestingly, a dose of 
100 μg/ml MSE is expected to contain 42 ug/ml MIT-like compound (based on 
the analysis described in section 2.4.1).  This is equivalent to 4.2 x 10-5 M or 42 
µM MIT-like compound. 
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Figure 2.13 Clonogenicity of SH-SY5Y cells treated with MIT. Bars are SEM of 
three experiments. 
 
2.4.6.1 The effect of chloroform and MSE on clonogenicity 
To determine whether chloroform contamination of MSE was a contribution to 
MSE cytotoxicity, clonogenicity assay were performed using chloroform/MSE 
combinations and SH-SY5Y cells.  These experiments were done in collaboration 
with Thomas Randall (ICL).  SH-SY5Y cells treated with chloroform in ethanol 
vehicle (Fig. 2.14A) appeared to be unaffected and were able to generate colonies 
even at the highest concentration of chloroform tested, 500 μM. A fixed 
concentration of chloroform (100 μM) was used with sub-toxic concentrations of 
MSE (0-25 μg/ml MSE).  If chloroform contamination of MSE contributed to the 
toxicity of MSE, then addition or synergistic cytotoxicity would be expected. 
 
There was no significant difference noted between the colony forming ability of 
MSE treated cells and combinations of MSE/CHCl3 treated cells, even at the 
highest concentration tested (25 µg/ml MSE / 100 µM CHCl3) (Fig. 2.14B).  This 
result suggests that chloroform did not enhance MSE-dependant cytotoxicity. 
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Fig. 2.14  Clonogenicity of SH-SY5Y cells after 24 hr treatment with A) 
chloroform and B) MSE and/or chloroform (100 µM). Values are mean from 
triplicate experiments. Bars are SEM. 
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2.4.7 Effect of metabolic activation on MSE cytotoxicity (clonogenicity) 
using Arochlor 1254- induced rat liver S9. 
Figure 2.15A shows that there is a clear dose- dependent toxicity effects seen 
upon MSE treated with rat S9 with substantial toxicity at concentrations of ≥50 
μg/ml. The colony forming ability is clearly inhibited at those concentrations. 
 
HEK 293 cells treated with MSE and Arochlor 1254-induced rat liver S9 
(Fig.2.15B) appeared to be more resistant to the toxicity effects compared to SH-
SY5Y cells (Fig. 2.15A).  These results indicate that MSE is being activated to a 
metabolic product that is cytotoxic to both cell lines; however the SH-SY5Y cells 
appear to be most susceptible. 
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Fig. 2.15 Clonogenicity assay of MSE with rat S9 treated A) SH-SY5Y and 
B)HEK 293 cells for 24 hr with MSE in the presence of Arochlor 1254-induced 
rat liver s9. N=3 ± SEM. *P<0.05, **P<0.01, ***P<0.001 vs control, ANOVA 
with Tukey-Kramer post test. 
 
 
2.4.8 Effect of metabolic inhibitors on the cytotoxicity of MSE and MIT in  
metabolically competent MCL-5 cells 
MCL-5, a human lymphoblastoid cells are competent cell line stably transfected 
with human CYP’s, 1A1, 1A2, 2A6, 2E1, 3A4 and human epoxide hydrolase 
(Crespi et al, 1991). Using four different enzyme inhibitors, ketoconazole (CYP 
3A4 inhibitor), dietyldithiocarbamate (CYP 2A6 inhibitor), α-naphthoflavone 
(CYP 1A inhibitor) and, 3-amino,1,2,4-triazole (CYP 2E1 inhibitor) were used to 
assess the possible metabolic activity in mediating the MSE and MIT toxicity in 
MCL-5 cells. 
62 
 
The results shown in fig. 2.16 indicated that MSE toxicity could be inhibited by 
dietyldithiocarbamate (DED) (bar graph B) and 3-amino-1,2,4-triazole (ATZ) (bar 
graph C) as both highly significant to reduced the toxicity exert by MSE at 100 
µg/ml at the 48 hr time point.  Alphanaphtoflavone (bar graph D) also showed 
some marginal difference in inhibiting the MSE toxicity. Cytotoxicity was 
apparently unaffected by ketoconazole.  
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Fig. 2.16 Effect of enzyme inhibitors on MSE treated MCL-5 cells with A) 25 µM 
ketoconazole (CYP-3A4 inhibitor) B) 100 µM diethydithiocarbamate (CYP-2A6 
inhibitor) C) 25 µM 3-amino-1,2,4-triazole (CYP 2E1 inhibitor) and D) 25 µM 
alpha-naphthoflavone (CYP 1A inhibitor) for 24 and 48 hr. The Alamar blue 
assay was used to assess cytotoxicity (fluorescence 530 nm excitation/590 nm 
emission). N=3 ± SEM.  ANOVA analysis for 48 hr treatment point, * p <0.05, 
**P <0.01 vs MSE only, Tukey-Kramer post test.  
 
To further confirm the outcome seen in the Alamar blue assay experiments (Fig. 
2.16), the trypan blue exclusion assay using DED and ATZ was employed.  From 
the result (Fig. 2.17), it would appear that ATZ a CYP 2E1 inhibitor significantly 
reduced MSE and MIT toxicity at concentration of 100 µg/ml MSE and 50 µM 
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MIT respectively. DED, a CYP 2A6 inhibitor also gave some protection against 
MSE and MIT toxicity, but was not effective as ATZ. 
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Fig. 2.17  Effects of enzyme inhibitors on  MSE and MIT treated MCL-5 cells 
with 100 µM DED and 25 µM of ATZ for 48 hr treatment.  Cell viability was 
assessed using Trypan blue exclusion.  N= 3 ± SEM.  **P<0.01 vs MSE or MIT, 
ANOVA with Tukey-Kramer post test. 
 
 
2.5 Discussion 
Holmes in 1907 has referred to Mitragyna speciosa Korth leaves as an opium 
substitute (Shellard, 1974).  Traditionally it is popularly used by manual labourers 
in Southeast Asia mainly Thailand and Malaysia to overcome the burden of hard 
work under scorching sun and as stimulant/euphoric. However, due to its 
narcotism properties, it has been misused by drug addicts as an alternative to 
opium or to moderate the withdrawal symptoms of opium. After years of research 
with this plant, mainly using crude alkaloid extracts, its dominant alkaloid 
mitragynine (MIT) and congeners, their analgesic properties have been confirmed 
in vitro and in vivo.  This medicinal property has, so far, been reported in the 
leaves of this plant but not from other species of Mitragyna.  Several countries 
like Thailand, Myammar, Malaysia and recently Australia have made this plant 
illegal due to its narcotism properties, whereas in other parts of the world the plant 
regardless of any form has been sold widely over the internet.  The popularity of 
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this herb in Western culture is increasing and some individuals are now taking it 
for self-treatment in chronic pain and as an aid to opioid withdrawal (Boyer, 
2007).  The potential toxicity of MSE and of other products derived from 
Mitragyna speciosa Korth is currently unknown.  
 
Therefore, for the first time, an in vitro toxicological assessment of this alkaloid 
extract (MSE) and its dominant alkaloid, MIT, has been examined.  Both agents 
exerted dose-dependent cytotoxic effects to human cancer cells.  The results from 
the wound study provided information that MSE itself is not able to promote 
cellular migration in vitro. The results from different cell lines used in the 
viability studies demonstrated that the human neuronal SH-SY5Y cell was the 
most sensitive cell line examined. The IC50 following 24 hr treatment of SH-
SY5Y cells were 91.2 μg/ml and 7.5 x 10-5 M (30 μg/ml) for MSE and MIT 
respectively. Analyses of MSE by UV-VIS spectroscopy confirmed the presence 
of MIT-like compound at a level of about 42% of the total extract, indicating that 
the MSE IC50 of 91.2 ug/ml is equivalent to 40 μg/ml MIT. This is slightly higher 
than the MIT IC50 of 30 ug/ml (7.5 x 10-5 M) as shown in this study. This result 
implies that MIT is one of the major compounds in the leaves of this plant 
contributing to MSE cytotoxicity.  
 
Apart from the acute cytotoxicity effects seen in different cell lines, another major 
finding in this part of the study was the longer term cytotoxicity effects as 
determined by colony forming ability (clonogenicity assay). The concentration of 
MSE required to reduce the ability of the cells to form colonies was seen to be 
five times higher compared to results obtained in acute viability assay (trypan blue 
exclusion).  This suggests that the uptake of dye (trypan blue) into the cells does 
not reflect the actual outcome of the cells in the longer term.  It is proposed that 
despite taking up the trypan blue dye, the cells were still alive but may not be 
fully functional.  It is speculated that one effect of the MSE treatment could be 
opening of membrane pores to allow the dyes to get in without proceeding to cell 
death.  However at higher dose of MSE, dye uptake is more likely to represent 
cell death. 
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The 1H-NMR analysis of MSE and MIT from two different sources revealed the 
similarity of most spectral peaks for both samples of MIT except there is an extra 
minor peak at 7.9 ppm indicating that there is some contamination of chloroform 
in the MIT from Japan.  This contamination was not seen in the MIT from 
Malaysia. The same peak was also observed in MSE. It was believed to be due to 
the incomplete removal of chloroform during the preparation of MSE.  With this 
finding, a concern arises whether this minor contamination would affect the 
toxicity of MSE or MIT (from Japan) in the cell based studies. We therefore chose 
to use spiking experiments where chloroform was added to MSE at known 
concentrations and the effect of the mixture on cell toxicity was determined. The 
clonogenicity experiments using SH-SY5Y cells indicated that the chloroform 
contamination did not pose any obvious cytotoxic effects to level up of 500 uM 
concentrations, which is far beyond that expectated to be in the MSE.  The 
combination effect of chloroform and MSE was also determined, and the results 
revealed that there is no significance difference for combinations of 25 μg/ml 
MSE + 100 μM chloroform with MSE effects alone or chloroform alone (these 
data are from collaboration experiments with Thomas Randall, ICL). Therefore, it 
was assumed that the minor contamination of chloroform in both MSE and MIT 
was not contributing to the toxicity.   
 
We observed that MSE exerted dose dependent cytotoxicity with several human 
cancer cells both via trypan blue exclusion assay and clonogenicity assay. Most 
xenobiotics undergo metabolic activation in the process of exerting their 
cytotoxicity effects. Cytochrome P450 oxidative enzymes are key enzymes 
involved in this xenobiotic metabolism.  To the best of my knowledge, apart from 
biotransformation of MIT in the fungus helminthosporum sp. to mitragynine 
pseudoindoxyl and hydroxy mitragynine pseudoindoxyl metabolites (Zarembo et 
al 1974), there is no other report on in vivo/in vitro biotransformation of MSE or 
MIT.  Therefore, in this part of the study, we examined if metabolism was 
involved in MSE cytotoxicity, using MCL-5 cells (metabolically competent 
express-CYP1A1/1A2, 2A6, 2E1, 3A4 and human epoxide hydrolase) and cHol 
cells (lack of metabolic activity). From the results, it appears that the 
concentration of MSE needed to exert the toxicity effect in metabolically 
competent cells, MCL-5 is greater than what is required for cHol cells. This 
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preliminary finding suggested that metabolism appeared to detoxify MSE rather 
than activated it. 
 
To further clarify the above finding, S9 from rat liver (induced by Arochlor 1254) 
was used with SH-SY5Y and HEK-293 cells as these cells have no metabolic 
activity.  Clonogenicity assays under these conditions revealed that colonies could 
not be generated at concentration as low as 50 μg/ml and 70 μg/ml MSE in SH-
SY5Y and HEK 293 cells respectively; this cytotoxic dose of MSE is ten fold 
lower than with cells treated without S9. To further examine the contribution of 
CYP 450 enzymes that could be involved in the MSE/MIT toxicity, four different 
enzyme inhibitors, ketoconazole (CYP 3A4 inhibitor), diethyldithiocarbamate 
(CYP 2A6 inhibitor), α-naphthoflavone (CYP 1A2 inhibitor) and 3-amino, 1,2,4-
triazole (CYP 2E1 inhibitor) were used with MCL-5 cells and analysed for 
cytotoxicity. The results proposed the possible involvement of CYP 2E1 in 
MSE/MIT toxicity. Due to time limitations, further work on the role of 
metabolism in MSE/MIT toxicity was not possible. 
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                                                  CHAPTER 3 
 
GENOTOXIC POTENTIAL OF MSE AND MIT 
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3.1  Introduction 
The results from trypan blue exclusion experiments and clonogenicity assays 
described in the previous chapter (chapter 2) demonstrated that MSE and MIT 
were cytotoxic in the cell lines examined.  Whether the cell death was 
accompanied by DNA damage was unknown.  DNA damage, which could lead to 
gene mutation and /or chromosome abnormalities, is a key factor in chemical-
mediated carcinogenesis (Bishop, 1987).  To date, there is no information or 
report on cancer or tumour incidence in humans consuming Mitragyna speciosa 
Korth leaves.  It is important to find out whether MSE and MIT cytotoxicity is 
accompanied by DNA damage. This chapter examines whether MSE or MIT have 
genotoxic potential and thereby the potential for carcinogenicity.   
 
Substantial national and international efforts have been devoted to develop and 
refined the test methods and guidelines for assessing the genotoxic potential of 
chemicals including pharmaceuticals, pesticides and industrial chemicals (Müller 
et al, 2003). Among the agreed international guidance documents are International 
Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH harmonised tripartite guideline on 
genotoxicity) and Organization for Economic Co-operation and Development 
(OECD) guideline for the testing of chemicals. In the U.K., the Committee on 
Mutagenicity of Chemicals in Food, Consumer products and the Environment 
(COM) play an important role in the assessment of genotoxic chemicals.  The 
general purpose of genotoxicity testing is to enable hazard identification with 
respect to DNA damage and fixation of such damage, including gene mutations 
and chromosomal damage/changes that may lead to genetic change (ICH, 1997).  
The genotoxic potential of chemicals requires comprehensive assessment using in 
vivo and in vitro tests, which complement each other in their ability to detect 
genotoxic agents. In the early stage of the testing, ICH has recommended an 
approach called standard test battery which includes three core tests as below: 
i) a test for gene mutation in bacteria (the Ames Test). 
ii) an in vitro test with cytogenetic evaluation of chromosomal damage with 
mammalian cells or an in vitro mutation assay preferably the mouse tk assay or a 
micronucleus assay. 
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iii) an in vivo test for chromosomal damage using rodent hematopoietic cells (in 
vivo micronucleus assay). 
Chemicals giving positive results in the standard battery tests, depending on their 
intended use, may need to be tested more extensively whereas negative results, 
will usually provide a sufficient level of assurance of safety (ICH, 1997). 
 
Based on the ICH recommendation for staged genotoxicity assessment, gene 
mutation in bacteria (the Ames test) was the appropriate first test to be performed; 
however since the leaves of Mitragyna speciosa Korth have long been used by 
humans, an in vitro test using mammalian cells was thought to be more relevant to 
perform in the current study.  In addition, the evaluation of genotoxic potential of 
MSE and MIT at present is for academic purposes and not a regulatory 
requirement.  
 
The mouse lymphoma tk gene mutation assay (MLA) is widely used and an 
accepted test system for the assessment of mammalian cell gene mutation; it 
involves assessment of the thymidine kinase (tk) locus using mouse lymphoma 
L5178Y cells.  This test not only examines mutagenicity status of the agent tested, 
but also gives information on a broad range of genetic events involving 
chromosomal changes/damage including point mutations, deletions, 
translocations, recombinations etc. (ICH, 1997). The capability of MLA to detect 
the chromosomal mutations is important as mutations play a central role in 
carcinogenesis (Mitchell et al, 1997).   The end point of this test, evaluating the 
size of the colony formations, determines the type of chromosomal changes 
induced. Small colony mutants are always a main concern as these have been 
shown predominantly due to the loss of all or a significant portion of the 
functional tk allele (Clive et al, 1990) as a consequence of structural or numerical 
alterations or recombinatorial events.  In pharmaceuticals safety testing, MLA is 
considered to be an acceptable alternative to the direct analysis of chromosomal 
damage in in vitro tests such as hypoxanthine-guanine phosphoribosyl transferase 
(HPRT) (ICH, 1997) or in vitro chromosomal aberration test (Honma et al, 1999).  
In fact, in terms of sensitivities, induced mutant frequencies at the tk locus were 
found to be greater than those seen at the hprt locus under the same treatment 
conditions (Clive et al, 1990). 
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3.2  Materials and methods 
3.2.1 Cell lines and conditions 
The cell line used was L5178Y TK+/- 3.7.2c. cells (mouse lymphoma cell line 
having heterozygous thymidine kinase (tk) gene) for detection of non-lethal gene 
mutations and structural chromosome damage.  These cells were a generous gift 
from Dr. Elizabeth Martin from Astra Zeneca Company (Alderley Park, Cheshire, 
U.K).  The suspension cells were maintained in RPMI 1640 Glutamax-1 medium 
containing 3.0 mM L-glutamine and 25 mM HEPES and supplemented with 1.8 
mM sodium pyruvate, 50 µg/ml streptomycin: 50 IU/ml penicillin, 0.1% pluronic 
F-68 and 10%(v/v) heat inactivated  donor horse serum(HIDHS). This medium is 
referred to as complete medium (CM10). 
 
The stock cultures of L5178Y cells were established from a frozen vial (2 x 106 
cell/ml) kept in vapour phase of liquid nitrogen.  Upon resuscitation (as described 
in chapter 2, section 2.2.3), the cells were treated prior to use in the assay 
(‘cleansing the cells’ to remove spontaneous accumulating mutants) with 
thymidine (9 µg/ml), hypoxanthine (15 µg/ml), methotrexate (0.3 µg/ml ) and 
glycine (22.5 µg/ml ) to maintain a low and stable background mutant frequency.  
The ‘cleansing’ compounds used were dissolved in incomplete media (CM0) 
which was prepared as the normal growth complete media (CM10) but without 
HIDHS.  The CM10 media (without pluronic acid) was used to maintain cell 
growth throughout the ‘cleansing process’. The treated cells (2 x 106 cell/ml), 
counted using Beckman Coulter counter, were incubated for 24 hr at 37ºC (5% 
CO2). After 24 hr incubation, the cells were pelleted by centrifugation (1000 rpm 
for 5 min) and the pellet resuspended again in the incomplete media (CM0). The 
cells were adjusted to 2 x 105 cells/ml and this was followed by the second 
treatment with thymidine, hypoxanthine and glycine.  The cells were sub-cultured 
up to 3 times at the same density (2 x 105 cells/ml) to dilute out the cleansing 
compounds. At the end of ‘cleansing process’, the cells were cryopreserved using 
CM10 media with 10% of DMSO but without pluronic F-68.  The cells were then 
ready to be used for the assay. 
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3.2.2 Chemicals and reagents 
The chemicals used in the assays unless indicated in the text were obtained from 
Invitrogen Company (U.K) and Sigma-Aldrich Company (U.K).  The Arochlor 
1254-induced rat liver S9 was a kind gift from Dr. Costas Ionnides of the 
University of Surrey, U.K.   
 
3.2.3 Mouse lymphoma thymidine kinase (tk) gene mutation assay (MLA) 
The MLA assay protocols were obtained from the Genetic Toxicology 
Department of GlaxoSmithKline Company (Ware, U.K). The MLA assay was 
carried out in the presence of S9 –mix for a treatment period of 3 hour and in the 
absence of S9-mix for a treatment period of 24 hours. 
 
3.2.3.1 Selection of concentrations and preparation of test solutions 
The selection of concentration range tests was based on the cytotoxicity data using 
trypan blue exclusion assay performed as described in the previous chapter 
(Chapter 2).  The default vehicle solution for MSE and MIT was ethanol.  7,12-
Dimethylbenz[a]anthracene (DMBA) was used as positive control in the presence 
of S9-mix at a final concentration of 5 μg/ml, dissolved in DMSO.  Methyl 
methanesulfonate (MMS) was used as a positive control in the absence of S9-mix 
at final concentration of 20 μg/ml, dissolved in DMSO.   
 
Arochlor 1254 rat liver S9-mix was used as the exogenous metabolising system 
and was prepared freshly on the day of the assay. The S9-mix was prepared by 
mixing 1 part of S9 with 9 parts of co-factor (5.56 mM NADP (Na2) and 27.8 mM 
G-6-P. Na2  in CM0 media with pH 7.5). 
  
3.2.3.2 Preparations of treatment cultures 
The cell titre of exponentially growing cells in CM10 media was determined using 
Beckman Coulter counter (0.5 ml cells added to 9.5 ml Isoton II diluent 
(Beckman)) and recorded in the MLA excel worksheet.  The volume of cells 
needed for each treatment period, 3 hr and 24 hr were automatically calculated in 
the worksheet. 
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Treatment cultures in the presence of S9 (3 hr) 
Cells from growing stock were centrifuged at 1000 rpm for 5 minute and the cell 
pellets were resuspended and counted using Coulter counter and cell suspension 
were prepared to a target concentration of 2 x 106 cells/ml.  Single cultures were 
established for each treatment concentration and in triplicate for vehicle control. 
For example, the preparation of 20 cultures will require 30 ml of cell stock (2 x 
106cells/ml), 59 ml of CM0 media and 10 ml of S9 mix (1 ml S9 + 9 ml S9-
cofactor). From this cell suspension preparation, 4.50 ml were transferred into 50 
ml tubes added with 50 µl test compound or vehicle or positive control for a final 
volume of 5 ml. The target cell concentration (6 x 105 cells/ml) for each culture 
was determined again using cell counter and recorded.  Tubes were incubated at 
37ºC (5% CO2) in a shaking incubator for 3 hour (to prevent cells from settling).  
 
Table 3.1: Preparation of treatment cultures in the presence of S9 (3 hr) per 
sample. 
Treatment 
(3 hr) 
Cell 
volume 
(ml) 
CM0 
volume 
(ml) 
S9-mix 
volume 
(ml) 
Vehicle/test 
substance 
volume (μl) 
Final 
culture 
volume 
(ml) 
Presence of 
S9-mix 
1.5 2.95 0.5 50 5.0 
 
3 hour post-treatment with the presence of S9 (denoted as day 0) 
The assessment of each treatment cultures were carried out via examination by 
eye for the presence of precipitation and/or medium colour changes and 
observations were recorded.  During this observation, any cultures having 
precipitation are discarded and the remaining cultures were centrifuged at 1000 
rpm for 5 minutes and the supernatant gently discarded leaving undisturbed pellet. 
The pellet was then resuspended in 5 ml pre-warmed PBS and re-centrifuged 
second times and supernatant was removed as before. The pellet were 
resuspended in 15 ml pre-warmed CM10 media and transferred into labelled 
vented tissue culture flasks (25 cm2) and were incubated at 37ºC (5% CO2) for 24 
hours. 
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Treatment cultures in the absence of S9 (24 hrs) 
The remaining cells suspension (2 x 106 cells/ml) prepared for the previous 
treatment cultures in the presence of S9 (3 hr) were used and the cells were diluted 
to 1.5 x 105 cells/ml in CM10 media and checked via Coulter counter.  The cell 
suspension (4.5 ml) was dispensed into labelled vented tissue culture flasks (25 
cm2), followed by adding test compounds, vehicle or positive control (50 µl). The 
treated cultures were incubated for 24 hrs at 37ºC (5% CO2). Refer table 3.2 for 
the preparation of 24 hrs cultures. 
 
Table 3.2: Preparation of 24 hrs treatment cultures (in the absence of S9) per 
sample. 
Treatment 
(24 hr) 
Cell volume 
(ml) 
CM 10 
volume (ml)
Vehicle/test 
substance 
volume (μl) 
Final 
culture 
volume (ml) 
Absence of 
S9-mix 
1.5      3.45 50 5.0 
 
24 hours post-treatment in the absence of (denoted as day 0) 
Treatment cultures were examined by eye for signs of precipitation and/or 
medium colour changes and observations were recorded. Each flask was gently 
shaken to dislodge cells from the bottom and transferred to centrifuge tubes for 
centrifugation at 1000 rpm for 5 minutes.  The supernatant was discarded,  
resuspended in 5 ml pre-warmed PBS and re-centrifuged for a second time 
followed by resuspending the pellet with 5 ml pre-warmed CM10 media. Cell 
counts for each culture were determined and adjusted to concentrations of 2 x 105 
cells/ml in a maximum volume of 10 ml of pre-warmed CM10 media. Cultures 
that had cell count less than 2 x 105 cells/ml were not diluted.  All the cultures 
were incubated for 24 hours. 
 
Day 1 post- culture treatment (presence and absence of S9 cultures) 
Cell count was performed and the cultures were adjusted to 2 x 105 cells/ml in 
fresh pre-warmed CM10 media to a maximum volume of 10 ml in new tissue 
74 
 
culture flasks. Cells were not diluted if less than 2 x 105 cells/ml. The cultures 
were further incubated for 24 hours. 
 
Day 2 post-culture treatment (presence and absence of S9 cultures) 
Cell count was performed and the suspension growth (SG) and relative suspension 
growth (RSG) were calculated for each culture. The calculation formulae are as 
follow: 
Suspension growth (SG) – a measure of the growth in suspension during treatment 
and the expression period. 
 
 SG (presence of S9) =         Day 1 and  x Day 2 cell count 
                                                          Day 1  x Day 2 cell density 
 
 SG (absence of S9) =      Day 0 x Day 1 x Day 2 cell count    
         Day 0 x Day 1 x Day 2 cell density 
 
Relative suspension growth (RSG) – a measure of viability in which the total 
suspension growth (SG) for 2 days expression period were calculated and SG of 
each test cultures were compared to control. The calculation formula is as follow: 
 
RSG  = SG (test)/ SG (mean control SG) X 100 
 
 
Based on the RSG value obtained, the concentrations chosen for the plating 
(viability assessment and mutant frequency) includes at least one dose level with 
an RSG value of 10-20%, a no effect dose, and a minimum of two further doses 
between this range of concentrations. 
 
Plating for Viability Assessment (presence and absence of S9 cultures) 
At the end of expression period, the cell density of selected cultures were 
determined via Coulter counter and a cell suspension of 1 x 105 cells/ml in pre-
warmed CM10 media was prepared in sterile universal bottles.  Ten μl of 1 x 105 
cells/ml was added to 9.99 ml CM10 media to give cell suspension of 1 x 102 
cells/ml.  Four ml of the 1 x 102 cells/ml suspension was added to 46 ml CM10 
media to give suspension of 8 cell/ml.  This final cell suspension was used for 
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plating in 96- well with flat bottom plates using multichannel microtitre pipette 
(200 μl/well) with average 1.6 cell/well plated for each chosen culture. The plates 
were incubated for 7 days (± 1 day). 
 
Plating for Mutant Frequency (3hr and 24 hr cultures) 
Five ml of cell suspension (1 x 105 cells/ml) of selected cultures which was 
prepared previously for viability assessment was taken and added to 43 ml pre-
warmed CM10 media and 2 ml of trifluorothymidine (TFT) of 100 μg/ml 
concentration. The procedure was done under subdued light due to TFT sensitivity 
to light.    This final cell suspension was used for plating in 96- well with flat 
bottom plates using multichannel microtitre pipette (200 μl/well) with average 1.6 
cell/well plated for each chosen culture. The plates were incubated for 11 days (± 
1 day). 
 
Scoring the plates 
After the incubation period, all the plates for viability assessment were scored 
using a modified mirror box for the absence or presence of colonies in each well.  
Only colonies of approximately ≥ 50 cells were scored.  The plates for mutant 
frequency assessment were scored based on the size of the colonies and 
categorised as a small colony if it appeared <¼ diameter of the well and large 
colony if it appeared to be >¼ diameter of the well.  The numbers of negative 
wells for viability plates and positive wells for mutant plates were also recorded. 
 
Test Acceptance Criteria and Evaluation of the Results 
Following the protocols obtained from GlaxoSmithKline Company (Ware, U.K), 
the assay was accepted based on the measurement of cytotoxicity by relative total 
growth (RTG) which reduced to approximately 10-20% when compared to 
concurrent vehicle control. This RTG takes into account all cell growth and cell 
loss during the treatment period and the 2 day expression period (RSG), and the 
cell’s ability to clone 2 days after treatment (viability). The calculation of RTG is 
as follow: 
 
RTG =  RSG x       Individual viability value         X 100 
                  Mean control viability value 
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Acceptance criteria for vehicle controls: 
• The mean vehicle control value for mutant frequency (MF) are between 
50-170 x 10-6 
• The mean cloning efficiency is between 65-120%. 
• The mean suspension growth are between 8-32 on day 2 (following 3 hr 
treatment with S9) 
• After exclusion of obvious outliers, at least 2 acceptable vehicle controls 
cultures remain. 
 
Acceptance criteria for positive controls: 
• Either: a definite increase in mean total MF of at least 300 x 10-6 (and at 
least 40% are small colonies). 
• Or: an increase of small colony MF of at least 150 x 10-6 above the 
concurrent vehicle control. 
• Mean RTG’s for positive controls are greater than 10%. 
 
The Mutant Frequency (MF) was calculated as follow: 
 
 MF =           - ln P(o) for mutant plates 
     Number of cells per well x (viability/100) 
 
 
 
To evaluate the individual assay results, the following definitions were applied: 
GEF = Global evaluation factor (for this microwell method, the standard GEF is 
125 x 10-6) (Moore et al, 2003) 
MF= Mutant frequency 
 
The MLA assay was considered valid in accordance with acceptance criteria 
discussed above; therefore: 
• The test compound is regarded negative if the MF is less than the sum of 
the mean control mutation frequency plus the GEF. 
• The test compound is regarded positive if the MF of any test concentration 
exceeds the sum of the mean control mutation frequency plus the GEF and 
there was a concentration dependent increase in MF. 
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3.3 Results 
3.3.1 Mouse lymphoma thymidine kinase (tk) gene mutation assay (MLA) 
The MLA principally detects gene mutation at tk locus (TK+/- → TK-/-) and is 
detected by resistance to the cytotoxic effects of the pyrimidine analogue 
trifluorothymidine (TFT). Therefore the mutant cells were able to proliferate in 
the presence of TFT while the normal cells (TK+/-) do not. Mouse lymphoma cells 
in this assay were exposed to the MSE or MIT, both with or without metabolic 
activation system, Arochlor 1254 induced rat liver S9, for at least 2 days and sub 
cultured to determine cytotoxicity and also to allow phenotypic expression prior 
to mutant selection.  Cytotoxicity was determined by measuring the relative total 
growth (RTG) of the cultures after the treatment period.  Mutant frequency was 
determined by seeding a known number of cells in medium containing TFT to 
detect mutant cells, and also in medium without TFT to determine the cloning 
efficiency (viability).  Colonies were counted after 7 days for viability. The 
mutant frequency was determined after 11 days incubation and the size of 
colonies was assessed according to the criteria described in section 3.2.3.2.   The 
mutant frequency value was determined from the derived number of mutant 
colonies in medium containing TFT and the number of colonies growing in non-
TFT medium.  The preliminary data on selection of dose range and final summary 
of the MLA results for the MSE and MIT are discussed below:  
 
3.3.1.1 MLA for MSE 
As shown in table 3.3a, in the presence of metabolic activation S9, the two highest 
concentrations of MSE at 25 and 20 µg/ml were too toxic to the cells as the cell 
count were very low thus causing low RSG. This implies that the presence of S9 
at these concentrations increase the metabolic activation of MSE to toxic 
derivatives which killed the majority of the cells.  However as shown by MSE 
treated groups in the absence of S9, MSE even at highest dose administered, did 
not show any toxic effects. Thus, the two lower doses tested, 10 and 5 µg/ml MSE 
were omitted from plating as their RSG value were nearly similar to the negative 
control groups.   
 
Based on the validation criteria for MLA as described in the section 3.2.3.2., table 
3.3bi) shows that MSE in the presence of S9 at dose concentration of 15 µg/ml 
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revealed a positive  MF (237.52 x 10-6) which was higher than the sum of Mean 
Control MF (77.42 x 10-6) plus standard GEF (126 x 10-6). However the RTG was 
in the toxic range (10-20% reduced of the concurrent vehicle control). In addition, 
the cloning efficiency of the cells or RSG value prior plating was also quite low 
(24%).  On this basis, it was assumed that the positive effect was due to the 
excessive cytotoxicity  in line with the ICH S2A guidelines (1995) and the result 
is considered invalid. The other concentrations tested were negative for genotoxic 
potential. The presence of S9 appeared to have a substantial effect on the RTG 
with MSE.  In fact there was a clear dose-dependant toxicity observed, suggesting 
that the MSE was being activated to a toxic derivatives. 
 
MSE in the absence of metabolic activation with S9 did not produce evidence of 
genotoxicity (Table 3.3b ii).  The survival rate and the relative total growth (RTG) 
for the dose range was high even at the highest dose tested, 40 µg/ml and the MF 
values were all within negative criteria. In the absence of S9, MSE appeared to be 
toxic compared to the control (lower RTG).  However this toxicity did not appear 
to be dose related. 
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Table 3.3a Preliminary data of MSE treated groups with and without the presence 
of S9. Dose selection for the Viability and Mutant Frequency (MF) plating were 
chosen based on the RSG calculation as described in section 3.2.3.2. 
 
Treatment 
groups 
Conc. 
µg/ml 
Cell conc. 
X 105 
Relative 
suspension growth 
(RSG) 
Conc. chosen to 
be plated 
Y=yes 
Neg.Con. A 8.91 91.26 Y 
Neg.Con. B 9.56 107.90 Y 
Neg.Con. C 9.40 100.84 Y 
25 1.27 3.20  
20 0.82 2.05  
15 8.18 24.41 Y 
10 9.84 53.40 Y 
5 8.25 79.61 Y 
 
 
 
MSE 
Treatment 
with S9 
(3 hr) 
DMBA 9.60 82.65 Y 
Neg.Con. A 9.60 108.76 Y 
Neg.Con. B 8.55 94.88 Y 
Neg.Con. C 8.51 96.36 Y 
40 8.98 83.32 Y 
30 8.41 72.85 Y 
20 8.73 83.30 Y 
10 8.98 99.52  
5 9.82 108.72  
 
 
MSE 
Treatment 
without S9 
(24 hr) 
MMS 9.02 99.38 Y 
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Table 3.3b Summary table of MLA result for MSE in the i) presence of S9 and ii) 
in the absence of S9. 
                                                                
(i) 3 hour + S9 treatment 
Treatment 
groups 
Conc. μg/ml RTG (%) MF x 10-6 Positive/Negative
0 85 87. 13 Negative 
0 113 71.91 Negative 
Negative 
control 
0 104 73.22 Negative 
15* 18 237.52 Positive 
10 40 196.36 Negative 
MSE  
5 85 88.95 Negative 
Positive 
control 
(DMBA) 
1 63 863.48 Positive 
Mean Control MF 77.42  
* Relative suspension growth (RSG) = 24%. 
                                                                 
(ii) 24 hour - S9 treatment 
Treatment 
groups 
Conc. μg/ml RTG (%) MF x 10-6 Positive/Negative
0 93 75.91 Negative 
0 111 88.95 Negative 
Negative 
control 
0 94 61.08 Negative 
40 75 105.83 Negative 
30 77 81.38 Negative 
MSE  
20 59 125.40 Negative 
Positive 
control 
(MMS) 
5 92 839.01 Positive 
Mean Control MF 75.31  
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3.3.1.2 MLA for MIT 
The preliminary data shown in table 3.4a, gives indication that the enzymes 
present in the S9 did not influence the MIT metabolism as the cells number were 
within the similar range as cells in negative control groups or positive control 
group and the RSG values were high and not much different with other groups. 
Interestingly, in the absence of S9, MIT showed dose-dependant cytotoxicity (low 
RSG) on its own. The preliminary data shown here are the results taken after 2 
days expression period prior to plating. There was no significant difference in cell 
numbers compared to negative control or positive control groups; however, based 
on the formula which takes into account the suspension growth for two days 
culturing period, low dose-dependant RSG was calculated. The low suspension 
growth was noted even after 24 hr post treatment (data not shown). Thus all 
concentration tested in this group were chosen for plating for the final step of 
assessment. 
 
As shown in the table 3.4b i) and ii), the MLA results for MIT in the presence or 
absence of rat liver S9 show no evidence of genotoxicity.  Interestingly, in the 
presence of rat liver S9, there appeared to be no effect of metabolism activity on 
RTG even at the highest concentration tested, 30 µg/ml MIT. The outcome of this 
experiment would seem to be contrary to what was seen for MSE.  In the absence 
of rat liver S9 (Table 3.4b ii), the RTG for 30 µg/ml MIT was reduced to 17% of 
the concurrent vehicle control implying excessive toxicity effects.  This was due 
to the measured RSG value being very low (18.57%) as shown in preliminary data 
(Table 3.4A) which therefore affected the final calculation for the RTG.  
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Table 3.4a Preliminary data of MIT treated groups with and without the presence 
of S9. Dose selection for the Viability and Mutant Frequency (MF) plating were 
chosen based on the RSG calculation as described in section 3.2.3.2. 
 
Treatment 
groups 
Conc. 
µg/ml 
Cell conc. 
X 105 
Relative 
suspension growth 
(RSG) 
Conc. chosen to 
be plated 
Y=yes 
Neg.Con. A 8.98 100.54 Y 
Neg.Con. B 8.43 98.43 Y 
Neg.Con. C 8.98 101.03 Y 
30 8.74 80.34 Y 
20 8.22 80.82 Y 
10 7.89 81.57 Y 
5 8.20 82.85 Y 
 
 
 
MIT 
Treatment 
with S9 
(3 hr) 
DMBA 8.71 83.37 Y 
Neg.Con. A 8.23 96.75 Y 
Neg.Con. B 8.24 100.32 Y 
Neg.Con. C 8.21 102.93 Y 
30 7.95 18.57 Y 
20 8.42 43.51 Y 
10 8.70 79.55 Y 
5 8.58 74.36 Y 
 
 
MIT 
Treatment 
without S9 
(24 hr) 
MMS 8.23 102.70 Y 
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Table 3.4b Summary table of MLA result for MIT in the i) presence of rat liver S9 
and ii) in the absence of rat liver S9. 
                                                                
(i) 3 hour + S9 treatment 
Treatment 
groups 
Conc. μg/ml RTG (%) MF x 10-6 Positive/Negative
0 86 91.77 Negative 
0 111 66.67 Negative 
Negative 
control 
0 102 71.39 Negative 
30 92 100.61 Negative 
20 96 106.13 Negative 
10 91 70.70 Negative 
 
 
MIT 
5 99 71.61 Negative 
Positive 
control 
(DMBA) 
1 78 550.20 Positive 
Mean Control MF 76.61  
                                   
(ii) 24 hour - S9 treatment 
Treatment 
groups 
Conc. μg/ml RTG (%) MF x 10-6 Positive/Negative
0 96 85.55 Negative 
0 110 88.29 Negative 
Negative 
control 
0 94 89.43 Negative 
 30* 17 114.28 Negative 
20 37 167.49 Negative 
10 81 103.65 Negative 
 
 
MIT 
5 74 56.28 Negative 
Positive 
control 
(MMS) 
5 87 590.04 Positive 
Mean Control MF 87.76  
*RSG= 18.57% 
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3.4 Discussion 
Mitragyna speciosa Korth (Kratom) leaves have been used by humans for 
decades.  There are no reports of increased cancer associated with consumption of 
Kratom leaves although such associations have never been examined in a proper 
controlled study. Neither is there any information available concerning the 
genotoxic potential of Kratom leaves. As part of establishing a database on the 
toxicological potential of the use of this plant, I have attempted to examine the 
possible toxicological effects this plant might have including potential for 
carcinogenicity via genotoxicity testing.  The basic toxicology data established in 
the previous chapter has informed us on the potential cytotoxicity of MSE and 
MIT on several human cell lines, which generally shows cytotoxicity with high 
dose.   The lethal effect of the extract and major alkaloid (MIT) on the cells 
examined prompted the question whether cell death was accompanied by DNA 
damage.  DNA damage as a result of endogenous sources (cellular metabolic 
processes) or exogenous sources (environmental factors such as chemical insult) 
could lead to reversible or irreversible genetic change.  Whether the cell chooses 
to repair such damage or proceed to cell death (apoptosis) or can survive with 
genetic alteration/structural changes (mutation), will affect the development of  
neoplastic processes.  
 
Based on the long term use of this plant by humans, testing for its genotoxic 
potential using mammalian cells was thought to be more appropriate than 
conventional first tier testing for gene mutation in bacteria.   In fact, the primary 
first tier bacterial genetic toxicology assay, the Ames Salmonella assay is 
incapable of detecting large scale deletion or recombination events of the 
mutations.  Such events are more common in mammalian cell mutagenesis (Clive 
et al, 1990). Therefore, the mouse lymphoma tk gene mutation assay (MLA) was 
chosen based on its’ wide acceptance as one of the standard battery tests that is 
eminently well suited for genotoxicity testing (Mitchell et al, 1997). 
 
In general, MSE with or without the presence of metabolic activation (Arochlor 
1254 induced rat liver S9) was negative for genotoxic potential. However the 
results shown for MSE at a concentration of 15 µg/ml MSE in the presence of S9 
turned out to be positive. This result was considered to be a ‘false positive’ due to 
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excessive cytotoxicity indicated by the low RTG and also low RSG (24%) prior 
plating.  Some genotoxic carcinogens could not be detected in in vitro 
genotoxicity assays unless the concentration tested induced some degree of 
cytotoxicity (ICH, 1995). However in the present investigation, very low survival 
level of cells at a dose of 15 µg/ml MSE were observed and  mechanisms other 
than direct genotoxicity per se can lead to false positive results, which are related 
to cytotoxicity and not genotoxicity, such as events associated with apoptosis etc 
(ICH, 1995).  Such events are likely to happen once a certain concentration 
threshold is reached for a toxic compound.  For instance, in figure 2.15A in the 
previous chapter (section 2.4.6), it was shown that clonogenicity assay of SH-
SY5Y at a dose of 20µg/ml MSE  in the presence of S9 reduced the colony 
formation to less than 10% of the vehicle treated control. A similar outcome was 
seen using S9 with L5178Y cells in this assay in the preliminary tests for selecting 
the range of concentrations performed prior to plating assessment.   In fact in the 
preliminary tests, 20 ug/ml MSE was found to be too toxic with RSG only 2% 
(Table 3.3A).     
 
The results for MIT as shown in table 3.4A and 3.4B also revealed a negative 
outcome for genotoxicity under conditions with or without the presence of 
metabolic activation by S9.  In this case, the metabolic activation by S9 did not 
activate the toxic effects of MIT which was contrary to what we had seen for 
MSE.  Interestingly, MIT in the absence of S9 did show cytotoxicity on its own at 
the highest concentration tested, 30 µg/ml MIT. The survival rate was reduced to 
17% of the vehicle treated control and this was thought due to the low viability 
rate (18.57% RSG) determined during the expression period (Table 3.4A).  The 
MF result for this concentration however was below the accepted criteria required 
to be positive.  In view of these findings, it is likely that the involvement of other 
chemicals that are present in the MSE most probably explained why metabolic 
activation by S9 increased MSE toxicity.  Interestingly, whilst S9 did not 
potentiate MIT toxicity, prolonged exposure of the cells to MIT did appear to 
induce dose-dependant toxicity.  The reason for this is not entirely clear.   
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In summary, MSE and MIT do not appear to be genotoxic in MLA.  This finding 
supports the suggestion that there is no overt evidence of cancer or tumour 
incidence upon consumptions of Mitragyna speciosa Korth leaves.  
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CHAPTER 4 
 
EFFECTS OF MSE AND MIT ON THE CELL CYCLE  
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4.1 Introduction 
Cytotoxicity and genotoxicity status of MSE and MIT were established in the 
previous chapters and both agents were determined to be toxic at high dose but 
not genotoxic. The molecular events leading to toxicity are yet to be fully 
understood.   This chapter attempts to examine whether there are any growth 
changes in terms of cell cycle arrest which could be associated with the toxicity 
seen.      
 
Cell cycle is an essential process for all living organisms with the ultimate goal to 
create new cells necessary for maintaining continued survival. 
Under normal circumstances, the four phases of the cell cycle, G1, S, G2 and M 
phases are tightly regulated. The entry of the cell into each phase of cell cycle is 
carefully regulated by cell cycle checkpoints which act as the cell cycle control 
systems. The cell cycle control system has been identified as a series of proteins 
(e.g. cyclins and Cdks) that work together to activate the different phases of cell 
cycle (Morgan, 2008; Alberts et al, 2002). There are three main checkpoints, G1/ 
S and G2/M and metaphase-anaphase transition (Murray and Hunt, 1993) and 
these checkpoints maintain cell cycle arrest which gives time for damaged cells to 
be repaired and then to continue proliferating. Unsuccessful repair processes may 
lead the cells to undergo apoptosis. 
 
In mammalian cells, an important protein that plays a central role in cell cycle 
arrest is p53. The accumulation of p53 will induce another important gene target 
product, a cyclin dependant kinase inhibitor (p21) that inhibits the formation of 
complexes for progression of the cell cycle, therefore leading to cycle arrest  (Ko 
and Prives, 1996; El-Diery et al, 1993) mainly G1 arrest (El-Diery et al, 1994), 
although some studies have shown positive links between p53 and p21 and G2/M 
arrest (Luk et al, 2005 ; Agarwal et al, 1995;), however recent findings have also 
indicated that the G2 arrest may also be induced in cells lacking functional 
p53/p21- signaling axis (Norman et al, 2005). These reports confirm the 
complexity of maintenance of the cell cycle. 
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4.2 Materials and methods 
4.2.1 Cell lines 
HEK 293, MCL-5 and SH-SY5Y cells were used in this analysis.  The cells were 
cultured and maintained as described in chapter 2, section 2.2.2. 
 
4.2.2 Chemicals and reagents 
The chemicals for cell cycle analysis; propidium iodide, RNase, triton-x100 and 
ethyl alcohol absolute were purchased from Sigma-Aldrich (U.K).  Chemicals and 
reagents for Immunoblot assay; 30% acrylamide/bis-acrylamide, sodium dodecyl 
sulphate (SDS), Tween ® 20, ammonium persulfate, tris base, glycerol, 
bromophenol blue, β-mercapthanol, glycine, ponceau s solution and dithiothreitol 
were purchased from Sigma-Aldrich (U.K); N,N,Ń,Ń-tetramethylethylenediamine 
(TEMED) from Bio-rad laboratories (Hemel Hempstead, U.K); methanol from 
Fischer Scientific (U.K.); SeeBlue® pre-stained standard marker was from 
Invitrogen (U.K.) and bicinchoninic acid (BCA) protein assay kit from Pierce 
(Rockford, IL). Primary antibodies were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA) and Oncogene Research Products (Darmstadt, 
Germany) and secondary antibodies were from Sigma-Aldrich (U.K.) and Santa 
Cruz Biotechnology (Santa Cruz, CA). 
 
4.2.3 Equipments 
The Immunoblot apparatus, mini-protean III electrophoresis, hybond 
nitrocellulose membrane and filter paper were purchased from Bio-rad 
laboratories (Hemel Hempstead, U.K). 
 
4.2.4 Methods 
4.2.4.1 Cell cycle analysis by flow cytometry 
HEK 293 or SH-SY5Y cells (105 cells per well) or MCL-5 cells (3.0 x 105 cells 
per well) were seeded in six-well plates.  After pre-equilibration period of 24 hrs 
for HEK 293 or SH-SY5Y cells and 2 hrs for MCL-5 cells, they were exposed to 
various concentrations of MSE and MIT for the designated period of treatment.  
The treatments were done in triplicate.  Immediately after the treatment period, 
cells were harvested as described in chapter 2, section 2.2.2. The SH-SY5Y and 
MCL-5 cells were washed with PBS and HEK 293 cells with D-PBS followed by 
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fixation in ice-cold 70% ethanol overnight. The fixed cells were then centrifuged 
(1200 r.p.m. for 5 min) to remove ethanol and resuspended thoroughly (to get 
single cell suspensions) in propidium iodide staining solution containing 5 mg/ml 
propidium iodide(PI),10 µg/µl RNase and 0.1% triton-x100 and incubated at 37ºC 
for 30 minutes.  Samples were analysed using the Cellquest Pro software on a 
Becton Dickinson FACSCalibur flow cytometer. For each sample, 10,000 or 
30,000 events were collected and aggregated cells were gated out of the analysis.  
The percentage of cells at different phases of the cell cycle was determined using 
ModFit LT MAC 3.1 software or CellQuest pro software.  PI was excited at 488 
nm using an Argon laser, and the fluorescence analysed at 620 nm. 
 
4.2.4.2 Immunoblot 
For this experiment, the procedure was adapted from Laemmli method (Laemmli 
1970). SH-SY5Y cells were used as it was the most sensitive cell line for the 
toxicity effects of MSE and MIT.  SH-SY5Y cells (105 cells per well) were 
seeded in 6 well plates and treated with various concentrations of MSE and MIT 
for the designated time period.  Cells were harvested by routine trypsinisation 
procedure as described in chapter 2 (section 2.2.2). After the centrifugation 
process, the supernatant was aspirated and the cell pellet was washed with PBS 
followed by centrifugation (1000 r.pm. for 5 minutes).  The washing process with 
PBS was repeated and the final centrifugation was performed (1200 r.p.m for 10 
minutes). The supernatant was aspirated and the cell pellet obtained was kept at -
80ºC until further analysis.   
 
The cell lysates and protein determination were carried out prior to immunoblot 
analysis.  The cell pellets kept at -80ºC were thawed at room temperature. 
Protease inhibitor cocktail, EDTA-free (Pierce, Rockford IL) at 10 µl/ml were 
mixed with PBS and 100 µl of this cocktail solutions were then added to the cell 
pellet followed by snap freezing in liquid nitrogen. The frozen samples were then 
re-thawed at room temperature. The samples were sonicated for about 30 seconds. 
Protein determination was performed using BCA protein assay kit (Pierce, 
Rockford IL), following the manufacturers instructions and the absorbance of 
protein was determined at 580 nm wavelength.  
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Sample cocktail buffer (0.5 M Tris, 10% SDS, glycerol, distilled water, 1 % 
dithiothreitol/bromophenol/β-mercaptanol) was added to cell lysates in two fold 
dilutions and heated at 100ºC for 5 minutes.  The pre-prepared polyacrylamide 
gels (varied depending on the size of protein of interest, refer to table 4.1) was set 
up on the mini-protean electrophoresis apparatus. Protein sample (10-20 µg) and  
SeeBlue® standard pre-stained marker were loaded and resolved at 200 mVolts in 
running buffer (3g Tris, 15 g glycine and 5 g SDS in 1L distilled water).  The gel 
fractionated protein was transferred onto hybond nitrocellulose membrane at 200 
mVolts, 400 mA for 90 minutes in the transfer buffer (3 g Tris, 14 g glycine in 1L 
distilled water and 20% v/v methanol). The presence of protein on the 
nitrocellulose membrane was checked using ponceau S red staining. The 
membrane was then soaked in blocking solution (5% powdered low fat milk in 
25mM phosphate buffer saline and 0.1% tween 20)(PBST) on a tilt table for 45 
minutes. The blocking solution was poured off and the membrane was washed 
twice with PBST, each for 5 minutes duration.  After washing, the membrane was 
incubated in appropriate primary antibody prepared in blocking solution (refer to 
table 4.2) and placed in the cold room (4ºC) on the tilt table overnight.  The 
membrane was washed again with PBST three times for 10 minutes duration each 
time and the appropriate secondary antibody (horseradish peroxidase conjugated) 
was added and further incubated in room temperature on the tilt table for 1 hour 
duration (refer to table 4.2).  The blots were then washed as before for three times.  
The membrane was incubated in chemiluminescent solutions (Supersignal 
Chemiluminescent substrates in 1:1 ratio, Pierce, Rockford IL) for 5 minutes at 
room temperature. The membrane was placed in a metal cassette and exposed to 
hyperfilm (Amersham, Germany) in the dark room for an appropriate time period 
and was developed in an automatic developer.  The membrane was washed for 10 
minutes with PBST and re-probed with β-actin to check the protein loading 
equality. 
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Table 4.1 Preparation of polyacrylamide SDS stacking gel (for 2 gels 
approximately 20 ml of total volume).  The gel percentage used for assessing p53 
was 10% (protein size between 20-80 kDa) and for p21 was 15% (protein size 
between 10-43 kDa). 
 
Percentage of Acrylamide 
                   10%                                  15% 
 
Chemicals/Reagents 
Lower gel      Upper gel Lower gel      Upper gel 
Water 5.1 ml 2.87 ml 2 ml 2.87 ml 
Lower gel buffer * 8 ml - 8 ml - 
Upper gel buffer ** - 1.25 ml - 1.25 ml 
30% Acryl. Bis. 6.7 ml 0.83 ml 10 ml 0.83 ml 
10% Ammonium persulphate 150 µl 100 µl 150 µl 100 µl 
TEMED 10 µl 5 µl 8 µl 5 µl 
* ( 91 g Tris, 2 g SDS in 500 ml distilled water, pH 8.8) 
** ( 30 g Tris, 2 g SDS in 500 ml distilled water, pH 8.8) 
Lower gel = resolving gel; Upper gel = stacking gel 
 
 
Table 4.2  Sources and dilutions of primary and secondary antibodies for p53 and 
p21 protein used for the immunoblot assay. 
 
Antibody Dilution Source 
Primary antibody 
 
 
Secondary antibody 
Anti-human p53 rabbit 
polyclonal IgG 
 
Goat anti-rabbit IgG-HRP 
1 in 2000 
 
 
1 in 4000 
Santa Cruz 
 
 
Santa Cruz 
Primary antibody 
 
 
Secondary antibody 
Anti-p53 mouse 
monoclonal IgG 
 
Goat anti-mouse IgG-HRP 
1 in 1000 
 
 
1 in 20,000 
Sigma-Aldrich 
 
 
Santa Cruz 
Primary antibody 
 
 
Secondary antibody 
P21 WAF 1 (Ab-5) 
polyclonal rabbit IgG 
 
Anti-rabbit IgG-HRP 
1 in 500 
 
 
1 in 1000 
Oncogene 
 
 
Santa Cruz 
Primary antibody 
 
 
Secondary antibody 
Monoclonal anti-β-actin 
clone AC-15 mouse IgG 
 
Goat anti-mouse IgG-HRP 
1 in 20,000 
 
 
1 in 40,000 
Sigma-Aldrich 
 
 
Santa Cruz 
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4.3 Results 
4.3.1 Effect of MSE  and MIT on the cell cycle distribution 
The DNA profiles of three different cell lines (HEK 293, MCL-5 and SH-SY5Y 
cells) treated with MSE and MIT were assessed using nucleic acid staining with 
PI and analysed with BD FacsCalibur flow cytometer in the Centre for Molecular 
Microbiology and Infection (CMMI) core facility unit, Flowers Building, South 
Kensington Campus. The procedures were as described in section 4.2.4.  
 
4.3.1.1 Human embryo kidney- HEK 293 cells 
Using HEK 293 cells, the effects of various concentration of MSE on the cell 
cycle profile was determined at 24 and 48 hr time period (Fig. 4.1).  The 10,000 
events were collected during the acquisition and the phases of the cell cycle were 
gated manually using CellQuest Pro software.  For 24 hr results, there were no 
apparent changes in the DNA profile between the control and low dose of MSE 
(11.3 µg/ml).  The accumulation of S and G2/M phase cells were more 
pronounced at the higher dose, 113 µg/ml MSE. The phases of the cell cycle could 
not be determined for the highest concentration tested, 1113 µg/ml MSE as the 
profile was completely destroyed.  Increasing subG1 phase was noted for all dose 
ranges tested at 48 hr treatment period, indicating an increase of the toxicity over 
time. The subG1 phase has been proposed to be a population of apoptotic cells 
(Darzynkiewicz et al, 1992).  
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                                               1113 µg/ml MSE 
 
 
Fig. 4.1 Effects of MSE on cell cycle distribution of HEK 293 cells after 24 and 
48 hours of treatment. Histograms are representative of three replicates of 
experiments with similar results and analysed by Cellquest Pro software. Values 
of each phase of the cell cycle were the mean of the three experiments with SEM. 
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Sub 
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G1:59.55±1.58% 
S: 16.22±1.19% 
G2/M: 21.28±2.41% 
SubG1: 1.03 ±0.128% 
G1:72.97±0.54% 
S: 11.88±0.16% 
G2/M: 11.02±0.35% 
SubG1: 2.60±0.27% 
G1:59.95±1.13% 
S: 20.91±2.99% 
G2/M: 15.34±2.7% 
SubG1: 2.05±0.113% 
G1:69±1.65% 
S: 16.8±1.88% 
G2/M: 10.49±1.44% 
SubG1: 3.25±0.86% 
G1:72.03±1.24% 
S: 18.33±0.81% 
G2/M: 7.13±1.46% 
SubG1: 0.95±0.13% 
G1:58.01±3.95% 
S: 22.54±3.33% 
G2/M: 11.45±1.27% 
SubG1: 6.09±0.46% 
Phases could not 
be determined 
Phases could not 
be determined 
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4.3.1.2   Human lymphoblastoid - MCL-5 cells 
 
For this cell line, the cell cycle analysis was carried out using Cellquest Pro 
software and the aggregated cells (doublet cells) were gated out. The DNA 
profiles were determined using Modfit LT cell cycle analysis software (Verity 
Software, Topsham, ME). The effect of MSE for 24 and 48 hr time period (Fig. 
4.2a) was analysed first. Decreasing of G2/M phase cells was noted for all doses 
compared to control cells for the first 24 hr treatment period. However, there were 
no apparent DNA profile changes seen for the 48 hr treatment group.  The subG1 
population was also observed to be higher at the concentration of 100 µg/ml MSE.  
The percentage of subG1 population unfortunately was not determined during the 
analysis and the evaluation of this population was qualitative.  
 
A further experiment was carried out using higher doses, up to 1000 µg/ml MSE 
for 48 hr time period (Fig. 4.2b).  This time, changes in the DNA profile were 
noted especially on the accumulation of cells in the G1 phase with concomitant 
decrease of G2/M phase cells at 100 µg/ml and more evident at 250 µg/ml MSE. 
At the higher dose level, ≥ 500 µg/ml MSE, the cells in the G1 phase appeared to 
decrease, but the overall profile was considerably altered.  
 
Since the DNA profile changes began to be visible at concentration ≥ 100 µg/ml 
MSE, the temporal aspects of these changes were examined.  Therefore, another 
set of experiments were performed using a fixed concentration, 100 µg/ml MSE 
and a different time-course (4, 8, 24, 48, 72 and 96 hr treatment) (Fig. 4.2c).  
There were no abrupt changes seen for the first 4 hr and 8 hr treatment periods. 
The changes in the DNA profiles were noted after 24 hr of treatment as seen in the 
fig. 4.2c.  Prominent reduction of G2/M phase cells was evident at this time point 
and an increase of S phase cells was also noted for the next 48 to 72 hr. The 
reduction of G2/M phase cells was seen to be consistent after 24 hr of treatment. 
At 96 hr time point, the G1 phase cells were observed to be higher than the other 
time points. Another interesting finding was noted in this experiment in which the 
DNA profiles started to be shifted to the right side at the concentration of  100 
µg/ml MSE (Fig. 4.2b) and again at the same concentrations as early as 24 hr after 
treatment (Fig. 4.2c). 
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                   24 hr                                                                                48 hr 
                                              Vehicle-treated control 
  Channels (FL2-H)0 40 80 120 160                                         Channels (FL2-H)0 40 80 120 160      
 
                                                6.25 μg/ml MSE   
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                                               12.5 μg/ml MSE   
 
   Channels (FL2-H)0 30 60 90 120 150                                           Channels (FL2-H)0 30 60 90 120                         
                                   
                                                  25 μg/ml MSE     
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                                                  100 μg/ml MSE   
   Channels (FL2-H)0 30 60 90 120                                                 Channels (FL2-H)0 30 60 90 120                                        
 
Fig.4.2a Effect of MSE on the cell cycle distribution of MCL-5 cells after 24 and 
48 hr treatment.  Histograms are representative of three replicates of experiments 
with similar results and analysed by Modfit software. Values of each phase of the 
cell cycle were the mean of the three experiments with SEM. 
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G2/M: 15.8±1.88% 
G1:61.9±1.18% 
S: 23.7±0.84% 
G2/M: 14.4±0.72% 
G1:60.95±1.3% 
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G1:61.8±0.93% 
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G1 
S G2/M 
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Fig. 4.2b Effects of higher dose of MSE on the cell cycle distribution of MCL-5 
after 48 hr treatment. Histograms are representative of three replicates of 
experiments with similar results and analysed by Modfit software. Values of each 
phase of the cell cycle were the mean of the three experiments with SEM. 
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Fig. 4.2c Effects of 100 µg/ml MSE on the cell cycle distribution of MCL-5 cells 
at different time points (4, 8, 24, 48, 72 and 96 hr treatment). Histograms are 
representative of three replicates of experiments with similar results and analysed 
by Modfit software. Values of each phase of the cell cycle were the mean of the 
three experiments with SEM. 
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4.3.1.3 Human neuroblastoma- SH-SY5Y cells 
The effects of MSE and MIT on the cell cycle of SH-SY5Y cells were also 
determined. Using this cell line, the DNA profiles were determined at 48 hr time 
point and the cells were dosed up to 1000 µg/ml MSE (Fig. 4.3a). The 
accumulation of G1 population was noted at the lower concentration tested, 50 
µg/ml up to 250 µg/ml. However, the accumulation of S phase and G2/M phase 
cells with concomitant G1 phase population reduction were seen ≥ 500 µg/ml 
MSE. The increase of subG1 population was also prominent at these two highest 
doses. 
 
Further assessment to examine the effects of fixed MSE concentration, 100 µg/ml 
at different time points was performed. In fig. 4.3b, it was noted that at 4 hr time 
point, there was an active DNA replication process occurring (increased S phase 
cells). This finding was found to be in contrast to the previous MCL-5 results 
(Fig. 4.2c). The control cells also show a similar DNA profile as the treated cells 
at the same time point.  The S phase population remains active until the 8 hr 
treatment period.  However, a drastic change was observed at 24 and 48 hr time 
points, where there was a two fold increase of G1 phase cells and loss of G2/M 
phase cells.  However, the G2/M populations seem to regain slowly at 72 hr 
onwards. The presence of subG1 cells in this experiment was clearly noted at 24 
hr treatment onwards.  
 
The DNA profiles of SH-SY5Y cells were also assessed after exposure to various 
concentrations of MIT at 24 hr treatment period (Fig. 4.3c). There were no major 
effects on the cycle seen at doses up to 30 µM MIT. However, striking changes 
were evident at the highest dose tested, 75 µM MIT, where cells accumulated at 
G1 phase and the population shifted to the right side of the scale. This 
phenomenon implies that the treated cells have taken up more PI dye, thus leading 
to a shift to the right.  Due to the amount of MIT compound available, repetition 
of this experiment was not possible. 
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Fig. 4.3a Effects of MSE on the cell cycle distribution of SH-SY5Ycells after 48 
hr of treatment. Histograms are representative of three replicates of experiments 
with similar results and analysed by Modfit software. Values of each phase of the 
cell cycle were the mean of the three experiments with SEM. 
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Fig. 4.3b Effects of 100 µg/ml MSE on the cell cycle distribution of SH-SY5Y 
cells at different time points (4, 8, 24, 48, 72 and 96 hr treatment). Histograms are 
representative of three replicates of experiments with similar results and analysed 
by Modfit software. Values of each phase of the cell cycle were the mean of the 
three experiments with SEM. * Indicates only one experimental result. 
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Fig. 4.3c Effect of MIT on cell cycle distribution of SH-SY5Y cells after 24 hr 
treatment.  Histograms and values of the cell cycle phases are representative of a 
single experiment analysed by Modfit software.  
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4.3.2 Effects of MSE and MIT on cell cycle proteins 
4.3.2.1 Protein concentrations of the cell lysates 
The bicinchoninic assay (BCA) is quick and works in a similar way to the Lowry 
method. The basis of this assay is the reduction of Cu2+ to Cu+ by protein in an 
alkaline medium (the bioret reaction) with the highly sensitive and selective 
colorimetric detection of Cu+ using a unique reagent containing bicinchoninic acid 
(Smith et al, 1985). It is one of the recommended assays for determining protein 
content of cell lysates used for gel electrophoresis in immunoblotting.  Following 
the manufacturer’s instruction, a typical standard curve was obtained from bovine 
serum albumin standard protein using BCA protein assay kit (Fig. 4.4). Routinely, 
BSA calibration curves were used to determine the protein concentrations in SH-
SY5Y cell lysates. 
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Fig. 4.4 A typical standard curve of protein concentration using BCA protein 
assay kit (Pierce, IL). The curve was generated following the manufacturer’s 
instruction and the protein determination from cell lysates were interpolated from 
the curve. Values were the mean of two readings. 
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4.3.2.2 Effect of MSE and MIT on p53 protein levels 
SH-SY5Y, a neuroblastoma cell known to have wild type p53 (Moll et al, 1995, 
1996) was examined by immunoblotting as described in section 4.2.4.  The 
quantitation of each immunoblot obtained was carried out using a UMAX 
powerlook 1100 scanner, and the p53 band intensity normalised to β-actin was 
analysed using Image J version 1.37 software.  The effects of MSE on p53 
expression levels were assessed.  The p53 protein level was found to be decreased 
in a dose-dependant manner especially at lower concentrations of MSE treatment 
for 24 hr as shown in fig. 4.5a. Interestingly, there was an absolute loss of p53 
protein in the cells treated with the two highest doses tested, 100 µg/ml and 250 
µg/ml.  A similar effect was noted for β-actin blot.  Further experiments were 
carried out to determine the time course of the down regulation or loss of p53 
(Fig. 4.5b). There was clear evidence that SH-SY5Y cells start losing p53 as early 
as 6hr after treatment with 100 µg/ml MSE. There was a dose dependant increase 
of p53 levels over time in the lower dose group tested, 10 µg/ml MSE and control 
groups, implying that this cell line expresses p53 protein and the lost of p53 
protein seen at high doses was due to treatment effects.  
 
Parallel immuno blotting experiments were also carried out for MIT as shown in 
fig. 4.5c. There was no significant difference in the p53 levels noted over the dose 
range used however they appeared to be down regulated compared to the control 
group. The time course of MIT induced p53 change was also carried as shown in 
fig. 4.5d.  There was a time dependant down regulation of p53 noted at the highest 
dose tested, 30 µM MIT indicating the loss of p53 protein over time.   The 
findings described above, suggest that the cell cycle arrest of MSE treated cells 
seen previously with flow cytometry was independent of p53 protein induction 
and to the lesser extent for MIT treated cells. It is also important to note that the 
MSE toxicity observed at high dose was found to result in loss of p53 protein but 
also loss of total protein as noted with the β-actin probe. 
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Fig. 4.5a  P53 levels of MSE treated SH-SY5Y cells after 24 hr treatment.  Bars 
are the mean of three experiments with SEM. The p53 value have been 
normalised to the β-actin controls. 
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Fig. 4.5b P53 levels of MSE treated SH-SY5Y cells at different time points (6, 12, 
24 and 48 hr).  The p53 values were means of duplicate experiments and have 
been normalised to the β-actin controls. 
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Fig. 4.5c  P53 levels of  MIT treated SH-SY5Y cells after 24 hr treatment.  Bars 
are the mean of the three experiments with SEM The p53 value have been 
normalised to the β-actin controls. 
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Fig. 4.5d P53 levels of  MIT treated SH-SY5Y cells at different time points (6, 12, 
24 and 48 hr).  The values are means of the duplicate experiments and have been 
normalised to the β-actin controls. 
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4.3.2.3 Effects of MSE and MIT on p53 target gene product, p21 
It is well established that induction of p53 can lead to expression of target gene, 
p21 and thereby cell cycle arrest. Our flow cytometry experiments suggested that 
MSE and MIT could induce cycle arrest, yet from the previous results it was 
clearly shown that p53 was lost at high dose, ≥100 µg/ml MSE even at the earliest 
time point, 6 hr.  Therefore, to further determine whether p21 is positively linked 
with p53, in response to MSE or MIT, we examined p21 levels using 
immunoblots.  The quantitation of p21 protein is described in section 4.3.2.2.  
There was a clear up regulation of p21 protein seen for the control group at 24 and 
48 hours, consistent with the upregulation of p53 noted earlier. Fig. 4.6a, 
demonstrated that p21 protein was undetectable at 100 µg/ml MSE at any time 
point.  This finding supports the previous p53 results. Only slight expression of 
p21 was noted for the low dose tested, 10 µg/ml MSE and it’s only seen at the 48 
hr time point. 
 
Parallel experiments were carried out to assess the effects of MIT on the 
expression of p21 protein. In the previous section, it was noted that there were no 
major differences in p53 band intensity over the dose range tested compared to the 
control group, implying that MIT does not induce the loss of protein as seen in the 
MSE treated cells. As with the p53 effects noted previously, MIT had little effect 
on p21 levels (Fig. 4.6b). 
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Fig. 4.6a P21 levels of MSE treated SH-SY5Y cells at different time points (6, 12, 
24 and 48 hr).  The blots were representatives of duplicate experiments.  Values 
are mean of duplicate experiments normalised to β-actin controls. 
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Fig. 4.6b P21 levels of  MIT treated SH-SY5Y cells at different time points (6, 12, 
24 and 48 hr).  The blots were representatives of duplicate experiments.  Values 
are mean of duplicate experiments normalised to β-actin controls. 
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4.4. Discussion 
In general, the overt toxicity of MSE and MIT in the human cell lines tested 
previously was evident at high doses, ≥ 100 µg/ml and 75 µM for MSE and MIT 
respectively (Chapter 2).  The nature of cell death observed was unknown, and to 
the best of my knowledge there are no reports or information available on 
Mitragyna speciosa Korth toxicity on mammalian cells.  In this study therefore, 
an attempt was made to characterise the MSE and MIT toxicity by looking at cell 
cycle distribution. Firstly, attempt was made to look at the cell cycle distribution 
in different cell lines using flow cytometry approach.  Propidium Iodide is one of 
the most common and recommended dyes to use to quantitatively assess DNA 
content by flow cytometry (Darzynkiewicz et al, 2001).  The dose response and 
temporal effects of treatment were examined in this assay in order to maximally 
evaluate the effect on the cell cycle.  
 
Cell cycle analysis was initially performed using HEK 293 cells and the DNA 
profile was determined manually using the Cellquest Pro software (Fig. 4.1). The 
effect of several concentrations of MSE was compared at two times, 24 and 48 hr.   
From this result, it was clearly indicated that cell cycle arrest at S and G2/M phase 
were pronounced at concentrations of ≥ 100 µg/ml MSE with concomitant 
increased subG1 population especially after 48 hr treatment. The subG1 phase is 
proposed to be an apoptotic population (Darzynkiewicz et al, 1992) as cells with 
condensed DNA appeared to stain less with PI and will appear to the left of the 
G1 peak.   DNA profiles could not be determined at concentrations ≥ 1000 µg/ml 
MSE due to substantial toxicity effects, even at 24 hr time point. This finding has 
positive correlations with the result from the trypan blue experiment from chapter 
2 (Fig 2.10). These current experiments suggest that cell cycle arrest could be an 
associated event for the toxicity effects seen. In order to assess these effects more 
fully, the well established Modfit software was employed for more detailed cell 
cycle analysis.  
 
In general, the DNA profiles for MSE treated MCL-5 cells (Fig. 4.2a) for both 24 
and 48 hr did not show obvious changes over the dose range tested, even for the 
highest concentration, 100 µg/ml MSE. This cell line was less vulnerable to MSE 
toxicity compared to other cell lines as its IC50 value extrapolated from acute 
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trypan blue viability assay was the highest (410.3 µg/ml MSE, table 2.1, Chapter 
2). Further assessment using high dose of MSE revealed that cell cycle arrest for 
this cell line was noted at G1 and S phases at a concentration of 100 µg/ml MSE 
and was more prominent at concentration ≥ 250 µg/ml MSE. A time-course 
experiment using fixed dose, 100 µg/ml MSE, suggested that 24 hr was the time 
point at which the changes began to be noted. On reflection, the interpretation of 
these latter experiments would have been improved by comparison to control 
groups for each time points.  
 
Subsequently, the cell cycle distribution of SH-SY5Y cells treated with MSE and 
MIT was examined as they were the most sensitive cells examined to date. As 
anticipated, cell cycle arrest with this cell line was evident at much lower 
concentration, 50 µg/ml MSE. The time- course experiments using a fixed dose, 
100 µg/ml MSE in this cell line revealed that cell cycle arrest was again noted at 
24 hr and more prominent at G1 phase. Again on reflection, inclusion of control 
group for each time points would have aided interpretation of these experiments. 
Based on the results of the three different cell lines examined, it is suggested that 
MSE causes cell cycle arrest at G1 phase and S phase. Cells treated with MIT 
however, appeared to be more resistant except at the highest dose tested, 75 µM 
where there was evidence for a G1 arrest.  
 
The observations on the right shifting of the DNA profiles which was pronounced 
in the high doses of MSE and MIT in MCL-5 and SH-SY5Y cells, has raised 
question in this study. This phenomenon implies that the live cells have taken up 
more PI, thus increasing the DNA staining intensity. At this stage, the possible 
explanation for this phenomenon is unknown however; it could be due to the 
plasma membrane integrity being compromised due the treatment effects, thus 
creating pores or increase membrane permeabilisation.  
 
A well known ‘gatekeeper’ or ‘guardian of the genome’, the cellular protein, p53 
has been identified to be a key tumor suppressor and is known to play important 
roles in response to DNA damage. Numerous studies have shown that wild-type 
p53 can restrain cell cycle progression and induce cell death via apoptosis when 
the cell is irreversibly damage (Sugrue et al, 1997).  Another important discovery 
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was that the cell cycle inhibitor p21/WAF 1 is a p53 target gene and both are well 
known to have positive correlation with cell cycle arrest (Morgan, 2007; Harper et 
al, 1993). 
 
The current studies suggested that MSE induced cell cycle arrest mainly at G1 and 
S phases at higher dose, ≥ 100 µg/ml MSE. Based on the literature, it was well 
known that p53 has the ability to induce G1 arrest and its target gene p21 
facilitates the arrest (Ko and Prives, 1996) by inhibiting the function of CDKs (Gu 
et al, 1993; Harper et al, 1993). Therefore, the role of p53 and p21 in MSE and 
MIT induced toxicity were examined. However, in the present studies, the cell 
cycle arrest noted appeared to be independent of induction of p53 and p21. Indeed 
cells treated with high dose MSE ≥ 100 µg/ml demonstrated dose-dependant loss 
of p53 and interestingly, loss of β-actin  was also noted.  The loss of the protein 
was strongly dose-dependant as there was a time dependant induction of p53 
expression observed in the control and lower dose groups indicating a normal p53 
expression response in this cell line.  The mechanism of how p53 and β-actin 
proteins could be lost remains unclear and interestingly the losses were evident 
even at the early stages of the treatment.   
 
The effect of MIT on the expression of p53 was also assessed. MIT has 
demonstrated weak toxicity effects compared to MSE. As anticipated, the 
experiments clearly showed that p53 was still being expressed in MIT treated 
groups and in control group but down regulated with time- dependant manner. 
However, at the higher doses of MIT (30 µM), the same pattern of p53 down 
regulations was seen as with the higher dose of MSE.   
 
The next experiment was carried out to further investigate if there was a 
correlation between p53 changes and its target gene p21 in response to MSE and 
MIT treatment.  The results demonstrated that there was a positive correlation 
with the previous p53 experiments, whereby there was no induced p21 protein 
expression at high dose, 100 µg/ml MSE. The control and low dose groups 
however did express p21 protein consistent with the p53 expression.  In the 
parallel experiment with MIT, again p21 was expressed in a time-dependant 
manner that correlated with p53 expression. The difference between treated and 
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control groups was not significant and again suggest that MIT exerts weaker 
toxicity effects compared to MSE.  Collectively, the current findings suggest that 
MSE induces a cycle arrest that appears to be independent of p53 pathway. In 
contrast, MIT appears to induce cell cycle arrest that is p53 dependant. 
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CHAPTER 5 
 
MECHANISMS OF MSE AND MIT-INDUCED CELL DEATH 
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5.1 Introduction 
In chapter four, cell cycle analysis of cells treated with MSE and MIT indicated 
that cell cycle arrest observed at high dose ≥ 100 µg/ml and 75 µM respectively, 
accompanied the cell death of the cell. However it appears that there was no 
involvement of the cell cycle protein p53 and the p21 pathway with MSE.  This 
was not the case with MIT.  Dose dependant lost of p53 and p21 observed at the 
same concentrations causing cell cycle arrest, remains unexplained. The data also 
suggested that the cell membrane integrity was compromised leading to the loss of 
cell content possibly through membrane opening or increased membrane 
permeability. In this chapter, further investigation was attempted to explain these 
observations and to examine the mode of cell death of the cells treated with MSE 
and MIT.   
 
In general, the two distinct pathways of cell death are via apoptosis or necrosis, 
which are distinguishable morphologically and biochemically (Majno and Joris, 
1995; Wyllie et al, 1980). The term of apoptosis was first coined by Kerr et al 
(1972), and it was described as an active way of killing the cells and organising its 
disposal, which was easily detected under a microscope as cells undergo 
condensation of nuclear chromatin, followed by formation of blebbing and 
segregation of the nucleus into fragments known as apoptotic bodies and finally 
disposed of by digestion via lysosomal pathway (Kerr et al, 1972). Whereas 
necrosis, described as a passive way of cell death, is morphologically marked by 
cellular swelling, chromatin condensation followed by cellular and nuclear lysis 
with subsequent inflammation (Wyllie et al, 1980). Recently necrosis was 
described as morphological alterations of cells after cell death (Majno and Joris, 
1995; Cruchten and Broeck, 2002). Programmed cell death or apoptosis follows 
multiple pathways and includes intracellular signalling, which signal the 
activation of a cysteine protease family, the caspases (Cysteinyl-aspatarte-specific 
proteinases) (Alnemri et al, 1996), which play a pivotal role in initiation and 
execution of apoptosis induced by various stimuli (Fig. 5.1). Apart from caspase 
involvement, apoptosis cascade could also be due to the alteration of 
mitochondrial functions such as an increase in production of reactive oxygen 
species (ROS) (Zamzami et al, 1995; Jacobson, 1996) which lead to intracellular 
oxidative stress and consequently cell death.  The ROS generated include, 
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predominantly, the superoxide anion (O2.-), hydrogen peroxide (H2O2), and 
hydroxyl radical (OH2.-). Among these ROS, H2O2 is the most stable and abundant 
(Esposti, 2002) and has a relatively long half-life(Lu et al, 2007).  
 
In this part of the study, morphological features of the cells treated with MSE 
were cytologically examined using Wright-Giemsa or Rapi-Diff staining.  Flow 
cytometry analysis using Annexin V conjugate assays were employed in order to 
distinguish the mode of cell death upon treatment with MSE and MIT. 
Biochemical analysis, using caspase enzymes and fluorescent dye, 2,7-
dichlorofluorescein diacetate (DCFH-DA) for detecting ROS generation in live 
cells,  were also conducted to confirm the mode of cell death. And finally the 
possible involvement of opioid receptors in mediating the MSE and MIT 
cytoxicity has also been investigated. 
 
                
 
Fig. 5.1 A diagram showing the extrinsic and intrinsic pathways of apoptotic cell 
death involving initiator caspases 8 and 9 and executioner caspases 3 and 7. The 
involvement of cell death receptors and its ligands, p53 protein and chemicals 
released from mitochondria in completing the cell death cascade are also shown.  
This diagram is taken from Haupt et al (2003). 
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5.2 Materials and methods 
5.2.1 Cell lines 
HEK 293, MCL-5 and SH-SY5Y cells were used. These cell lines were cultured 
and maintained as described in chapter 2 section 2.2.2. 
 
5.2.2 Chemicals and reagents 
For flow cytometry analysis, Alexa Fluor® 647-Annexin V conjugate staining kit, 
7-Amino-actinomycin D (7-AAD) dye and HEPES buffer were obtained from 
Invitrogen, U.K. For cytological examinations, Rapi-Diff staining was purchased 
from Bios Europe, U.K. and Wright-Giemsa staining was from Sigma-Aldrich, 
U.K. The opioid receptor antagonists, naloxone, naltrindole and cyprodime 
hydrobromide were purchased from Sigma-Aldrich, U.K. For the caspase studies, 
the Apo One® Homogenous Caspase 3/7 kit was purchased from Promega, U.K., 
the caspase inhibitor IV set was from Calbiochem, U.K and ApoTarget™ Caspase 
-8 and Caspase-9 Protease Kits were from Invitrogen, U.K. The fluorescent dye, 
2,7-dichlorofluorescein diacetate (DCFH-DA) and hydrogen peroxide (H202) for 
ROS assay were purchased from Sigma-Aldrich, U.K. 
 
5.2.3 Methods 
5.2.3.1 Cytological examination of MSE treated cells 
Cytological examinations were carried out using SH-SY5Y, HEK 293 and MCL-5 
cells. Staining of these treated cells were performed using Wright-Giemsa or 
Rapi-Diff staining as they offered a quick and a general purpose stain.  
 
HEK 293, MCL-5 and SH-SY5Y cells (2 x 105) were cultured in 25 cm2 flasks 
containing 6 ml media and were acclimatised overnight for HEK 293 and SH-
SY5Y cells and 2 hr for MCL-5 cells prior to treatment with various concentration 
of MSE. The treated cells were then incubated at 37ºC (5% CO2) for the 
designated time period.  The adherent cells (HEK 293 and SH-SY5Y cells) were 
harvested, trypsinised and centrifuged as per routine procedures described in 
chapter 2 sections 2.2.2, however with the exception that the supernatant for each 
treatment were not aspirated but were collected and pooled with the cell pellets.  
After centrifugation (1000 rpm for 5 minutes), the cell pellets of HEK 293 and 
SH-SY5Y cells were washed in pre-warmed D-PBS and PBS respectively and 
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were cultured again in new media for another 24 hr. After this incubation the cells 
were harvested as previously described (section 2.2.2). The cell pellets obtained 
were re-suspended in 1 ml cold PBS or D-PBS. Cell counting for each cell type 
was performed and 2 x 104 cells were transferred onto microscopic slides 
followed by centrifugation (cytospin at 450 rpm for 5 minute).The slides were 
then air-dried for 10 minutes and stained with Wright-Giemsa staining. Briefly the 
slides were fixed with absolute methanol for three minutes, followed by 
immersion in Wright-Giemsa stain for 1 minute, rinsed in PBS for 1 minute and 
finally in water for 1 minute. The slides were mounted with DPX and were 
examined using Zeiss Axiovert 200 widefield microscope at 1000x magnification.  
 
For MCL-5 cells, after designated incubation period, the treated cells were 
transferred into a centrifuge tube followed by centrifugation (1000 rpm for 5 
minute). The cells were counted and 2 x 104 cells were transferred onto 
microscope slides followed by centrifugation (cytospin at 450 rpm for 5 minute). 
The slides were then air-dried for 10 minutes and stained with Rapi-Diff staining 
following the manufacturer’s instructions. Briefly, the slides were immersed in 
fixing solution (thiazine dye in methanol) for 5 seconds, followed by transferring 
the slides without rinsing/drying into acid dye solution (eosin Y in phosphate 
buffer) for  5 seconds. The excess stain was then drained onto absorbent paper and 
the slides were transferred into basic solution dye (methylene blue in phosphate 
buffer) for another 5 seconds. Finally the slides were rinsed briefly in the buffered 
water (pH 7.2) and allowed to dry. The slides were mounted with DPX and 
microscopic examination was then carried out similarly as described for Wright-
Giemsa staining procedure.  
 
5.2.3.2 Annexin V conjugates/7-AAD double staining for apoptosis detection 
In principle, the cell membrane of live cells is covered by phospholipids (lipid 
bilayer), in which phosphatidylserine is located on the inner layer of the plasma 
membrane. In early stages of apoptosis, the phosphatidylserine is exposed to the 
outer surface of the plasma membrane (Darynkiewicz et al, 2001; Fadok et al, 
1992). The anticoagulant protein, Annexin V was found to bind with high affinity 
to phosphatidylserine, therefore fluorochrome-conjugated Annexin V is a good 
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marker for apoptotic cells, specifically for their detection using flow cytometry 
(Darynkiewicz et al, 2001; van Engeland et al, 1998). 
 
Double staining for cellular DNA using Alexa Fluor® 647-Annexin V conjugate 
staining kit and 7-AAD were performed following manufacturer’s instruction. 
MCL-5 or SH-SY5Y cells (1 x 106) in exponential growth phase were incubated 
for 2 hours and overnight respectively, and treated with various concentrations of 
MSE and MIT and further incubated at 37°C (5% CO2) for 24 hour. After routine 
harvesting as described in chapter 2 section 2.2.2, the cell pellets of each cell line 
were washed with cold PBS followed by centrifugation (1200 r.pm.).  Cells were 
re-suspended in Annexin-binding buffer (10mM HEPES, 150 mM NaCl and 2.5 
mM CaCl2  at pH 7.4) and then counted and the cell density adjusted to 1 x 106 
cells/ml, preparing a sufficient volume to have 100 µl per assay.  Alexa Fluor® 
647-Annexin V conjugate (5 µl) was added to each 100 µl of assay and incubated 
at room temperature in the dark for 15 min.  The Annexin-binding buffer (200 µl) 
was added to the suspension and kept on ice followed by adding 2 µl/100 µl cells 
suspension of the 7-AAD (1 mg/ml in phosphate buffer). The cells were then 
incubated on ice for 5 minutes until data acquisition with a Becton Dickinson 
FACSCalibur flow cytometer using CellQuest Pro software.  The fluorescence of 
AlexaFluor®647- Annexin V conjugate  was measured at 650 nm excitation and 
665 nm emission and 7-AAD at 488 nm excitation and 620 nm emission. Thirty 
thousand (30,000) cells were analysed for each treatment using FLOW JO 8.1.1 
software. 
 
5.2.3.3 Caspases enzyme assay 
Caspases play an important role in mammalian apoptosis. In this part of the study, 
two initiator caspases, caspases-8 and 9 and two executioner caspases, 3 and 7 
were used to investigate the mechanism of caspase activation in MSE and MIT 
induced cell death. In parallel, caspase inhibitors were employed to confirm the 
outcome of the former assays.  
 
5.2.3.3.1 ApoTarget™ caspase -8 and caspase-9 protease assays 
The caspase-8 and caspase-9 colorimetric assays purchased from Invitrogen, U.K. 
offer a simple and convenient means for assaying the activity of caspase-8 and 
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caspase-9 enzymes that recognise the amino acid sequences, IETD and LEHD 
respectively. These assays were carried out according to manufacturer 
instructions. Briefly, SH-SY5Y cells/ (2.5 x 106 cells/75 cm2 flask) were cultured 
overnight and treated the next day with high dose of MSE for 4 hr and 24 hr 
incubation time points.  After incubation, the cells were harvested by routine 
trypsinisation procedure as described in chapter 2 section 2.2.2.  Cells (3 to 5 x 
106/sample) were counted and transferred into centrifuge tube for centrifugation at 
1000 rpm for 5 minutes. The supernatants were aspirated and the cell pellets were 
re-suspended with 60 µl of lysis buffer and incubated on ice for 10 minutes. Then 
the lysates were centrifuged at 10,000g for 1 minute and the supernatant (cytosol 
exract) was collected and kept on ice. Protein determination was carried out using 
BCA protein assay kit and for each sample, 10 µl were taken and added to 200 µl 
of 1:20 working reagents  B(containing 4% cupric sulphate):A (containing sodium 
carbonate, sodium bicarbonate, bicinchoninic acid and sodium tartrate in 0.1M 
sodium hydroxide) (Pierce, U.K) and absorbance was read at 560 nm. Each 
cytosol extract sample was diluted to four concentrations (50, 100, 150 and 200 
µg/ml protein) per 50 µl lysis buffer.  One set of similar concentrations were also 
prepared as a negative control (without adding caspase substrate). Samples were 
transferred into 96 well plates and 50 µl 2x reaction buffer plus DTT solutions (10 
µl of DTT/ml of 2x reaction buffer) were added.  Then 5 µl of either caspase -8 
(IETD-ρNA) or caspase -9 (LEHD) substrate were added to the test samples. The 
plate was incubated for 2 hr in the dark at 37ºC prior reading the absorbance at 
405 nm using plate reader. 
 
5.2.3.3.2 Apo One® homogenous caspase 3/7 assay 
SH-SY5Y cells were used in this study and 1 x105 cells/ well of six well plates 
were cultured overnight. Then the cells were treated with MSE and MIT for 4 hr 
and 18 hr incubation time points. After each incubation time point, the cells were 
harvested by trypsinisation and centrifugation as described in chapter 2, section 
2.2.2. This assay was performed as instructed by the manufacturer, Promega, 
USA. The cell counting for each treatment group was carried out and 20,000 cells 
in 100 µl volume were transferred to 96 well black plates with four replicates for 
each concentration, 3 wells for negative control and 3 wells for blank (reagents 
and media only).  One hundred microliter of caspase 3/7 reagents (mixture of 
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caspase substrate and caspase buffer) was added to each well, shaken for 30 
seconds and incubated at room temperature for designated time periods. Serial 
fluorescence readings were performed using a plate reader at 485 nm excitation 
and 520 nm emission.  
 
5.2.3.3.3 Caspase inhibition study 
The SH-SY5Y cells were again used in this assay and the caspase inhibitors  
purchased from Calbiochem included Caspase-3 inhibitor II (Z-DEVD-FMK), 
Caspase-8 inhibitor II (Z-IETD-FMK), Caspase-9 inhibitor I (Z-LEHD-FMK), 
Caspase  general inhibitor I (Z-VAD-FMK), negative control (Z-FA-FMK) and 
positive control, doxorubicin HCL.  One hundred thousand cells/well in 6 well 
plates were cultured overnight. The cells were then treated with 10 µM of each 
inhibitor 30 minutes prior to adding the MSE. The treated cultures were incubated 
at 37ºC (5% CO2) for 48 hr time period.  After incubation, the cells were 
harvested and trypsinised as described in chapter 2 section 2.2.2. The cell pellets 
were then prepared for flow cytometry analysis using PI staining as described in 
chapter 4, section 4.2.4. The cells stained with PI were analysed using BD 
FacsCalibur flow cytometer. PI was excited at 488 nm and 620 nm emissions. Ten 
thousand cells were analysed by CellQuest Pro software and the subG1 population 
representing apoptotic cells were gated manually. 
 
5.2.3.4 Reactive oxygen species (ROS) analysis in SH-SY5Y cells treated with  
MSE and MIT 
ROS generation assay was carried out using SH-SY5Y cells by using a 
fluorescent dye 2,7-dichlorofluorescein diacetate (DCFH-DA).  Principally, this 
dye diffuses through the cell membrane and is hydrolysed enzymatically by 
intracellular esterases to form monofluorescent dichlorofluorescein (DCFH) in the 
presence of ROS. The intensity of the fluorescence is therefore, proportional to 
the levels of intracellular ROS (Galvano et al, 2002). 
  
A fluorescence-based method to measure ROS generation in live cells was a 
modification of the procedure described by Esposti and McLennan (1998). 
Briefly, SH-SY5Y cells (5 x 105 cells/well) in 6 well plates were cultured 
overnight. Then the medium was aspirated and washed with PBS to remove all 
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traces of albumin present in the medium. This is to ensure that the free-radical 
quencher albumin present in the serum used as a media supplement is removed as 
it interferes with the quantitative analysis of ROS (Esposti, 2002). PBS (2 ml) was 
added per well followed by addition of freshly prepared DCFH-DA dye dissolved 
in DMSO (100 µM) under subdued lighting. Anti-oxidant, N-acetyl-L-cysteine 
(NAC) (5mM) was also added to appropriate wells. Fluorescent was measured 
using a plate reader with 485 nm excitation and 530 nm emission. After 30 
minutes, cells in each well were treated with H202, MSE and MIT and the 
fluorescent readings were continually read at 10 min intervals for up to 1 hr 
period.  This preliminary assay was performed to establish the working conditions 
for the assay. 
 
Further optimisation of the ROS assay was performed using SH-SY5Y cells (2 x 
103 cells/well) in 24-well plates cultured overnight. As described earlier, the 
cultured medium was aspirated and fresh PBS (1 ml) was added to each well. The 
fluorescent dye, DCFH-DA (100 µM) was then added to the wells under subdued 
lighting and NAC was also added to appropriate wells.  The cells were incubated 
at 37ºC (5% CO2) for 30 minutes. As the addition of DCFH-DA dye led to 
precipitation as seen in the preliminary experiment,  after 30 min the cultured 
solutions were aspirated and fresh PBS (1 ml) was added to each well prior to 
adding the test compounds (H202, MSE and MIT). The fluorescence readings were 
then taken every 10 minutes interval up to 1 hr as described earlier. 
 
5.2.3.5 Opioid receptor antagonist study 
For the purpose of investigation of the possible role of opioid receptors in 
mediating MSE and MIT toxicity, three opioid receptor antagonists were used; 
naloxone (µ and δ opioid antagonist), naltrindole (δ opioid antagonist) and 
cyprodime hydrobromide (µ opioid antagonist). Trypan blue exclusion and 
clonogenicity assays were employed in this study. SH-SY5Y cells, a 
neuroblastoma cell known to express µ and δ were used.  
 
The trypan blue assay employed for this study was performed as described in 
chapter 2, section 2.2.7. Briefly 50,000 cells were used and cultured in 6 well 
plates. The cells were then treated with opioid antagonist 30 minutes prior adding 
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the MSE or MIT and incubated at 37ºC (5% CO2) for designated time period. For 
clonogenicity assay, 50,000 cells were cultured in 6 well plates and again the cells 
were treated with opioid antagonist 30 minutes prior adding MSE or MIT and 
incubated at 37ºC(5% CO2)  for 24 hr. The procedure for clonogenicity assay was 
carried out as described in chapter 2, section 2.2.8. These experiments were 
conducted with Thomas Randall. 
 
5.3 Statistical analysis 
One way Analysis of variance (ANOVA) with Dunnet or Bonferroni post tests 
was conducted to calculate significant differences, where p-values of <0.05 were 
considered significant. 
 
5.4 Results 
5.4.1 Cytological examinations of MSE treated cells 
The cells stained either with Wright-Giemsa or Rapi-diff stains were examined 
microscopically as described in section 5.2.3.1.  The morphology of MSE treated 
cells are discussed as follows. The HEK 293 and SH-SY5Y cells which were 
treated for 24 hr were allowed to grow for another 24 hr in fresh untreated 
medium prior to microscopic examination, in order to allow a further doubling 
time.  
 
5.4.1.1 Wright-Giemsa staining- SH-SY5Y cells and HEK 293 cells 
The morphology of SH-SY5Y cells treated with low dose of MSE (10 and 50 
µg/ml MSE) appear to have a mixture of necrotic cells ( lysis of cell membrane 
and lost of cell content) and apoptotic cells ( typically chromatin condensation 
with some blebbing formation) (Fig.5.2a).  More pronounced apoptotic cells were 
observed at higher concentration, ≥ 100 µg/ml MSE.  At the highest concentration 
(250 µg/ml MSE), fewer cells remained with the majority of them apoptotic with 
typical chromatin condensation appearance. 
 
For the HEK 293 treated cells (Fig. 5.2b), it appears that this cell line was much 
less sensitive compared to the SH-SY5Y cells, as discussed previously.  The 
necrotic cells were more pronounced than apoptotic cells at concentration cells ≥ 
50 µg/ml MSE. These results suggest that the mode of cell death is cell type 
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dependant with apoptosis more evident in SH-SY5Y cells and necrosis in HEK 
293 cells. 
 
    
                  Control                                                           10 µg/ml MSE 
   
                    50 µg/ml MSE                                           100 µg/ml MSE 
 
          250 µg/ml MSE 
Fig. 5.2a  Cytological examination of SH-SY5Y cells after 48 hr treatment with 
MSE (24 hr treatment and 24 hr doubling time). Each photo is representative of 3 
similar experiments with the same treatment concentration stained with Wright-
Giemsa staining.(    ) indicates apoptotic cells with chromatin condensation and 
blebbing (   ); (    ) shows necrotic cells with cell membrane lysis morphology.  
Magnification (x 1000).   
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                     Control                                                     10 µg/ml MSE 
    
                    50 µg/ml MSE                                        100 µg/ml MSE 
 
                    250 µg/ml MSE 
 
Fig. 5.2b Cytological examination of HEK-293 cells after 48 hr treatment with 
MSE (24 hr treatment and 24 hr doubling time). Each photo is representative of 3 
similar experiment with the same treatment concentration stained with Wright-
Giemsa staining.(   ) indicates apoptotic cells with chromatin condensation and 
fragmentations and blebbing (      ); (      ) shows necrotic cells with cell membrane 
lysis morphology. Magnification (x 1000). 
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5.4.1.2 Rapi-Diff staining- MCL-5 cells 
The quality of the Rapi-Diff staining performed with the MCL-5 cells was not as 
good as the Wright-Giemsa staining however; it is still possible to note that 
morphologically predominant necrotic cells were observed at the concentration ≥ 
50 µg/ml MSE (Fig. 5.2c).  Necrotic cells were noted based on the lysis of 
membrane appearance and swelling of cells with reduced staining intensity 
compared to control and low dose groups. 
     
                       Control                                                  10 µg/ml MSE 
                                        
          
                50 µg/ml MSE              100 µg/ml MSE 
 
    
 
               250 µg/ml MSE 
 
Fig. 5.2c Cytological examination of MCL-5 cells after 24 hr treatment with 
MSE. Each photo is representative of 3 similar experiment with the same 
treatment concentration stained with Rapi-Diff staining. (     ) indicates apoptotic 
cells with chromatin condensation and (    ) shows necrotic cells with cell 
membrane lysis morphology. Magnification (x 1000). 
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5.4.2 Annexin V conjugate assay for apoptosis detection 
Annexin V conjugate /7-AAD double staining was carried out using SH-SY5Y 
and MCL-5 cells treated with MSE and MIT as described in section 5.2.3.2. As 
translocation of phosphatidylserine to the outer plasma membrane indicates early 
apoptotic cell death, Annexin V staining was used as a marker for apoptotic cells 
(van Engeland, 1998).  The cells become reactive with Annexin V prior to the loss 
of the ability of the plasma membrane to exclude 7-AAD staining and  thus 
enables detection of unaffected (live) cells, early apoptotic, necrotic and late 
apoptotic cells (Darynkiewicz et al, 2001). 
 
Each sample was analysed using Flow Jo 8.1.1 software. Briefly the cell 
populations were gated according to four different quadrants (Fig. 5.3a). The first 
bottom left quadrant (Q1) represent the live cells which exclude both stains 
(Annexin V and 7-AAD), the top left quadrant (Q2) represent the Annexin V 
positive cells indicating early apoptosis population, the top right quadrant (Q3) 
represents the Annexin V and 7-AAD positive cell population indicating necrosis 
and the last bottom right quadrant (Q4) represents the 7-AAD positive cell 
population indicating late stage of apoptosis population.  
 
The cytological examinations performed previously indicated that SH-SY5Y cells 
treated with MSE commit to death predominantly via apoptosis especially at high 
dose of MSE.  In fig. 5.3a, the lowest dose of MSE, 1 µg/ml MSE appeared to 
have little effect compared to control group and shows similar profile in terms of 
distribution of percentages of four quadrants. Interestingly at higher MSE 
concentration, the profile of the four different populations was drastically changed 
as the whole population shifted to the right side of the scale. This shift was clearly 
noted at concentrations as low as 10 µg/ml MSE. This finding is consistent with 
the result of the previous flow cytometry analysis with PI staining performed in 
chapter 4, section 4.2.4. DNA profile was noted to be shifted to the right side of 
the scale at concentration ≥ 50 µg/ml MSE.  
 
For MIT treated cells, changes of the four populations were not as drastic as MSE 
treated cells. However, at the highest concentration tested, 75 µM it appears that 
the profile was shifted to the right side with concomitant increase of cells in Q2, 
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Q3 and Q4 indicating increased of apoptotic and necrotic cells.  Again this 
phenomenon was also observed during cell cycle analysis using PI staining at the 
same concentration (chapter 4, section 4.3.1). 
 
For MCL-5 cells (Fig 5.3c), the profile of cell populations seems to completely 
shift to the right side starting at the concentration of 50 µg/ml MSE onwards. The 
majority of the cells were evidently located in the Q3 and Q4 indicating the 
necrotic and late stage of apoptotic populations. This finding supports the 
cytological examinations previously noted, where the cells were predominantly 
necrotic and in the late stage of apoptosis. 
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                      Control                          1 µg/ml MSE                 10 µg/ml MSE                 
             
                  50 µg/ml MSE                100 µg/ml MSE                250 µg/ml MSE                 
MSE 
Conc.(µg/ml) 
Q1 (%) Q2 (%) Q3 (%) Q4 (%) 
Control 91.5 ± 1.328 3.31 ± 0.586 5  ± 0.743 0.2  ± 0.050 
1 92 ± 1.015 2.9 ± 0.253 4.8 ± 0.747 0.3 ± 0.070 
10 81.6 ± 2.281** 2.3 ± 0.081 7.4 ± 1.361 8.8 ± 1.186 
50 0.7 ± 0.086** 0.09  ± 0.008** 11.3 ± 1.452 87.9 ±1.543** 
100 0.04 ± 0.008** 0** 21 ± 1.033 79 ± 1.058** 
250 0.003 ± 0.003** 0** 36.2 ± 10.446** 63.7±10.427** 
   
 
Fig. 5.3a Detection of apoptosis and necrosis of SH-SY5Y cells after 24 hr 
treatment with MSE, by flow cytometry analysis after staining with Alexa Fluor® 
647-Annexin V conjugate and 7-AAD.  
Four quadrants (Q) representing normal cells (Q1), early apoptosis cells (Q2), 
necrotic cells (Q3) and late apoptotic cells (Q4). Table show values of triplicate 
readings of each quadrant from 3 similar experiments. N= 3 ± SEM. ** P<0.01 vs 
control of each Q, ANOVA with Dunnet post test. 
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129 
 
 
        
100 101 102 103 104
7-AAD
100
101
102
103
104
An
ne
xi
nV
-A
le
xa
 6
47
2.32 4.53
0.6492.5
 
100 101 102 103 104
7-AAD
100
101
102
103
104
An
ne
xi
nV
-A
le
xa
 6
47
1.61 4.59
1.0692.7
100 101 102 103 104
7-AAD
100
101
102
103
104
An
ne
xi
nV
-A
le
xa
 6
47
2.51 5.75
0.990.8
 
                    Control                                    0.3 µM                           3 µM 
        
100 101 102 103 104
7-AAD
100
101
102
103
104
An
ne
xi
nV
-A
le
xa
 6
47
1.73 4.82
0.5992.9
   
100 101 102 103 104
7-AAD
100
101
102
103
104
A
nn
ex
in
V
-A
le
xa
 6
47
1.41 5.75
3.1789.7
    
100 101 102 103 104
7-AAD
100
101
102
103
104
A
nn
ex
in
V
-A
le
xa
 6
47
3.62 10.3
9.8176.3
 
                     15 µM                                30 µM                              75 µM 
MIT 
Conc.(µM) 
Q1 (%) Q2 (%) Q3 (%) Q4 (%) 
Control 91.3 ±1.25 1.95 ±0.23 5.36 ±0.94 1.4 ± 0.56 
0.3 91.9 ± 0.6 1.8 ± 0.13 5.09 ± 0.36 1.21 ± 0.27 
3 90.8 ± 0.43 1.97 ± 0.3 5.92 ± 0.33 1.26 ± 0.18 
15 92.2 ± 0.47 1.57 ± 0.09 4.97 ± 0.3 1.27 ± 0.34 
30 89.9 ± 1.1 1.37 ± 0.04 5.94 ± 0.63 2.84 ± 0.5 
75 78.4 ± 1.42** 2.3 ± 0.65 9.3 ± 0.5** 9.9 ± 0.95** 
 
 
Fig. 5.3b Detection of apoptosis and necrosis of SH-SY5Y cells after 24 hr 
treatment with MIT by flow cytometry analysis after staining with Alexa Fluor® 
647-Annexin V conjugate and 7-AAD.  
Four quadrants (Q) representing normal cells (Q1), early apoptosis cells (Q2), 
necrotic cells (Q3) and late apoptotic cells (Q4). Table show values of triplicate 
readings of each quadrant from 3 similar experiments. N= 3 ± SEM. ** P<0.01 vs 
control of each Q, ANOVA with Dunnet post test. 
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                              Control                                            50 µg/ml MSE 
                                
                          100 µg/ml MSE                                   250 µg/ml MSE 
 
MSE 
Conc.(µg/ml) 
Q1 (%) Q2 (%) Q3 (%) Q4 (%) 
Control 73.5 ± 0.593 15 ± 0.681 10.5 ± 0.7 1 ± 0.084 
50 0.16 ± 0.042** 0.28 ± 0.077** 27.7 ± 0.351** 71.8 ±0.393** 
100 0.03 ± 0.008** 0 ** 41 ± 2.252** 59 ± 2.236** 
250 0.008 ± 0.004** 0** 4.15 ± 3.585 95.8 ±3.626** 
 
 
Fig.5.3c Detection of apoptosis and necrosis of MCL-5 cells after 24 hr treatment 
with MSE by flow cytometry analysis after staining with Alexa Fluor® 647-
Annexin V conjugate and 7-AAD.  
Four quadrants (Q) representing normal cells (Q1), early apoptosis cells (Q2), 
necrotic cells (Q3) and late apoptotic cells (Q4). Table show values of triplicate 
reading of each quadrant from 3 similar experiments. N= 3 ± SEM. ** P<0.01 vs 
control of each Q, ANOVA with Dunnet post test. 
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5.4.3 A possible role of caspases  in MSE and MIT induced cell death 
Programmed cell death or apoptosis is one way cells can commit to death induced 
by numerous factors. In the present study a possible involvement of caspase 
proteases, both pro-apoptotic caspases (caspase 8 and 9) and executor caspases 
(caspase 3 and 7) were examined using commercially available kits as described 
in section 5.2.3.3.  
 
5.4.3.1 Possible involvement of pro-apoptotic caspases (8 and 9) 
The caspase 8 colorimetric assay performed on SH-SY5Y cell lysates indicated 
little difference between all MSE treated groups and control group for both 4 hr 
and 24 hr incubation time period (Fig.5.4 A and B). The same outcome was also 
noted for caspase 9 assay which was performed using the same cell lysates (Fig. 
5.4 C and D). At the 24 hr time point of both caspase assays (Fig. 5.4 B and D) 
the same outliers were noted at concentration of 150 µg lysates, possibly 
indicating the amount of protein used was less than expected and this could be due 
to a technical error during the dilution process.   
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      Fig. 5.4 Activity of initiator caspase 8 after A) 4 hr incubation and B) 24 hr 
incubation time period and initiator caspase 9 after C) 4 hr incubation and D) 24 
hr incubation time period of SH-SY5Y cells treated with MSE.  The reading of 
each concentration is from 2 pooled lysates. 
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5.4.3.2 Possible involvement of caspases executor ( 3 and 7) 
The fluorometric measurement of the activity of caspase 3/7 was carried out for 
SH-SY5Y cells treated with high dose of MSE and MIT incubated for 4 and 18 
hrs respectively as described in the section 5.2.3.3.2. As shown in fig.5.5 A, there 
was a non-significant difference noted for caspase 3 and 7 activities for MSE 
treated cells compared to control groups at 4 hr incubation time point.  For MIT 
treated cells (Fig. 5.5 A), both 100 µM and 300 µM showed significant 
differences compared to control group for all fluorometric readings. 
 
For 18 hr incubation time period (Fig. 5.5 B), again there was no significance 
difference between MSE treated groups and control group. Whereas for MIT, as 
shown in previous 4 hr incubation time point, similar results were observed for 
both MIT treated groups. These results suggest that caspase 3 and 7 activities 
were more pronounced in MIT treated cells and are likely not to be involved in 
the MSE treated cells. 
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Fig. 5.5 Activity of executor caspases 3/7 on SH-SY5Y cells treated with various 
concentrations of MSE and MIT at A) 4 hr and B) 18 hr incubation time period. 
N=3 ± SEM, *P<0.05, **P<0.01 vs control of the same time reading, ANOVA 
with Dunnet post test. 
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5.4.3.3 Caspase inhibition study 
Since the possible involvement of caspases 3/7 in the MSE treated SH-SY5Y cells 
was not established in my preliminary experiments, further assays were carried 
out to confirm this finding. The inhibitors used were caspase 3 inhibitor, caspase 8 
inhibitor, caspase 9 inhibitor, general caspase inhibitor, negative control and 
doxorubicin as a positive control ( as described in section 5.2.3.3.3). In fig. 5.6, it 
was confirmed that there was no difference noted between all caspase inhibitor 
groups and negative control and control groups. The positive control doxorubicin 
confirmed the assay works by showing a highly significant response for apoptosis.  
Thus, this finding supported the notion that there was no involvement of caspase 
executioner nor caspase initiator activation in cell death induced by high dose 
MSE.         
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Fig. 5.6 Flow cytometry analysis of the subG1 population (apoptotic cells) of SH-
SY5Y cells after 48 hr treatment with various caspase inhibitors and MSE. N=3 ± 
SEM, ** P<0.01 vs control, ANOVA with Dunnet post test. 
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5.4.4 ROS generation in SH-SY5Y cells treated with MSE and MIT 
As described in section 5.2.3.4, intracellular ROS generated from mitochondria of 
SH-SY5Y cells was measured by fluorescence in which the intensity of 
fluorescent product, DCFH is proportional to the levels of intracellular ROS 
generated.  Results of the preliminary assay as shown in fig. 5.7 indicated that the 
positive control, H202 significantly released ROS as soon as it was added to the 
cells (at the 30 minute time interval) and was consistently higher than other group 
treatments.   The incubation of anti-oxidant, NAC 30 minutes prior to adding 
H202, appears to reduce the ROS production. Interestingly, both high doses of 
MSE and MIT, appeared similar to control groups and indicate that there was no 
ROS generation in this cell line.  
 
Another important microscopic observation was made after the final readings at 
the 1 hr time point, which showed that all cells in the Control group appeared 
rounded and floating in the middle of the well. Similar observations were also 
noted for H202, MSE and MIT groups. Interestingly, the majority of the cells 
which were treated with NAC prior to treatment with H202, appeared firmly 
attached to the bottom of the wells and had normal cell appearance. Brownish 
precipitations were also noted floating in all wells, believed to be the hydrophobic 
fluorescent dye, DCFH-DA.  
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Fig. 5.7 Measurement of ROS with DCFH-DA (100 µM) in SH-SY5Y cells 
treated with H202, MSE and MIT with or without anti-oxidant, NAC (added at 30 
minutes). The  fluorescence product, DCF was measured at 485 nm ex. and 530 
nm em. The result was generated from a single preliminary experiment. 
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After this preliminary experiment, optimisation of the assay was conducted as 
described in section 5.2.3.4 as there was a concern over the presence of DCFH-
DA precipitations seen in the preliminary assay, which could interfere with the 
fluorescence readings.   As shown in fig. 5.8A and B, a similar pattern of results 
was noted as in the preliminary assay (Fig. 5.7).  Again the positive control group, 
H202 treated cells in both experiments seems to generate higher ROS levels 
compared to other groups. Cells pre-treated with anti-oxidant, NAC produced 
lower ROS levels than cells treated with H202 alone. Cells treated with both high 
concentrations of MSE (Fig. 5.8A) and cells pre-treated with NAC appeared 
similar to Control group. This infers that MSE did not generate ROS, which 
confirmed the earlier finding.  Microscopic observations were also carried out 
after the final readings, and again similar observations were noted; cells appeared 
rounded and floating in the middle of the well for Control,  H202 and MSE groups, 
and live cells attached firmly on the bottom of the wells for the H202/NAC, MSE 
100 µg/ml/NAC and MSE 350 µg/ml/NAC groups. 
 
With MIT treatment groups (Fig. 5.8B), similar findings were clearly seen.  Both 
MIT concentrations and combinations of MIT/NAC appeared no different 
compared to Control group. This result again indicated no generation of ROS 
upon treatment with MIT.  However, an interesting finding was noted upon 
microscopic observation of the cells pre-treated with NAC as the majority of them 
were floating and very few cells appeared attached to the bottom of wells. This 
observation is in contrast of what was seen for MSE pre-treated NAC groups. 
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Fig. 5.8 Measurement of ROS with DCFH-DA in SH-SY5Y cells treated with A) 
H202, MSE with or without NAC and and B) H202, MIT with or without NAC.  
The fluorescent readings are normalised to Control group. N=3 ± SEM.   
ANOVA, **P < 0.01  test  vs control at 33 min; +P <0.05, ++P <0.01 test vs control 
at 63 min with Dunnet post test;  # # #P<0.001 H202 vs H202+ NAC at both 33 and 
63 min with Bonferroni post test. 
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5.4.5 Effects of opioid receptor antagonists on treated SH-SY5Y cells 
The SH-SY5Y cells were chosen for this study; they provide a good model to 
study opioid receptor system as they express predominantly the µ and δ receptor 
(Kazmi and Mishra, 1986). The trypan blue assay and clonogenicity assay were 
employed as described in chapter 2, section 2.2.8 and 2.2.9.  The effects of 
selective opioid receptors antagonist, naloxone (µ and δ antagonists), naltrindole 
(δ antagonist) and cyrpodime hydrobromide (µ antagonist) on various 
concentrations of MSE and MIT are discussed as follows: 
 
Effects of naloxone on MSE and MIT treated cells: 
Fig. 5.9A indicates that after 24 hr of treatment (trypan blue exclusion), naloxone 
at the concentration of 1 µM successfully inhibits MSE toxicity especially at high 
dose, 100 µg/ml MSE. Naloxone also appears to successfully inhibit the MIT 
toxicity (Fig. 5.9B).  However, on the longer term effects of treatment 
(clonogenicity assay) as shown in fig. 5.10A, 1 µM naloxone was found not 
sufficient to inhibit the MSE toxicity at the same concentration used for previous 
experiments. Increasing the concentration of naloxone up to 5 µM did give a 
positive response. With the clonogenicity assay, longer term treatment effects of 
MIT, naloxone appears to give protection only for the lower dose (25 µM) but not 
on the high dose (100 µM) even when the naloxone concentration was increased 
to 5 µM (Fig. 5.10A).   
 
Effects of naltrindole on MSE and MIT treated cells: 
The effects of naltrindole on acute treatment (Fig. 5.9C) suggests that naltrindole 
at 1 µM concentration also gave some protection against MSE toxicity at high 
dose but not sufficient to be significant when compared to Control groups. For 
MIT treated cells (Fig. 5.9D), it appears that naltrindole again successfully 
inhibited MIT toxicity at all concentrations tested.  Whereas for the longer term 
effects (clonogenicity assay), fig. 5.10B shown that naltrindole at both 
concentration 1 and 5 µM, successfully gave protection against MSE toxicity at 
all dose range, however it was not that effective for MIT at high dose. 
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Effects of cyprodime hydrobromide on MSE and MIT treated cells: 
Cyprodime hydrobromide which is a selective antagonist for µ opioid receptor 
gave confirmation that MSE mediates its toxicity via this receptor, as shown in 
acute treatment of MSE (trypan blue exclusion, Fig. 5.9E), giving protection 
against MSE toxicity at high dose. In fig. 5.9F, cyprodime hydrobromide also 
gave some protection effects against MIT toxicity (as measured by trypan blue 
exclusion).  For longer term assessment, cyprodime hydrobromide again shows 
protective effects for both MSE and MIT toxicity effects even at 1 µM 
concentration (Fig. 5.10C). 
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Fig. 5.9   Trypan blue exclusion assay of SH-SY5Y cells after 24 hr treatment 
with A) MSE ± Naloxone (N), B) MIT ± naloxone (N), C) MSE ± Naltrindole, 
D)MIT ± Naltrindole, E) MSE ± Cyprodime hydrobromide, F) MIT ± Cyprodime 
hydrobromide. N= 3 ± SEM, * P<0.05, MSE vs MSE + Naloxone or Cyprodime 
hydrobromide, +P<0.05, MIT vs MIT + Naloxone, ANOVA with Bonferroni post 
test. 
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Fig. 5.10  Clonogenicity of SH-SY5Y cells after 24 hr treatment with A) MSE and 
MIT ± Naloxone (N), B) MSE and MIT ± Naltrindole (Nt) and C) MSE and MIT 
± Cyprodime hydrobromide (C). *P<0.05, **P<0.01, ***P<0.001 MSE vs MSE + 
N or Nt, +P<0.05, MIT vs MIT + Nt, ANOVA with Bonferroni post test. These 
experiments were conducted with Thomas Randall. 
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5.5 Discussion 
Cytotoxicity studies performed in the previous chapters provide evidence for the 
first time that MSE and MIT induce toxicity leading to cell death at high dose, ≥ 
100 µg/ml and 75 µM respectively. The nature of cell death and mechanism 
associated with it is yet to be reported. Thus, in this part of this thesis, several 
investigations were attempted to provide possible mechanism of the nature and 
mode of cell death seen with a selected panel of human cell lines. The cytological 
examination using three different cell lines (SH-SY5Y, HEK 293 and MCL-5 
cells) was the first investigation. As anticipated, toxicity effects seen at high doses 
suggested apoptotic morphology with evidence of chromatin condensation, which 
was predominantly seen in SH-SY5Y cells. Nuclear alterations are key in many 
descriptions of apoptosis. The changes involving the condensation of nuclear 
chromatin has been ascribed to the early stages of apoptosis and can be easily seen 
by light microscopy (Häcker, 2000). The severity of MSE insult in the SH-SY5Y 
cell line was obvious at the highest dose tested, as there were very few cells 
present on the slide and all of them showed apoptotic morphology.  This finding 
supports the result from trypan blue exclusion experiments in chapter 2, which 
showed that SH-SY5Y was the most sensitive cell line examined with IC50 of 92 
µg/ml MSE.  
 
For HEK 293 cells, the nature of cell death was more necrotic than apoptotic as 
morphologically the cell membrane integrity was compromised leaving a reduced 
stained intensity and indicating lysis of cell membrane and subsequent lost of cell 
content.  Although Rapi-Diff staining is often used for cell morphology, in this 
case, the quality of staining was not as good as Wright-Giemsa staining, however 
it still provided an indication of the different modes of cell death of MCL-5 cells. 
Comparison between treated cells especially at dose ≥ 50 µg/ml MSE, with 
control and lower dose groups, showed there was a clear necrotic appearance with 
swelling of cells, lysis of cell membrane and lost of cell content. All these 
morphological observations suggested that the mode of cell death was cell type 
dependant with apoptosis pronounced in SH-SY5Y cells and necrosis for HEK 
293 and MCL-5 cells. 
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In chapter four, the cell cycle analysis using PI staining clearly indicated that the 
cell cycle arrest seen at high dose ≥ 100 µg/ml MSE  in three different cell lines, 
HEK 293, SH-SY5Y and MCL-5 cells accompanied the death of these cells line. 
Marked increase of subG1 populations with concomitant cell cycle arrest 
observed at high dose of MSE and MIT would suggest that the apoptotic 
populations as described by Darynkiewicz (1992) were actually a mixture of 
apoptotic and necrotic cells. Furthermore, the cell cycle protein analysis (p53 and 
p21) performed using immunoblotting approach indicates the loss of these 
proteins at high doses of MSE and to the lesser extent MIT. The mechanism of 
this phenomenon is not obvious.  However, one hypothesis that could be proposed 
is the possibility of the membrane integrity being compromised especially at high 
dose of treatment or in other words the lost of cell content through membrane 
opening. In principle, in DNA cycle analysis, the movement of DNA profiles to 
the right side of the scale indicates more dye has been taken up. This would be the 
implication if the pores of the plasma membrane open or if there was a 
mechanism in which the dyes could diffuse more easily into the cell. 
 
Another flow cytometry analysis was carried out in this chapter, this time using 
double staining with Annexin V conjugates-7-AAD to further determine the 
nature of cell death.  Surprisingly this time, a similar outcome was observed for 
both, SH-SY5Y and MCL-5 cells and the shifting of the whole populations was 
evident at much lower concentrations of MSE than in the previous PI staining in 
chapter 2.  This phenomenon is obviously due to the treatment effects as the 
control and lowest concentration of the MSE tested as seen in fig. 5.3a, b and c. 
remain as normal profile for this double staining.  The hypothesis of plasma 
membrane opening is supported with this finding. This phenomenon creates 
disadvantages for this assay as when the whole FACS profile shifts to the right 
side of the scale, the determination of the stages of cell death is difficult to 
interpret as the cells are no longer located in specific quadrants.  From fig. 5.3a, b 
and c, it appears that most of the cells were necrotic and late apoptotic 
populations.  This observation is clearly in contrast with the previous cytological 
examinations which indicated that SH-SY5Y cells treated with high dose of MSE 
undergo apoptosis rather than necrosis.  The right shifting phenomenon for MIT 
treated cells observed in fig.5.3b were less pronounced compared to cells treated 
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with MSE. For HEK 293 and MCL-5 cells the effects seen were in agreement 
with the cytological examinations. Since the Annexin V-conjugate-7-AAD double 
staining provide inconclusive results especially for the SH-SY5Y cells,  further 
experiments  looking at biochemical effects of MSE treatment was warranted.   
 
Discovery of a family of cysteine protesases named caspases (Srinivasula et al, 
2001; Alnemri et al, 1996) in mammalian cells has made important discoveries 
towards its function in cell death mainly in apoptosis. Their characteristic ability 
is to perform proteolytic cleavage at defined aspartate acid residues in various 
cellular substrates (Srinivasula et al, 2001). The biochemical basis of 
morphological alterations for apoptosis was reported to be associated with 
caspase-mediated proteolysis of nuclear proteins and degradation of chromosomal 
DNA (Häcker, 2000).  Therefore the inference that MSE and MIT induced 
apoptosis, which was suggested by cytological examination, was further 
determined using caspases activation pathway. In the first instance, an assay was 
performed to look for possible activation of caspases 8 and 9 which are the main 
initiators in activating another caspases. The fluorometric readings with SH-SY5Y 
cells which were treated with high doses of MSE as early as 4 hr failed to show 
any significant caspase 8 and 9 activities. A second incubation time point at 18 hr 
also showed negative results.  These findings could mean either there was cell 
death independent of caspase 8 and 9 activation or it could be related to the lost of 
caspase 8 and 9 as seen for the lost of p53/p21 due to the phenomenon of 
membrane pore opening.  
 
The next step was investigating the possibility of involvement of executioner 
caspases such as caspase 3 and 7. The executioner caspases are also known as 
downstream caspases as they depend on active initiator caspases for their 
activation by proteolytic cleavage (Srinivasula et al, 2001). As anticipated, there 
was no activation of caspases 3 and 7 activities in cells treated with high dose of 
MSE at both 4 hr and 18 hr incubation time points. Interestingly, for MIT, there 
was a clear significant difference of caspases 3 and 7 activities at both 
concentrations of MIT tested. This finding suggests that the mode of the cell death 
of MIT treated cells is dependant on caspase 3 and 7 activation pathway. Further 
confirmation of non-involvement of caspase enzyme pathway in MSE treated 
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cells was supported by the flow cytometry analysis of the caspase inhibition 
study. There were no significant differences in the subG1 population (apoptosis 
population) between treated groups (caspase 3 inhibitor, caspase 8 inhibitor, 
caspase 9 inhibitor and general caspase inhibitor treated with high dose of MSE) 
and the control and negative control groups. At this stage, it seems that despite 
having high MIT content in the MSE, the high dose MSE treatment in SH-SY5Y 
cells does not activate caspase enzymes. This probably could be due to other 
chemicals that present in MSE preventing the activation of caspase enzymes. 
 
Cell death of SH-SY5Y cells after MSE and MIT appeared to be predominantly 
via apoptosis based on its morphological appearance, however biochemically, the 
results discussed above fail to support a caspase mediating event.  As apoptosis 
could follow various pathways and often vary in different cells (Esposti and 
McLennan, 1998, Hetts, 1998) this prompted us to further investigate if other 
pathways could contribute. A great number of studies have demonstrated that 
central execution of apoptosis by mitochondria can play a critical role in cell death 
(Esposti and McLennan, 1998). The majority of mitochondrial alterations which 
lead to apoptosis involve an increase of ROS production (Zamzami et al, 1995).  
An example of involvement of ROS production in early stages of apoptosis 
pathway is provided by ceramide-induced apoptosis (Radin, 2001; 2003).  A 
modification of the procedure of ROS detection in live cells adapted from Esposti 
and McLennan method (1998) was performed; it revealed that both MSE and MIT 
at high doses did not generate ROS.  This result suggests that the mitochondria are 
still functioning normally or if the MSE and MIT could cause membrane opening 
or change the membrane permeability, the DCFH-DA dye could leak out from 
cells and thus not allowing ROS to be detected. Interesting observations made at 
the end of 1 hr incubations of the cells informed that the control cells for both 
MSE and MIT treated experiments become rounded and floating, implying that 
the cells are probably dying perhaps due to lack of nutrient. Yet co-treatment of 
cells with NAC prevented this toxicity, particularly with MSE. These observations 
give information that there are possibly other chemicals present in the MSE that 
could have, together with NAC maintain the cell growth in media that lack 
nutrients, thereby permitting the cells to survive longer. NAC alone is reported to 
have beneficial effects preventing oxidative stress and damage to cells (Yedjou 
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and Tchounwou, 2007) and also plays an important role in the production of 
glutathione to help prevent oxidative stress (De Vries and De Flora, 1993).  
 
The final experiment in this chapter was to investigate whether the opioid 
receptors, such as µ and δ receptors which have been reported to be responsible 
for the pharmaceutical effects exerted by MIT (Watanabe et al, 1997; 
Thongpradichote et al, 1998) could play important roles in mediating the 
cytotoxicity effects seen so far.  Thus three different opioid receptor antagonists 
were used that selectively inhibit these two types of opioid receptors, namely 
naloxone (µ and δ receptor antagonists), naltrindole (δ receptor antagonist) and 
cyprodime hydrobromide (µ receptor antagonist). Interestingly, all these opioid 
receptor antagonists successfully inhibited MSE toxicity and indicates that the 
toxicity effects of MSE was mediated by both µ and δ receptor. Whilst for MIT, 
the results suggest that the main receptor involved is µ opioid receptors. This 
result implies that there are possibly other chemicals present in the leaves of this 
plant which could be contributor to the MSE cytotoxicity. 
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CHAPTER 6 
 
GENERAL DISCUSSION AND CONCLUSIONS 
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6.1 General Discussion 
 
There is an increasing popularity of use of Mitragyna speciosa Korth (Kratom) 
leaves as self-treatment for opioid withdrawal and chronic pain among Americans 
(Boyer et al, 2007).  This in fact reflects increasing interest in constituents of this 
plant, MIT and its congener 7-hydroxymitragynine which have been shown to 
exert potent analgesic effects in various in vivo and in vitro studies (Matsumoto et 
al, 2004). Furthermore, with the recent report on the use of this plant to treat 
chronic pain with lesser effects of withdrawal, compared to opioid prescription 
treatment, people are using this plant as an alternative to opium drugs (Boyer et 
al, 2008). In addition, the increasing number of vendors supplying the leaves of 
this plant in any form via the internet has made the plant globally available as 
there is no restriction or legislation against possession of this plant, except in the 
source countries (Malaysia, Thailand, etc). Apart from the effects of using this 
plant seen with traditional users and drug addicts, as described previously in 
chapter 1(section 1.2.3), there are no reports of overt toxicity effects associated 
with its longer term use. With the introduction of legislation against possession of 
this plant in Malaysia, the access of this plant to the public, especially to drug 
addicts, is now under tighter control. Like many other traditional remedies that 
exist in the market, the potential toxicity of this plant and its derivatives are not 
fully known. 
 
Based on the long use of this plant by humans with no reports on serious health 
effects or cancer formation, it might be assumed that the use of this plant is safe. 
However, as quote famously by Paracelsus, ‘All substances are poisons; there is 
none that is not a poison. The right dose differentiates a poison and a remedy’. 
Thus based on this basic toxicology principle, this study hypothesised that ‘the 
use of MSE and MIT may have potential cytotoxic effects’. The hypothesis was 
tested using various in vitro techniques which assessed the cellular and 
biochemical consequences of exposure.  
 
Methanol-chloroform extraction of Mitragyna speciosa Korth leaves, as modified 
from Houghton and Ikram (1986), was employed in this study as it was expected 
to give the highest yield of the major alkaloid  MIT as compared to other type of 
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extractions (Baharuldin, 2002).  Based on UV-VIS spectrometer analysis, MSE 
extract obtained by this method was estimated to contain approximately 42% of 
MIT-like compound.  Since the percentage of MIT present in the MSE is high, 
MIT was assumed to be the major contributor for the MSE effects. However it 
should be born in mind that the methanol-chloroform extract of Mitragyna 
speciosa Korth used in the current study (MSE) was prepared to maximise the 
MIT-like chemical content of the extract and is probably not bioequivalent to 
aqueous extract that humans are exposed to as the result of chewing leaves. 
 
Prior to this study, MIT was thought to be the compound responsible for the 
narcotic effects of this plant. In the early part of this study, basic in vitro 
toxicology revealed that MSE and MIT have dose dependant toxicity to several 
human cell lines, and the SH-SY5Y cell was the most sensitive. This is not 
surprising as the central nervous system was pharmacologically determined as the 
target system for the biological effects of this plant, thus a toxicity response might 
be anticipated in neuronal cells. In the present study, it is suggested that the 
toxicity effects seen for MSE were predominantly due to MIT, as shown by 
similar IC50 values for MIT and MSE treated SH-SY5Y cells.  
 
The role of metabolism was also assessed, in which the toxicity of MSE treated 
SH-SY5Y cells was found to increase 10-fold when the metabolic activation 
system, post mitochondrial rat liver S9 induced by Arochlor 1254, was added to 
the treatment.   However, contradictory results were noted when metabolically 
competent MCL-5 cells appeared to detoxify MSE rather than activate it. This 
contradictory finding is most probably due to the presence of other enzymes 
including different subfamilies of CYP 450’s, in the S9 that contribute to 
activating MSE toxicity. Arochlor 1254 is known to be a potent inducer of wide 
range of mixed-function oxidase enzymes (Puga and Wallace, 1998; Ryan et al, 
1977). Further assessment looking at the possible contribution of CYP 450’s 
revealed that CYP 2E1 may have a role in activating MSE toxicity. CYP 2E1 is an 
important xenobiotic metabolising enzymes for human and rodents which is 
expressed in the liver. CYP 2E1 can metabolise various substrates including 
paracetamol, fluoxetin, alcohol, caffeine and many others (Tanaka et al, 2000).  
Based on my findings (Chapter 2), MSE toxicity may be enhanced in vivo if the 
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leaves of this plant are consumed together with CYP 2E1 inducers, for example 
alcohol. If time had permitted, the role of metabolism in activating MSE and MIT 
would have been an important area to pursue. 
 
As part of a toxicological assessment, genotoxic potential of a compound is 
important to characterise. A genotoxic agent is capable of causing DNA damage 
and if repair is unsuccessful it can lead to further major problems such as 
carcinogenesis. Although, to date there is no report of cancer associated with 
consuming the leaves of this plant, a genotoxic assessment such as mutagenicity 
aids prediction of carcinogenicity potential. Thus, for the first time, I have shown 
that genotoxicity testing using the mouse lymphoma tk gene mutation assay 
(MLA), suggests that MSE and MIT have no genotoxic potential. Though, it has 
been noted that the highest dose of MSE (15 µg/ml) in the presence of S9 
produced a positive result, this was considered invalid and a ‘false positive’ due to 
the excessive toxicity effects. This MSE toxicity was similar to that noted for 
MSE with the human cell lines (SH-SY5Y and HEK 293 cells) in the presence of 
S9. This finding again, strongly supported the suggestion that MSE toxicity 
requires metabolic activation. However, in parallel assessments, MIT toxicity was 
not enhanced by metabolic activation. 
 
As previously noted, the toxicity of MSE and to a lesser extent, MIT was dose-
dependant and the SH-SY5Y cell was the most sensitive cell line examined. Cell 
cycle arrest, which is known to be highly associated with cytotoxicity, was seen in 
the present study and SH-SY5Y cell again was the most vulnerable cell line to the 
MSE and MIT effects. Cell cycle arrest was cell type dependant and was mainly 
observed at G1 and S phases for the SH-SY5Y and MCL-5 cells and at S and 
G2/M phases for the HEK 293 cells. Apart from the cell cycle arrest, there is 
another interesting finding observed in the cell cycle analysis, in which there was 
a shifting of the DNA profile to the right (increased x axis fluorescence) 
especially at the higher doses of MSE (≥ 100 µg/ml) or MIT (75 µM). This 
phenomenon was found in all cell lines examined and indicates that more PI dye 
was taken up by the cells thus an increase in the DNA staining intensity. The 
reason for this is not entirely clear, however it is hypothesised that MSE and MIT 
produce an increase in the plasma membrane permeability or cause pore opening 
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thus allowing more dye to get into the cell. A similar phenomenon has been 
described in the literature with dynorphins, endogenous opioid peptides which 
function as ligands for the kappa-opioid receptor and induce non-opioid 
excitotoxic effects. Dynorphins are believed to cause excitotoxic effects by 
inducing perturbations or pore formation on the lipid bilayer of plasma membrane 
(Hugonin et al, 2006).  Hugonin et al (2006) also mentioned in their work that the 
high positive charge of the compound contributed to the mechanism as it will bind 
with the negative charge of the glycosaminoglycan of plasma membrane and thus 
enhance the dynorphin activities. Whether the MSE or MIT could possibly induce 
the same mechanism, requires further investigations.  
 
As cell cycle arrest was noted, further assessment using immunoblotting was 
carried out using SH-SY5Y cells to determine the expression of p53, which is 
known to play a central role in cell cycle arrest. Another fascinating finding noted 
was that p53 protein was found to be lost in a dose-dependant manner with MSE 
treatment and to a lesser extent in the MIT treated cells. The absolute loss of p53 
was prominent at doses ≥100 µg/ml MSE. Interestingly a similar loss was also 
noted for the ß-actin protein control. This phenomenon was noted to be parallel to 
the cell cycle arrest and the right shifting of the DNA profile in the cell cycle 
analysis. These events only occurred at high doses of MSE or MIT.  SH-SY5Y 
cells which are known to have wild-type p53, have constitutive expression of p53 
in the control and lower doses groups. The loss of p53 protein was noted as early 
as 6 hr after MSE treatment.  A similar finding was also observed for p21 protein. 
P21 is one of the main target genes for p53 and both p53 and p21 are well known 
to have a positive correlation in assisting the cycle arrest by inhibiting the cyclin-
Cdks complex formation (Morgan, 2007). Based on these observations, two 
possibilities are considered: 1) the effect is cell cycle arrest, independent of p53 
and p21 pathway or 2) the loss of these proteins could be due to the leakage due to 
the increased membrane permeability or through pore opening. It is likely that the 
latter events occur as the loss of p53 and p21 at higher doses of MSE parallel the 
loss of ß-actin protein. ß-actin protein is found in abundance in cells and therefore 
the loss of this protein indicates substantial membrane rupture and protein 
leakage. 
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The toxicity findings noted thus far are consistent with my hypothesis, in which 
the dose is the main factor in determining the level of the cytotoxicity seen. The 
cytotoxicity events initially seen as cell cycle arrest proceed to cell death with 
increasing doses of MSE and MIT. My investigations of morphological 
microscopic examination on three different cell lines showed different modes of 
cell death. Prominent apoptotic-like cell death is mainly observed for SH-SY5Y 
cells and a necrotic type of cell death for the MCL-5 and HEK-293 cells. Further 
confirmation on these findings in differentiating the stages of cell death was 
carried out using Annexin V conjugate assay via flow cytometry analysis with 
SH-SY5Y and MCL-5 cells. Unfortunately, difficulties in interpreting the analysis 
were encountered as dose-dependant shifts in dye uptake were found as in the 
earlier cell cycle analysis. The right shifting of the whole cell population made the 
interpretation of apoptotic and necrotic populations very difficult as they were not 
located in the anticipated quadrants, thus the results remain inconclusive. This 
finding however, gives strong justification to the hypothesised mechanism 
discussed earlier, in which MSE and MIT may have the ability to change 
membrane permeabilisation or cause pore opening.  
 
In this study, SH-SY5Y cell death induced by MSE appeared to be independent of 
p53 and p21 pathway. However, the morphological features indicated apoptotic-
like type of cell death. Based on these findings, it was postulated that the 
mechanism of cell death of SH-SY5Y cells upon MSE treatment may not follow 
the common intrinsic pathway which requires the activation of tumour suppressor 
protein p53. Therefore the possible involvement of the caspase enzymes such as 
upstream caspases 8 and 9 which are involved in both intrinsic and extrinsic 
pathways and also the executioner caspases 3 and 7, were investigated. MSE 
mediated cell death was found to not involve any of the caspase cascades 
examined. Thus this finding is consistent with the previous data, which indicates 
that the apoptotic-like cell death seen for MSE treated SH-SY5Y cells is p53- 
independent and caspase independent. Other pathways may be considered for 
MSE induced cell death with no involvement of caspase activation, but yet 
following the programmed fashion. There is accumulating evidence that indicates 
that apoptotic-like programmed cell death can also be executed with the release of 
other death factors from different organelles such as lysosomes and endoplasmic 
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reticulum (ER) and also a cross-talk of proteins released from mitochondria 
(Bröker et al, 2005). Involvement of several enzymes from lysosomal pathways 
such cathepsins and calpains were shown to highly correlate to apoptotic-like or 
even necrotic cell death (Jiang et al, 2006; Yamashita et al, 2003). Mitochondria 
which play a key role in the intrinsic pathway for apoptosis may also again be 
involved, as  apoptotic inducing factor (AIF), which is usually released after 
activation of Bcl-2 family, acted with the EndoG protein released from plasma 
membrane to trigger apoptotic-like cell death ( Jiang et al, 2001). Many agents are 
currently known to induce cell death via caspase independent pathways, as 
described above, such as campothecin, doxorubicin and paclitaxel. The necrotic 
type of cell death induced by MSE which is morphologically seen in cell lines 
such as, MCL-5 and HEK 293 cells could not be confirmed biochemically due to 
time limitations. 
 
Unlike MSE, MIT treated SH-SY5Y cells have shown a different mechanism of 
cell death in which there was an involvement of caspases 3 and 7. This is 
consistent with the immmunoblot finding which indicates that p53 and p21 
proteins were marginally expressed even at high doses of MIT. These findings 
indicate that MIT treated SH-SY5Y cells may execute cell death via an apoptosis 
pathway. If time had permitted, more detailed examination of the involvement of 
caspases and other apoptosis-related proteins in MIT treated cells would have 
been desirable. 
 
Prior to this study, most of the investigations on the biological effects of this plant 
such as antinociceptives effects were mostly comparisons with opiate drugs such 
as morphine and its related compounds. Thus an important issue is whether MSE 
or MIT induced cell death may share similar mechanisms as opiate induced cell 
death. In general, opioids have been shown to induce in vitro apoptosis in cell 
lines, including neuronal cells (Mao et al, 2002). The recent review by Zhang et al 
(2008) stated that morphine, for instance, induces neurotoxicity and apoptosis 
after chronic use and heroin also induced apoptotic cell death via mitochondrial 
malfunction, caspase activation leading to PARP cleavage and DNA 
fragmentation. Thus, MIT may show a similar trend of apoptotic cell death as 
opiates but confirmation of this finding requires further investigations. This does 
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not appear to be the case with MSE as death appears to be caspase-independent, 
and thus chemicals other than MIT present in MSE appear to complicate the 
interpretation of my biochemical findings. 
 
Despite having a crucial role for cellular energy metabolism, mitochondria are 
also known to be a key player in cell death. Upon responding to apoptotic stimuli, 
mitochondria can release cytochrome c, AIF and also apoptosis promoting protein 
Smac/DIABLO in completing the cell death cascade.  Mitochondria have also 
been shown as an important factor in other caspase-independant apoptosis. 
Generation of reactive oxygen species (ROS) is also a part of the mitochondrial 
function. Under normal circumstances, the low levels of ROS generated by 
mitochondria as a normal by product of oxygen metabolism are usually removed 
by an abundance of endogenous free radical scavengers such as enzyme 
superoxide dismutases, glutathione and other cellular antioxidants such as 
ascorbic acid and vitamin E (Yazdanparast and Ardestani, 2007; Fridovich, 1999). 
However xenobiotic insult, which causes mitochondrial malfunctions, may lead to 
generation of ROS in higher levels thus triggering further serious problems such 
as oxidative stress, lipid peroxidation and finally cell death. Since in my present 
study, the apoptotic-like cell death induced by MSE was suggested to be caspases-
independent, an investigation looking at generation of ROS in mediating the 
apoptotic events was carried out. Unfortunately, the results in my study showed 
that there was no ROS generation upon treatment with high doses of MSE or 
MIT. During the ROS study, another interesting observation was made, 
specifically that MSE co-treatment with NAC appeared to protect the cells from 
death and that chemicals present in the MSE emphasised this effect. 
 
Pharmacologically, the extract of this plant and MIT were shown to exert their 
biological activities via opioid receptors mainly µ-, and δ- and to a lesser extent κ-
opioid receptors (Tsuchiya et al, 2002; Thongpradichote et al, 1998; Tohda et al, 
1997). The opioid analgesic, morphine is also known to exert its biological 
activities mainly via µ-opioid and also δ- and κ-opioid receptors (Corbett et al, 
2006) however the selective binding site of MIT for µ-receptor is found to be of a 
different subtype from morphine (Thongpradichote et al, 1998). Cell death 
induced by opioids is highly associated with their opioid receptor signalling, such 
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as neuronal apoptosis induced by morphine which was associated with morphine 
tolerance  due to opioid receptor desensitisation and uncoupling to pertussis toxin 
(PTX)-sensitive inhibitory G protein (Gi) (Tegeder et al, 2003). Thus this 
information poses the question of whether the opioid receptors mediating the 
biological activity of the Mitragyna speciosa Korth plant may also mediate the 
MSE and MIT induced toxicity or cell death. I therefore predicted that opiate 
receptor antagonists would protect against MSE and MIT induced cell death. As 
anticipated, naloxone (µ- and δ-receptor antagonists), naltrindole (δ-receptor 
antagonist) and cyprodime hydrobromide (µ- receptor antagonists) all successfully 
gave protection against MSE toxicity both in acute and longer term treatment. 
However for MIT, µ- receptor was found to be the main player in mediating its 
toxicity. Thus, it is suggested that apart from MIT there are other chemicals 
present in the leaves of Mitragyna specioa Korth contributing to the MSE 
cytotoxicity. A summary of the cytotoxic events leading to MSE or MIT induced 
SH-SY5Y cell death as discussed above are shown in fig. 6.1.  
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Fig. 6.1 Mechanisms of MSE and MIT induced SH-SY5Y cells arrest and cell 
death. Arrows (            MSE;            MIT) represent actual events occur in this 
study which leads to cell death. Dotted arrows (           MSE;          MIT) represent 
possible mechanism of cell death as discussed in the text.  (     ) indicates the loss 
of p53 and p21 protein in this study hypothesised to be due to loss through pore 
opening or increased membrane permeability. The cell cycle arrest by MIT insult 
was associated with a positive link between p53 and p21; however cell cycle 
arrest due to MSE insult remains unclear due to loss of p53 and p21. µ and δ refer 
to opioid receptors.  
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There is another interesting finding to note apart from the toxicology implications 
of MSE and MIT as discussed above. Low doses of MSE (< 100 µg/ml) and MIT 
(< 75 µM) stimulate cells to proliferate in most of the human cell lines examined. 
Thus, this finding may support the pharmacology of the Mitragyna speciosa Korth 
leaves which produce stimulation effects when consumed at low doses. The 
stimulation effects claimed at low doses are based on anecdotal reports from users 
however, the specific clinical pharmacology and controlled dosage for humans is 
still poorly understood. 
 
One of the main reasons for conducting toxicology studies is to determine the risk 
or in other words to determine the potential for harm towards human health or the 
environment upon exposure to naturally occurring or synthetic agents.  Thus, the 
findings of this study will hopefully contribute to a better understanding in 
predicting the risk upon consuming Mitragyna speciosa Korth leaves. Based on 
human consumption of 20 leaves/day as described in chapter 1 (section 1.2.2), it 
has been estimated to result in exposure to about 17 mg MIT.  Assuming total 
body distribution of the drug (70 kg BW/person), in vivo concentrations are 
probably in order of 10-9 to 10-7 M MIT. Extrapolating cell based in vitro studies 
to whole animal studies require huge assumptions, but since the in vitro toxicity of 
MIT is not obvious until ≥ 75 µM, human consumption of Mitragyna speciosa 
Korth leaves at pharmacologically active doses would appear to be substantially 
lower than the threshold of toxicity predicted from my in vitro study.  
 
Taking into account all the findings of my studies, MSE and MIT could be 
potentially harmful in humans at high doses. The safety assessment assumptions 
suggest that the use of Mitragyna speciosa Korth leaves within the range of 
pharmacologically active doses as reported in the literature is probably safe, 
however caution should be taken as MSE toxicity in this study was found to be 
enhanced by metabolism, particularly by CYP 2E1. Thus, the combination 
consumption of Mitragyna speciosa Korth leaves with CYP 2E1 inducers may 
shift toxicity closer to doses that are pharmacologically active.  
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6.2 Conclusions 
Based on the current findings observed in the present studies, it is concluded that 
the methanol-chloroform extract (MSE) of the Mitragyna speciosa Korth 
(Kratom) leaves and its dominant alkaloid, mitragynine (MIT) have potential to 
cause cytotoxicity to mammalian cells at high doses and is possibly harmful to 
human users. MIT is proposed to be a major contributor to MSE cytotoxicity. The 
main target system of MSE and MIT cytotoxicity is the central nervous system as 
shown by sensitivity of neuroblastoma cell lines (SH-SY5Y) throughout the 
studies. In general, MSE and to a lesser extent MIT were found to exert their dose 
dependant cytotoxicity effects in all human cell lines examined both in acute 
treatment and also in the longer term as assessed by the clonogenicity assay.  
MSE was found to induce cell cycle arrest in all p53 wild type human cells 
however this appeared to be cell type dependant in which, G1 and S phase arrest 
was seen for SH-SY5Y and MCL-5 cells and S and G2/M arrest for HEK 293 
cells. MIT has a lesser effect and cells arrest mainly at G1 phase in SH-SY5Y 
cells. The cell arrest occurring at high doses of MIT was found to be correlated 
with p53 and p21 expression although the expression changes were marginal 
compared to control and lower dose groups. The mechanism for cell cycle arrest 
in the cells treated with high doses of MSE remains unclear as there was no 
correlation with p53 and p21 as both proteins were lost after the treatment.  
 
The level of MSE toxicity for SH-SY5Y and HEK 293 cells was found to be 
increased 10-fold when metabolic activation system (post mitochondrial rat liver 
S9 induced with Arochlor 1254) was added to the treatment. This implies that 
MSE cytotoxicity requires metabolism for its activation and CYP2E1 was thought 
to be involved in this metabolic activation. However, MIT in parallel experiments 
did not show any enhancement of toxicity in the presence of S9, and was 
inherently cytotoxic. Based on this information, it may be prudent to advise when 
consuming the leaves of this plant with any CYP 2E1 inducers such as alcohol; it 
might trigger greater toxicity effects. MLA in this study revealed that MSE and 
MIT have no genotoxic potential, which is consistent with a lack of published 
evidence on the incidence of tumours or cancer in human upon consuming the 
leaves of this plant.  
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In determining the mechanism of cell death induced by MSE and MIT, it was 
noted that MSE caused a different mode of cell death depending on cell type. 
Morphologically, after MSE insult, SH-SY5Y cells appeared to die via apoptosis-
like cell death, whereas MCL-5 and HEK 293 cells show predominantly a 
necrotic type of cell death.  Biochemical investigations confirmed that MSE 
induced SH-SY5Y cell death independent of p53 or caspases, therefore the 
mechanism of apoptotic-like morphology features is not entirely clear, however a 
few possible mechanisms for this type of cell death can be proposed. MIT induced 
cell death in SH-SY5Y cells appeared to be associated with p53 and caspases-
dependant pathway however, lacking morphological examinations restricts the 
confirmation of this finding. The study also confirmed that there was no 
involvement of ROS production in MSE and MIT induced cell death, implying 
that mitochondrial integrity is not compromised. Finally, evidence from this study 
also suggested that the opioid receptors are highly involved in mediating MSE and 
MIT cytotoxicity . 
 
Overall, the first ever in vitro toxicology assessment of extract of Mitragyna 
speciosa Korth leaves as used in this study provide information that the 
consumption of Mitragyna speciosa Korth leaves may pose harmful effects to 
users if taken in high dose. In addition, this study also suggests that metabolism 
particularly the activation of CYP 2E1, appeared to increase the MSE 
cytotoxicity, thus caution should be taken as this is likely to occur in vivo, if 
Mitragyna speciosa Korth leaves were to be taken with CYP 2E1 inducers. 
 
6.3 Future work 
Prior to this study, nothing was known about the cytotoxicity effects of MSE and 
MIT. Thus, this study provides the first information on the toxicological 
implications of the exposure to MSE and MIT. The limited amount of MIT 
available to me throughout the studies, have restricted the testing of MIT in 
parallel with all MSE assessments. This limitation has compromised a 
comprehensive investigation on MIT induced cytotoxicity and cell death.  It is 
therefore important for future in vitro investigations to look for morphological 
assessment of MIT induced cell death and further confirmation on the 
involvement of initiator caspases, 8 and 9 to support the current findings. Future 
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work also needs to focus on the involvement of metabolism in activating MSE 
and should be supported by in vivo studies. Metabonomic studies using cell lines 
or urine from animal models or perhaps urine from humans exposed to this plant 
are also suggested. In connection with these in vivo studies, I have completed a 
preliminary mouse study with oral gavage of MSE at 2000 mg/kg BW. Analysis 
of this study is underway. 
 
The suggestion that ‘MSE and MIT insult at high doses could increase 
membrane permeabilisation or pore opening of the plasma membrane of human 
cell lines’ is an important area that needs to be investigated as this phenomenon 
appeared to mask the mechanism of cell arrest and cell death. Last but not least 
the stimulation effects of MSE and MIT at low doses is another potential area to 
be investigated as it could prove to be of potential therapeutic values.  
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Appendix 1: Calculations of MIT-like compound estimated from MSE 
fractions using UV-VIS spectrometer 
 
MSE (0.4076 g) was weighed and dissolved in 3 ml methanol: 21 ml 20% formic 
acid.  Filtration of MSE mixture yield 18.7 ml filtrate. 
4.5 ml filtrate used for each SPE extraction (4 replicates): 
From MIT standard curve generated in fig. 2.3 , the equations used to calculated 
the estimation of MIT-like compound in MSE is Y= 0.0044X + 0.0232 , MIT 
molecular weight = 398.5 
The absorbance reading for each fraction at 227 nm was determined as follows: 
 
SPE A: 
Fraction 1 (sample fraction containing methanol: 20% formic acid) in 1:10 
dilution 
Abs = 0.181= Y 
X= Y- 0.0232/ 0.0044 
  = 0.181- 0.0232 /0.044 = 35.86 x 10 dilution factor (df) = 358.6  
 Total volume = 4.5 ml 
= 358.6 x 398.5 / 1000  x 4.5 ml = 0.643 mg per 4.5 ml filtrate. 
 
Fraction 2 ( 2% formic acid) in 1: 10 dilution 
Abs = 0.175 
X= 34.5 x 10 df = 345  
Total volume = 4.5 ml 
= 345 x 398.5/1000 x 4.5 ml = 0.6187 mg per 4.5 ml filtrate. 
 
Fraction 3 (methanol) in 1:100 dilution 
Abs = 0.254 
X= 52.5 x 100 df = 5250 
Total volume = 4.5 ml 
= 5250 x 398.5/1000 x 4.5 ml = 9.415 mg per 4.5 ml filtrate. 
 
 
 
179 
 
Fraction 4 (ammonia:methanol: acetonitril) in 1:100 dilution 
Abs = 0.474 
X= 102.5 x 100 df = 10250 
Total volume = 4.5 ml 
= 10250 x 398.5/1000 x 4.5 ml = 18.381 mg per 4.5 ml filtrate 
 
Total MIT in four fractions = 0.643 + 0.6187 + 9.415 + 18.381 mg  
                                            = 29.0577 mg per 4.5 ml filtrate 
 
Therefore in 24 ml original MSE sample = 154.9744 mg MIT-like compound 
in 407.6 mg MSE 
154.9744 mg / 407.6 mg  x 100 = 38% MIT-like compound 
 
The same calculations were applied to three other SPE replicates: 
SPE Fractions Absorbance at 227 nm 
1 0.230 
2 0.189 
3 0.234 
 
 
B 
4 0.545 
1 0.323 
2 0.199 
3 0.279 
 
 
C 
4 0.555 
1 0.325 
2 0.105 
3 0.240 
 
 
D 
4 0.620 
 
Total MIT-like compound for B extraction = 31.377 mg MIT-like compound 
in 4.5 ml filtrate 
Therefore, in 24 ml original MSE sample = 167.344 / 407.6 x 100 = 41% MIT-
like compound 
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Total MIT-like compound for C extraction = 34.0438 mg MIT-like compound 
in 4.5 ml filtrate 
Therefore, in 24 ml original MSE sample = 181.5669 /407.6 x 100 = 44.5% 
MIT-like compound 
 
Total MIT-like compound for D extraction = 34.721 mg MIT-like compound 
in 4.5 ml filtrate 
Therefore, in 24 ml original MSE sample = 185.1787 /407.6 x 100 = 45 % 
MIT-like compound 
 
Average percentage of MIT-like compound in 24 ml MSE sample (0.4076g)  
= 38 + 41 + 44.5 + 45 /4 = 42 % MIT-like compound 
